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Abstract 
 
Previous work has suggested that triclabendazole (Tcbz), a member of the benzimidazole group 
of compounds, possessed efficacy against Schistosoma mansoni (S. mansoni). In view of recent 
indications in praziquantel (Pzq) treatment failures and loss of sensitivity, it is imperative that 
new anti schistosomals are developed as contingent treatment options, while resistance alleles, 
if any, remain at low frequencies. While recent studies have indicated that Tcbz monotherapy 
exert weak anti schistosomal effects, the combined application of Tcbz with Pzq has not been 
explored. To assess this hypothesis, triclabendazole and its metabolites were initially assessed 
against the many life stages of S. mansoni in vitro. Combination drug and isobologram analyses 
against adult S. mansoni was also performed, and subsequently assessed against other parasite 
species  to  assess  the  specificity  of  such  effects.  Subsequently,  the  drug  combinations  were 
assessed against S. mansoni in vivo. A cost effectiveness model was then developed to predict 
the feasibility of administering Pzq Tcbz drug combinations in Senegal. It was concluded that 
triclabendazole and its metabolites possessed good efficacy against immature schistosomula, 
although weak efficacy was observed against adult S. mansoni. Upon combination with Pzq, 
however, a strong synergistic effect against adult worms were observed in vitro. Praziquantel 
and Tcbz were also shown to possess unique and independent ovicidal modes of action that can 
be clinically significant. More importantly, in vivo drug trials concluded that the combinations 
exerted additive effects against S. mansoni harbored in mice. Economic modeling and cost 
effectiveness analysis further demonstrated the feasibility of this drug combination and showed 
that  the  drug  combinations  may  represent  a  new  line  of  treatment  against  mansonial 
schistosomiasis. 
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1.0 General Introduction 
Schistosomiasis (bilharziasis or snail fever) is the most widely distributed parasitic disease of 
humans.  Endemic  in  75  countries,  600  million  people  are  at  risk  of  infection,  with 
approximately 200 million people infected with schistosomiasis annually (Yosry, 2006). The 
causative agents are dioecious parasites of the blood vascular system belonging to the genus 
Schistosoma. At present, 19 species of schistosomes have been identified, with five species 
primarily  capable  of  human  transmission,  namely:  Schistosoma  mansoni  (S.  mansoni), 
Schistosoma japonicum, Schistosoma haematobium, Schistosoma intercalatum and Schistosoma 
mekongi. Of these, S. mansoni remains the main causative agent of human schistosomiasis.  
 
1.1 Life cycle 
The life cycle of S. mansoni follows a common pathway of all schistosome species, from the 
sexual  generation  of  adult  schistosomula  within  the  vascular  system  of  the  definitive  host 
through to asexual reproduction within intermediate aquatic snails, and eventually a return to the 
definitive host by infective cercariae (Kojima, 1998; see Figure 1.1). Adult schistosomes are 
approximately 7 20mm in length, featuring two terminal suckers, a complex tegument, a blind 
digestive  tract  and  reproductive  organs.  Paired  adult  schistosomes  remain  permanently  in 
copula, residing in the mesenteric venous plexus (Gryseels et al., 2006). Female schistosomes 
can produce hundreds of eggs per day. Each egg contains a ciliated miracidium, the first free 
swimming larval stage of the parasite. The proteolytic enzymes secreted by the miracidium help 
the egg migrate through intestinal parenchyma into the lumen to be excreted in the faeces. 
 
Schistosoma  mansoni  spends  a  proportion  of  its  life cycle  developing  in  the  intermediate 
pulmonate molluscs of the genus Biomphalaria (Southgate et al., 1998). The emergence of the 
miracidium is induced by a response to physical stimuli such as sunlight and fresh water. Upon 
contact, penetration of the intermediate snail host occurs via the foot, tentacle or edge of the 
mantle. The miracidium then multiply asexually into multicellular sporocytes and subsequently 
into cercarial larvae. Typically circadian, cercarial shedding for S. mansoni occurs during the     Chapter 1 
  2   
photophase (Pitchford et al., 1969). Upon finding the definitive mammalian hosts, the cercariae 
penetrates the skin, migrate in the blood via the lungs to the liver and transforms into immature 
schistosomulae (Wheater & Wilson, 1979; Miller & Wilson, 1980; Wilson & Coulson, 1986). 
Once the trapped schistosomula have transformed into liver stage worms, the mature worms 
begin to pair with the opposite sex. The worm pairs eventually migrate into their mesenteric 
destination where the cycle begins again (Gryseels et al., 2006). 
 
 
 
Figure 1.1: Life cycle of Schistosoma mansoni.  
 
 
(A) Egg laying and subsequent excretion of eggs in feces,  
(B) Hatching of miracidium in the presence of fresh water,  
(C) Infection of freshwater snail host and subsequent development into mother and daughter 
sporocysts within the host, 
(D) Shedding of human infective cercariae into fresh water,  
(E) Cercarial infection and penetration of definitive host and  
(F) Development of lung stage worms followed bymigration into the liver and pairing of male and 
female worms. Sexual reproduction then leads to egg laying and excretion of eggs in feces.  
 
Image reproduced from the WHO/TDR website at 
<www.who.int/tdr/diseases/schisto/lifecycle.htm> (accessed on 1/3/2007). 
 
 
 
A  B 
C 
D  E 
F     Chapter 1 
  3   
1.2 Pathology  
The pathology of schistosomiasis results from parasite migration through different tissue types 
in  the  mammalian  hosts  (Kojima,  1998).  Initial  clinical  manifestation  following  cercarial 
penetration includes dermatitis, coughing and mild fever as the schistosomulum migrates to the 
lungs. Following a latent period of a month, the acute phase of disease, known as ‘Katayama 
fever’, coincides with the onset of egg laying in the portal veins of the intestinal mesentery, 
accompanied by dysentery or diarrhoea as the eggs are discharged into the intestinal canal. The 
eggs are eventually deposited in the liver as the disease progresses.  
 
The formation of granulomas to schistosome eggs signals the onset of chronic schistosomiasis, 
characterized  by  cellular  and  granulomatous  inflammation  of  the  liver  tissues  surrounded 
deposited eggs, with subsequent tissue fibrosis. Granulomatous inflammation also occurs in the 
intestines as a consequence of T cell mediated hypersensitivity to soluble egg antigens. Chronic 
schistosomiasis,  often  referred  to  as  hepatosplenic  schistosomiasis,  is  characterised  by  the 
formation of polyps in the intestines, with egg granulomas in the liver eventually replaced by 
fibrotic tissues. The liver decreases in size but increases in hardness as fibrosis extends to the 
parenchyma. The severity of the disease is related to the intensity of the infection as well as the 
immune responses of the host (Gryseels et al., 2006). 
1.3 Immunology 
Schistosomiasis is a multifaceted, immunopathological disease characterised mainly by host 
hypersensitivity to eggs trapped within tissues. Generally, the intensity of infection declines 
with  age,  conditioned  by  behavioural  and  immunological  development  of  the  host.  Once 
challenged,  the  host  mounts  both  cellular  and  humoral  immune  responses  against  antigens 
derived  from  the  various  developmental  stages  of  schistosome  development.  While  the 
significance of complement fixing antibodies is yet to be established, protective immunity by 
antibodies  is  likely  to  result  in  the  cytotoxic  destruction  of  schistosomulum  targets,  with 
antibody dependent cellular toxicity acting as the main mechanism for parasitic death in the 
human host (Capron, 1998).      Chapter 1 
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A critical feature of the transformed schistosomulum is its ability to mimic host molecules, 
rendering it resistant to antibody mediated defences. Initially susceptible to host immunity, the 
young schistosomula gradually become highly resistant with subsequent transformation. It has 
been suggested that the modulation in the expression of schistosomulum surface antigens may 
be an important mechanism of immune escape (Simpson, 1992). Furthermore, the continual 
shedding of the tegumental surface (Pearce et al., 1986) and the role of immunomodulatory 
proteases  (Fishelson,  1995)  may  enhance  immune  evasion.  The  physical  resistance  of  the 
tegumental inner bilayer membrane to host complement is also believed to play critical role in 
evasion and protection (Kusel & Gordon, 1989).  
1.4 Genomics and biochemistry 
 
Sequencing of the entire genome of S. mansoni was completed in 2004. The 270Mb haploid 
Schistosoma genome is contained in eight pairs of chromosome with a total GC content of 
approximately 34% (LoVerde et al., 2004). Schistosoma was shown to possess seven pairs of 
autosomes and one pair of sex chromosomes for each of the sexes, with an estimated total of 
15,000 to 20,000 expressed genes. A range of highly and moderately repetitive elements has 
been identified (4–8% highly repetitive and 30–35% moderately repetitive), with 60% of the 
genome being single copy sequences.  The anaerobic schistosomes derived most of their energy 
from ATP synthesised through oxidative phosphorylation. Glycolysis appears to generate the 
bulk  of  the  ATP  required,  with  lactate  production  dependent  on  the  availability  of  high 
concentrations of pyruvate. Although schistosomes generally undergo homolactic fermentation 
with the production of lactate as a metabolite, oxygen utilisation by adult schistosome is not 
uncommon (Rumjanek, 1987). The ability of schistosomes to consume large amounts of glucose 
exceeded that of red blood cells, and as such, schistosomes are often described as fast growing 
tumours (Rumjanek, 1987). Paired schistosomes absorb copious amount of glucose through 
their tegument while residing in the blood stream, consuming their dry weight in glucose every 
five  hours  (Beuding,  1950).  Adult  schistosomes  are  also  capable  of  ingesting  red  blood 
corpuscles with subsequent utilization of haemoglobins and serum globulins following enzymic 
cleavage (Kojima, 1998).     Chapter 1 
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1.5 Transmission and epidemiology 
Intestinal schistosomiasis is currently endemic in 54 countries in the Middle East and most of 
the  African  continent,  including  Madagascar  and  Mauritius  (Chitsulo  et  al.,  2000).  Due  to 
cultural  and  social  biases  in  behaviour  and  occupation,  men  are  generally  more  at  risk  of 
infection  than  women.  In  areas  where  intestinal  schistosomiasis  is  endemic,  the  highest 
prevalence of infection occurs in individuals of age 10 to 24 years and the most heavily infected 
individuals are those aged between 10 to 14 years (Schmunis & López Antuñano, 1998). The 
economic cost of schistosomiasis is measured as a reduction in work capacity as a result of 
morbidity. The prevalence of schistosomiasis has increased in many endemic countries due to 
the  impoundment  of  water  for  large scale  irrigation  and  electricity  production  to  support 
growing human populations (Hunter, 2003). Current control strategies are designed to reduce 
the morbidity associated with schistosomiasis rather than the eradication of infections as the 
costs of eradication is beyond the financial means of most endemic countries.  
1.6 Diagnosis 
Mircoscopic  examination  of  excreta  is  the  cornerstone  for  the  diagnosis  of  schistosomiasis 
(Feldmeier & Poggensee, 1993). The technique currently recommended by the World Health 
Organisation (WHO) for definitive and semi quantitative diagnosis of intestinal schistosomiasis 
is  the  Kato Ktaz  smear  technique.  The  Kato  Katz  method  is  a  simple  and  inexpensive 
procedure,  which  has  led to  its  widespread  use  in the  classical  endemic  areas  of  intestinal 
schistosomiaisis. However, its low sensitivity is compounded by high intra  and inter specimen 
variations in egg counts (Utzinger et al., 2001; Teesdale, 1985; Feldmeier & Poggensee, 1993). 
This is particularly evident in areas recently introduced with schistosomiasis or areas where 
control efforts have reduced parasitic burdens (Alarcon de Noya et al., 1997; Graeff Teixeira et 
al., 2004; Noya et al., 2002). Current antibody based assays are sensitive but are incapable of 
distinguishing the history of exposure from active infections and are not easily applied in the 
field  (Feldmeier  &  Poggensee,  1993).  Immunoassays  tools  for  the  detection  of  S.  mansoni 
antigens  may  not  have  the  expected  high  sensitivity  and  specificity  when  employed  for 
diagnosis in regions of low endemicity or for light infections in travellers (van Lieshout et al.,     Chapter 1 
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1995;  2000).  Molecular  diagnostic  methods  are  sensitive  alternatives,  but  require  more 
extensive validation in areas of low endemicity. Other methods such as urine based antigen 
detection field strips have considerable potential, but may be less sensitive (van Dam et al., 
2004). The use of differential fecal concentration methods, increased amounts of fecal samples 
and mathematical modelling have been attempted to improve the sensitivity of parasitological 
diagnoses, but have not been convincing enough to warrant extensive field trials (Eberl et al., 
2002; Polman et al., 2000). Diagnoses of the disease in hospital settings are currently achieved 
using cytoscopy and endoscopy. In hepatic schistosomiasis, contrast radiography, myelography, 
computed tomography imaging and magnetic resonance imaging are routinely used for detailed 
imaging, particularly for neuro schistosomiasis (Palmer & Reeder, 2006; Lambertucci et al., 
2000).  
1.7 Control 
The  control  of  schistosomiasis  is  an  ongoing  and  evolutionary  process.  While  successful 
treatment of individuals can be achieved, reinfection by the parasite continues to be a perennial 
challenge.  Control  measures  for  intestinal  schistosomiasis  are  often  complicated  by  the 
maintenance of the parasite in reservoir hosts such as domestic animals and rodents. As a result, 
the commitments of schistosomiasis control programs are long term. Concerted efforts in snail 
control,  health  education,  diagnosis  as  well  as  effective  chemotherapy  measures  must  be 
systematically maintained. 
 
Antimony  potassium  tartrate,  a  trivalent  antimonial,  was  the  first  compound  used  to  treat 
schistosomiasis in the early 1900s (Marshall, 1987). The effectiveness of different drugs varies 
depending on the species, sex and developmental stages of the parasite. There is also evidence 
that different parasite strains vary in their susceptibility to drugs (Keiser et al., 2006). The 
antimonials  were  gradually  replaced  by  compounds  such  as  oxamniquine  and  metrifonate. 
Despite being the cornerstone of anti schistosomal treatment for the last 20 years, resistance to 
oxamniquine has been indicated (Lambertucci et al., 2000; Saconato & Atallah, 2000) and is 
gradually  being  replaced  by  cheaper  alternatives.  Metrifonate  is  no  longer  commercially     Chapter 1 
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available due to insufficient market demand (Fenwick et al., 2003). The subsequent discovery of 
the  anthelmintic  properties  of  praziquantel  in  the  70s  has  dramatically  revolutionised  the 
treatment of schistosomiasis.  
 
Recently,  the  antimalarial  artemisinin  and  derivatives  were  shown  to  have  putative  anti 
schistosomal activities against both immature and mature worms (Chen et al., 1980, Xiao et al., 
2000; Xiao et al., 2002, Utzinger et al., 2001; Li et al., 1996). More recent studies into the 
effects of artemisinins and other synthetic compounds such as the trioxolanes demonstrate broad 
spectrum activities against trematodes such as S. japonicum, S. mansoni, Clonorchis sinensis, F. 
hepatica and Opisthorchis viverrini (Keiser & Utzinger, 2007; Xiao et al, 2007). Keiser et al. 
(2007) further demonstrated the in vivo effects of tribendimidine, a broad spectrum anthelmintic 
against S. mansoni and other trematodes.  
 
1.7.1 Praziquantel control 
 
The pyrazinoisoquinolone praziquantel (Pzq) has been registered for human and veterinary use 
since  the  early  1980s.  Praziquantel  is  2 cyclohexylcarbonyl 1,2,3,6,7,11b 
hexahydropyrazino{2,1 a}isoquinolin 4 one  (see  Figure  1.2),  with  the  R  or  ( )  form  as  the 
active enantiomer. Available as a white crystalline racemate, the compound is stable, melting at 
136 to 140°C with decomposition. Praziquantel is sparingly soluble in ethanol, chloroform and 
dimethylsulphoxide (DMSO) and is slightly soluble in water. 
 
 
 
 
 
 
 
Figure 1.2: Praziquantel chemical structure 
 
N
N
O
O
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1.7.1.1 Pharmacodynamics and metabolism  
Praziquantel is rapidly and well absorbed following oral administration; with peak plasma levels 
achieved one to two hours post ingestion. With a half life of 0.8 to 2.0 hours, the drug is 80% 
reversibly bound to plasma proteins in animals and man (Dayan, 2003). Rapid metabolism is 
achieved  in  the  liver  with  extensive  first  pass  hydroxylation  of  the  parent  compound  into 
inactive, conjugated metabolites (Marshall, 1987). Eighty percent of the drug dose is excreted in 
the  urine  mainly  as  4 hydroxycyclo hexylcarbonyl  with  a  small  amount  of  the  parent 
compound.  
 
1.7.1.2 Mechanism of action  
Praziquantel is highly effective against all human schistosomes. Its utility has been repeatedly 
demonstrated in large scale control efforts in many endemic countries. Active against a range of 
platyhelminths, it  has  been  proposed  that  drug  action  was  limited  to organisms  within  this 
phylum (Andrews et al., 1983).  
 
At  lower  therapeutic  concentrations,  the  drug  induces  an  increase  in  worm  motor  activity, 
followed  by  muscular  contraction  and  subsequently,  spastic  paralysis.  At  higher  and  more 
effective  concentrations,  Pzq  induce  tegumental  damage,  leading  to  the  activation  of  host 
immunity which ultimately results in the elimination of parasite (Fallon et al., 1992; Linder & 
Thors,  1992;  Brindley,  1994).  Praziquantel  was  shown  to  cause  increased  membrane 
permeability to monovalent and divalent cations, particularly to Ca
2+ (Pax et al., 1978; Blair et 
al., 1992), causing disruption in membrane calcium homeostasis (Kohn et al., 2001). Removal 
of  Ca
2+  from  the  medium  blocked  both  responses,  indicating  that  the  action  was  calcium 
dependent.  Tegumental  damage  includes  severe  swelling,  vacuolisation,  fusion  of  the 
tegumental ridges, loss and shortening of spines on tubercles with collapse and peeling (Shuhua 
et  al.,  2000).  Alterations  in  glycogen  content  and  energy  metabolism  of  the  schistosome 
appeared to be a secondary effect (Dollery, 1999).  
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Praziquantel’s  molecular  mechanism  of  action  is  unclear,  although  several  potential 
mechanisms have been suggested based on the elucidation of novel sequences with no clear 
homology to genes from other phyla (Hu et al., 2004; LoVerde et al., 2004; McManus et al., 
2004;  Verjovski Almeida  et  al.,  2004).  GSH  S Transferase  Sj26,  a  molecular  target  for 
praziquantel action was recently challenged by Milhon et al. (1997). Similarly, direct action of 
Pzq on (Na
+, K
+) ATPase and (Ca
2+, Mg
2+) ATPase activity has been disproved (Nechay et al., 
1980; Cunha & Noel, 1997). The apparent relationship between Pzq and calcium redistribution 
in  worm  tissues  suggested  that  the  target  site  of  the  drug  could  very  well  be  a  calcium 
permeable  membrane  channel  (Köhler,  2001).  Studies  by  Chubb  et  al.  (1978)  have 
demonstrated that 50 M of Pzq prolonged the Ca
2+ dependent plateau phase of cardiac action 
potential in rats. In addition, Fetterer et al. (1980) demonstrated that methoxyverapamil (D 
600), an inhibitor of L type mammalian Ca
2+ channels, did not block the Pzq dependent Ca
2+ 
influx in schistosomes but blocked tonic contraction resulting from increased K
+ concentrations. 
Although Ca
2+ contractility induced by Pzq has been demonstrated in isolated muscle cells from 
S. mansoni, direct incontrovertible evidence for native Ca
2+ currents from schistosome cells 
have not been observed.  
 
Recently, Kohn et al. (2001) proposed the β subunit of voltage gated calcium channels as a 
potential target of Pzq. Voltage gated calcium channels are members of the voltage gated ion 
channel superfamily that are regulators of Ca
2+ homeostasis in excitable cells.  Voltage gated 
calcium  channels  are  heteromultimeric  transmembrane  protein  complexes  that  contribute  to 
impulse propagation by opening in response to changes in membrane potential (Greenberg, 
2005).  These  channels  are  composed  of  a  pore forming,  voltage sensing  α subunit  that  is 
modulated by auxiliary subunits such as α2/δ, β and γ. The α subunit is composed of four 
domains,  each  consisting  of  six  transmembrane  regions  (S1 S6).  The  fifth  and  sixth 
transmembrane regions (S5 and S6) along with the P loop form a tetrameric structure that is the 
building block of ion channels. The residues residing within the P loop are responsible for much 
of the pharmacology and ionic selectivity of the channel (Greenberg, 2005). The intracellular β      Chapter 1 
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subunits (Cavβs) are critical modulators of the α1 subunits by increasing current densities and 
ligand binding when co expressed with the α1 subunits. Homology modelling has indicated that 
Cavβs were members of the membrane associated guanylate kinase family of proteins (Hanlon 
et  al.,  1999).  Membrane associated  guanylate  kinase  proteins  are  usually  concentrated  at 
synapses  and  are  responsible  for  clustering  at  ion  channels  and  neurotransmitter  receptors 
(Dimitratos et al., 1999).  
 
In view of this purported mode of action, it appeared likely that the mode of resistance can be 
acquired through a simple structural mutation in the variant subunit. However, Valle et al. 
(2003) were unable to demonstrate any quantifiable differences between the expression of the 
subunit between sensitive and insensitive isolates. In addition, Valle et al. (2003) found that 
adult and immature schistosomes demonstrated no appreciable differences in the level of β  
subunit mRNA expression, despite significant differences in Pzq sensitivity between the various 
life stages. It is likely that the β subunit of calcium channels was not the mode of resistance to 
Pzq in schistosomes. It has been further proposed that the anatomical localization of the calcium 
channel subunits may be a contributing factor in conferring Pzq sensitivity. However, the lack 
of evidence for β subunit generated resistance demonstrated by Valle et al. (2003) must be 
critically reviewed as the mechanism of drug action is not necessarily similar to those involved 
in the mechanism of resistance. Furthermore, the drug structure or drug availability may be 
modified in the insensitive schistosomes even in the absence of target molecule modifications 
(Valle et al., 2003).  
 
1.7.2 Triclabendazole control 
Recent studies on the efficacy of the benzimidazole (Bz) class of compounds have generated 
renewed interest on the use of these compounds for the treatment of human schistosomiasis. 
Benzimidazoles are classically broad spectrum anthelmintics used for the control of nematodes, 
cestodes  and  trematodes.  Triclabendazole  (Tcbz)  is  principally  used  to  treat  fascioliasis  in 
humans and livestock. Recent reports have also suggested that the drug is effective against S.     Chapter 1 
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mansoni  (el  Sayed  &  Allam,  1997;  Mansoury,  1997;  Schmidt,  1998;  Khalil,  2000).  Using 
scanning microscopy, el Sayed & Allam (1997) examined the effects of Tcbz on the tegument.  
When adult worms was exposed to Tcbz at 15 g/mL and 75 g/mL for a period of 24 hrs, there 
were rapid disruptions to the tegument with contraction and subsequent immobilization of the 
worm within one hour of Tcbz uptake. One hundred percent mortality was observed following 
24 hrs exposure. Further in vitro Tcbz challenge studies on adult worms showed disruptions to 
the teguments and oral sucker (Mansoury, 1997). Khalil (2000) compared the in vivo efficacy of 
both Pzq and Tcbz in mice based on egg excretion, number, sex and distribution of worms, 
oogram changes and tissue egg load. Triclabendazole was shown to be more efficacious on male 
worms. A return of surviving worms from the hepatic to the mesenteric veins was also noted. 
More importantly, there was evidence of a cessation of eff laying with Tcbz treated mice.  
 
The halogenated Tcbz is distinct from other Bz carbamates because it possesses chloride atoms 
and  a  thiomethyl  group  in  place  of  a  carbamate  moiety  (see  figure  1.2).  In  particular, 
computational chemistry has demonstrated that the methylthio substituent (as well as active 
metabolites  bearing  sulphoxide  and  sulphone substituents) at  the  2 position  imparts  distinct 
shape and electronic distribution when compared to other Bzs. While most Bzs are L shaped, 
the  U shape  of  Tcbz  may  be  responsible  for  its  select  spectrum  of  activity  (Lipkowitz  & 
McCracken, 1991). 
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Figure 2: Triclabendazole chemical structure     Chapter 1 
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1.7.2.1 Pharmacodynamics and metabolism 
Mottier et al. (2004) characterised the in vitro biotransformation of Tcbz in sheep liver and 
Fasciola hepatica (F. hepatica) microsomal preparations. Sheep liver microsomes metabolised 
Tcbz  into  its  active  sulphoxide  and  sulphone  metabolites  in  30  min  while  F.  hepatica 
metabolised Tcbz into its active metabolites following 60 min of incubation at a metabolic rate 
of 0.09 nmol min
 1 mg protein
 1. The high correlation between drug lipophilicity expressed as 
octanol water partition coefficients and drug availability measured within the parasite indicated 
that the parent compound as well as its active metabolites are absorbed by F. hepatica.  
 
The  maximum  concentrations  of  Tcbz sulphoxide  (Tcbz Sx)  and  Tcbz sulphone  (Tcbz Sp) 
observed  in  the  plasma  reached  maximum  concentrations  at  >  13 g/mL  at  18  and  36  hr 
respectively  (Hennessey  et  al.,  1987).  Active  Tcbz  metabolites  were  specifically  bound  to 
plasma albumin. In bile, major Tcbz metabolites were hydroxylated in the 4’ position and were 
secreted as sulphate esters and to a lesser extent, glucuronide conjugates. Conjugated hydroxy 
Tcbz Sx is the major biliary metabolite and can reach concentrations in excess of 40 g/mL in 
bile. 
1.7.2.2 Mechanism of action  
By binding directly to β tubulin, Bzs cause the depolymerization of cytoplasmic microtubules, 
subsequently  leading  to  the  disruption  of  microtubule based  processes.  Microtubules  are 
cytoskeletal elements involved in mitosis, intracellular transport and axonemal motility. The 
100 KDa  subunit  of  microtubule  is  tubulin,  comprising  of  a  heterodimer  of  α  and  β 
polypeptides (Dustin, 1984). The specificity of Bzs appear to be due to its higher affinity for 
helminth tubulin compared to mammalian tubulin (Lacey, 1988). Triclabendazole demonstrates 
high  efficacy  against  both  adult  and  juvenile  flukes  of  F.  hepatica,  F.  gigantica  and 
Fascioloides magna, but lacks activity against nematodes, cestodes and other trematodes (Boray 
et al., 1983; Smeal & Hall, 1983). Despite its widespread use and high levels of efficacy, the     Chapter 1 
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exact mechanism of action is unclear. The active sulphoxide of Tcbz was shown to effectively 
inhibit the movement of tegumental secretory bodies from the cell body to the apical surface of 
the  tegument  (Stitt  &  Fairweather,  1994),  leading  to  progressive  and  total  loss  of  worm 
tegument following 24 hrs of exposure in vitro (Stitt & Fairweather, 1993). In addition, Tcbz 
induced  inhibition  of  proteolytic  enzyme  secretion  in  F.  hepatica  has  been  attributed  to 
microtubule based secretory processes (Bennet & Köhler, 1987). The active metabolite of Tcbz 
also inhibits mitosis in the spermatogenic cells in the testis and the stem vitelline cells of F. 
hepatica. While the effect of Tcbz on energy producing pathways is yet to be established, a 
stimulation of acetate and propionate production was observed to coincide with reduced worm 
motility. Carr et al. (1993) also demonstrated that Tcbz and its metabolites have the ability to 
uncouple oxidative phosphorylation in rat liver mitochodria. The changes induced by Tcbz are 
typical of microtubule inhibition and are consistent with changes induced by tubulozole C and 
colchicine, both potent microtubule inhibitors.  Much of the data presented from morphological 
studies suggested that Tcbz caused microtubule disruption, although additional action against 
protein synthesis may also occur.  
 
Fetterer (1986) and Bennet & Köhler (1987) demonstrated the potential interaction of Tcbz with 
tubulin  from  F.  hepatica by  showing  competitive  binding  between Tcbz  and colchicine.  In 
addition, many studies investigating the effects of colchicine and tubulozole C on F. hepatica 
have demonstrated similar morphological changes to those observed with worms challenged by 
Tcbz (Stitt et al., 1992; Stitt & Fairweather, 1993; Stoitsova & Gorchilova 1997), suggesting 
that Tcbz acted via microtubule inhibition. Interestingly, studies have shown that Tcbz and 
tubulozole C  may  bind  to  the  same  site  on  β tubulin  compared  to  the  preferred  colchicine 
binding site of other Bzs (Fairweather & Boray, 1999). 
 
Consequently, further work with tubulozole C will be useful for determining not only the mode 
of action of Tcbz against Fasciola but also the mechanism of resistance. This is because Bz 
resistance in Haemonchus contortus is associated with the substitution of tyrosine at position     Chapter 1 
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200 of β tubulin isotype 1. This alters the three dimensional conformation of the protein and 
reduces the affinity of BZs for the target molecule (Kwa et al., 1994; Lubega & Prichard, 1991). 
Tubulin isolated from Tcbz sensitive and Tcbz resistant F. hepatica possesses a tyrosine residue 
at position 200 (Robinson et al., 2002), which suggests that Tcbz has a unique binding site and 
mode of action that is distinctive to other Bzs. It is possible that Tcbz resistance in Fasciola may 
arise from a similar β tubulin isotype variant selection mechanism as many eukarypotic species 
encode  more  than  one β tubulin  isotype (Brennan  et  al.,  2007).  However, it has  also been 
suggested that adult F. hepatica has the ability to convert triclabendazole sulphoxide into its 
relatively inert sulphone metabolite. Robinson et al. (2004) demonstrated that the production of 
triclabendazole sulphone  was  greater  within  Tcbz resistant  F.  hepatica  compared  with 
susceptible flukes. The study indicates that more than one mechanism of resistance may be 
conferred.  
 
1.7.2.3 Cytoskeletal proteins as Schistosoma drug targets 
The schistosome body wall is an essential host interactive layer involved in nutrition, immune 
evasion and modulation, excretion, osmoregulation, sensory reception and signal transduction 
(Jones et al., 2004). While the significance of cytoskeletons from eukaryotic cells has been 
emphasised in recent studies, schistosome cytoskeletal proteins are often overlooked as potential 
targets  for  chemotherapy  or  vaccine  research.  Intuitively,  cytoskeletal  molecules  do  not 
represent good targets for immune therapy due to their internal localization. Despite this, some 
schistosome cytoskeletal molecules can be involved in host humoral responses (Jones et al., 
2004) and may represent potential drug and/or vaccine targets. 
 
The  high  transcriptional  activity  of  cytoskeletal  and  motor  proteins  in  all  life  stages  of 
schistosomes  has  been  demonstrated  through  expressed  sequence  tag  (EST)  datasets 
(Prosdocimi et al., 2002; Verjovski Almeida et al., 2003; Hu et al., 2003). dbESTs indicated 
that schistosomes possess major components of a microtubular and actin based cytosekeletal 
system,  with  alpha,  beta  and  epsilon  tubulin  transcripts  well  represented  in  the  tegument     Chapter 1 
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(Verjovski Almeida et al., 2003; Hu et al., 2003; Duvaux Miret et al., 1991). Other proteins 
such  as  microtubule associated  motors,  actin,  microfilamented  associated  motors,  myosins, 
kinesins and dyneins were also highly expressed in the tegument.  
 
The lack of information on the tegumentary distribution of schistosome cytoskeletal proteins is 
largely  due to the unavailability  of  antisera  against schistosome  proteins  as  well  as a  poor 
understanding of the multi and syncytial nature of schistosome tissues (Jones et al., 2004). 
Microtubules  appeared  to  be  poorly  presented  within  the  distal  cytoplasm  of  the  tegument 
(Duvaux Miret  et  al.,  1991;  MacGregor  &  Shore,  1990).  The  cytoplasmic  bridges  of  the 
tegumentary  cytoplasm,  on  the  other  hand,  are  shown  to  possess  a  peripheral  ring  of 
microtubules.  Stabilized  microtubules  are  common  in  Platyhelminthes,  particularly  in  the 
nervous system, cilia and flagella, and sperm (Iomini et al., 1998; Hartenstein & Jones, 2003). It 
has  thus  been  suggested  that  this  microtubular  array  was  involved  in  anterograde  transport 
through the cytoplasmic bridges as the disruption of the micrtubular skeleton of schistosomes 
also disrupted surface expression of major components including some carbohydrates (Weist et 
al., 1988; Schmidt, 1998).  
 
The  potential  for  the  exploitation  of  cytoskeletal  molecules  in  anthelmintic  design  and 
vaccinology  was  suggested  by  Jones  et  al.  (2004).  While  data  concerning  microtubule 
disruption  by  microtubule  inhibitors  such  as  the  Bzs  are  fragmentary,  these  compounds 
appeared to disrupt anterograde transport in the tegument of cestodes and other digeneans but 
not in schistosomes (Schmidt, 1998). Following exposure to albendazole, the tegument of the 
trematode F. hepatica showed a marked increase in tubulin immunofluorescence, but lacking 
the ordered array of untreated microtubular cytoskeleton (Buchanan et al., 2003). This may have 
been due to the exposure of otherwise hidden antigenic epitopes on tubulin by albendazole. 
Alternatively,  this  increase  could  be  attributed  to  a  compensatory  microtubule associated 
secretory burst (Jones et al., 2004). Such studies are yet to be replicated on schistosomes.  
     Chapter 1 
  16   
1.8 Mass chemotherapy regimes for the treatment of schistosomiasis 
Significant advances in control of schistosomiasis has been achieved through education, snail 
control and sanitation management. However, the long term maintenance of these programmes 
is cost prohibitive. The introduction of single dose Pzq mass treatment appeared to be an ideal 
option.  In  1984,  the  WHO  implemented  mass  treatment  regimes  with  Pzq  as  the  major 
operational component due to its cost effectiveness and availability. There is also indication that 
different generic brands of Pzq may have varying levels of efficacy, and as such, may contribute 
to the development of resistance as a result of sub optimal dosing (Guyatt & Chan, 1998). 
Furthermore, most international agencies still procure Pzq on the basis of cost, despite growing 
concerns that insufficient credence is given to the efficacy evaluation of generic Pzq brands 
(Guyatt & Chan, 1998). Treatment and control is now largely reliant on the use of Pzq. The 
relative  success  of  this treatment  regime  has  prompted  efforts to  expand the use  of cheap, 
generic Pzq in endemic areas with high levels of parasite transmission (Hagan et al., 2004). 
However,  the  absolute  reliance  of  a  single  compound  for  control  may  have  indeterminate 
consequences on the epidemiology of disease (Colley et al. 2001; Raso, et al. 2004; Anon, 
2004). Indeed, there are significant shortcomings in disease treatment with Pzq. Despite the 
previous  successes  of  Pzq  control  programs,  schistosomiasis  is  spreading  into  new  areas 
(McManus & Loukas, 2008).  Praziquantel is also marketed as a racemate of the R and S 
isomers of which the R isomer is the only active enantiomer. The unnecessary administration of 
inactive isomers may increase the likelihood of drug side effects. Praziquantel is also ineffective 
against immature schistosomula (4 6 weeks) and can result in treatment failures and does not 
protect against re infections (Lawn et al. 2003; Cioli et al. 2003, McManus & Loukas, 2008). In 
addition, Pzq treatment is based on body weight and required distribution by trained personnels. 
This can increase operational costs of drug regimens, and ultimately limits its application in 
mass  chemotherapeutic  regimes.  Moreover,  early  suggestions  of  praziquantel  resistance  (or 
tolerance) and treatment failures have surfaced (Stelma et al., 1993, 1995; Guisse et al., 1997; 
Picquet et al., 1998; Alonso et al., 2006; Silva et al., 2005).  
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1.9 Refractoriness to praziquantel treatment 
Schistosoma resistance is defined  as  a significant  decrease  in  the response  of  a susceptible 
population to a schistosomicide (Coles & Kinoti, 1997). Specifically, the classic phenotype of 
drug resistance is defined as a significant increase in the 50% effective dose value of isolates 
retrieved from patients not responding to the drug (Ismail et al., 1999). Strong evidence exists to 
suggest  that  schistosomes  have  the  potential  to  evade  the  therapeutic  action  of  anti 
schistosomals (Rodger & Bueding, 1971).  Fallon et al. (1996) and Kusel & Hagan (1999) 
demonstrated  the  possibility  of  inducing  laboratory  resistance  by  selecting  for  parasites 
refractory to Pzq treatment. The first indication of Pzq resistance appeared in northern Senegal, 
where low cure rates were observed (Gryseels et al., 1994; Stelma et al., 1995). Additional 
evidence  was  presented  in  Egypt,  in  which  isolates  obtained  from  patients  unsuccessfully 
treated with Pzq was established in the laboratory. These isolates were subsequently shown to 
have a lower susceptibility to Pzq in vitro (Ismail et al., 1999) and in vivo (Bennett et al., 1997). 
There have also been reports demonstrating treatment failures with standard doses of 40mg/kg 
Pzq.  Dabo  et  al.  (2000)  showed  consistent  reinfection  of  children  with  S.  mansoni  and  S. 
hematobium,  despite  repeated  Pzq  treatment.  Wolfe  (2003)  reported  treatment  failure  for  a 
returned traveller infected with S. mansoni at 40mg/kg of Pzq.  Silva et al. (2005) also reported 
the therapaeutic failure of Pzq in the treatment of several S. haematobium infections. More 
recently,  Alonso  et  al.  (2006)  reported  repeated  treatment  failures  of  two  travellers  with 
genitourinary schistosomiasis using standard 40mg/kg of Pzq.  
 
1.10 Combination chemotherapy  
Drug combinations are increasingly being used for the treatment of parasitic diseases. Where 
resistance is conferred as a result of mutations in genes encoding drug targets, the application of 
combination therapy has sound scientific rationale (Nduati & Kamau, 2005). Provided that the 
mutations resulting in resistance reside in unlinked genes, the probability that a single parasite 
simultaneously carrying mutations to each of the drugs is remote, and is the product of the 
mutation rates to resistance for each individual drug in combination (White & Olliaro, 1996). In     Chapter 1 
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effect, the application of combination therapy enables the mutual protection of one inhibition 
mechanism by another, thereby extending the therapeutic lives of the components (White et al., 
1999). By exerting efficacy through independent mechanisms of action, drug combinations have 
the capacity to produce a quantitative effect that is greater than the sole additive effect of the 
combined drugs (Yeo et al., 1997).  
 
Drug  combinations  with  independent  mechanisms  of  action  were  first  developed  against 
tuberculosis  and  have  since  been  successfully  adapted  for  anti cancer,  AIDS/HIV  and 
antimalarial control (White et al., 1999). The aims of combinatorial treatments are to exert 
amplified effects at lower doses, which in turn, minimize drug side effects. Combination drug 
therapy can also enable the mutual protection of one inhibition mechanism by another, thereby 
extending the therapeutic lives of the components (White et al., 1999).   
 
A major strategy in the global effort to eliminate lymphatic filariasis is through the introduction 
of new drug combinations such as diethylcarbamazine, ivermectin and albendazole (Sunish et 
al., 2006). In particular, drug combinations have been widely adopted for the control of malaria, 
where multidrug resistance has rendered existing monotherapies useless in many parts of the 
world (Kremsner & Krishna, 2004). Drug combinations are a routine practice in the animal 
health sector. A combination of febantel, pyrantel and Pzq was shown to be highly effective for 
the treatment of giardiasis in dogs (Payne et al., 2002) and kittens (Scorza et al., 2005). In 
human  parasitic  infections,  a  combination  of  albendazole  and  ivermection  or  diethyl 
carbamazine, and between mebendazole and levamisole or pyrantel has been indicated for the 
treatment of soil transmitted helminths (Albonico, 2003; Utzinger & Keiser, 2004).  
 
The use of drug combinations against schistosomiasis has been explored more than two decades 
ago (Utzinger et al., 2003). A combination of Pzq and oxamniquine (Oxm) has been shown to 
reduce worm and egg burden in mice infected with S. mansoni and S. japonicum infections in 
two  separate  studies  (Pugh  &  Teesdale,  1983;  Shaw  and  Brammer,  1983).  However, 
inconsistencies in experimental methodologies suggested that therapeutic efficacies may have     Chapter 1 
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been  overestimated  (Utzinger  et  al.,  2003).  It  was  further  determined  that  the  similarity  in 
activities, half lives and stage specific susceptibilities of both Pzq and Oxm was unlikely to lead 
to  improved  outcomes.  More  recently,  Mattos  et  al.  (2007)  successfully  demonstrated  the 
efficacy of this combination on the intramolluscan phase of S. mansoni. The WHO has recently 
established protocols for Phase 1 clinical trials for a Pzq and Oxm combination (Mattock & 
Pink, 2005). A separate proposal has been established for the assessment of triclabendazole 
against  Schistosoma  and  Fasciola  co infections  (TDR,  2005).  Combinations  of  Pzq  and 
artemisinin derivatives have also been extensively studied (Xiao et al., 2000; Utzinger et al., 
2001; DeCelrcq et al., 2000; Borrman et al., 2001). An in vivo study by Shu hua et al. (2006) 
further demonstrated the utility of artemisinin Pzq combinations in the treatment of mice co 
infected  with  P.  berghei  and  S.  mansoni,  suggesting  that  artemisinin based  combination 
therapies may have ancilliary benefits against schistosomiasis. However, it has been suggested 
that  artemisinin based  combinations  should  not  be  administered  in  areas  where  both 
schistosome  and  plasmodium  co exist  to  prevent  the  development  of  resistance  to  malaria 
(Utzinger et al., 2003; Menar et al., 2005). This is particularly evident in light of reports that 
helminth  infections  (soil transmitted  helminths  and  S.  mansoni)  can  aversely  affect  clinical 
outcomes as well as enhances the incidence and severity of malaria infections (Nacher et al., 
2002, Spiegel et al., 2003, Sokhna et al., 2004). It is clear that rigorous monitoring of the effects 
of  artemisinin  is  warranted  when  used  for  malaria  control  in  settings  where  malaria  and 
schistosoma co exist (Shu hua et al., 2006).  Other limiting factors include high costs, limited 
knowledge  and  public  awareness,  limited  knowledge  on  efficacy  and  safety  in  pregnancy, 
operational  issues  such  as  indiscriminate  use,  lack  of  suitable  formulations,  lack  of  post 
marketing  surveillance  as well  as  an imbalance  between  supply  and  demand  (Mutabingwa, 
2005). 
 
1.11 Cost effectiveness of praziquantel for control 
Cost effectiveness analysis is the predominant type of economic evaluation for the assessment                                                  
of health care interventions relating to parasitic diseases (Walker & Fox Rushby, 2000). Cost     Chapter 1 
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effectiveness analyses play critical roles in assessing the most optimal option for the control of 
schistosomiasis through the evaluation of resource, social, ethical and political constraints. By 
assessing the gains (effectiveness) and resource input requirements (costs) of different methods 
of interventions in common natural units, the effectiveness of the objective can be evaluated. In 
light of budgetary limitations and logistical inadequacies in endemic and developing countries, 
cost effectiveness analyses can serve to determine the most effective means to deliver control 
strategies  and  ultimately,  to  strengthen  political  will  to  commit  these  funds.  While  cost 
effectiveness information primarily serves to guide policy and decision makers at the earliest 
stage of programme implementation, this information can also support the rational allocation of 
funds to more closely match the real funding need over time (Marseille et al., 2002). 
 
Guyatt et al. (1994) developed a framework for the evaluation of delivery strategies in the 
Kilombero District of Tanzania by comparing the primary health care system, the mobile team 
mass treatment system and the reagent strip testing system. Korte et al. (1986) compared the 
cost effectiveness of metrifonate regimens and Pzq regimens in the Peoples Republic of Congo 
and Mali. The study demonstrated that the feasibility and cost effectiveness of a single dose Pzq 
programme  compared  to  a  three  course  metrifonate  regimen  was  largely  due  to  lower 
operational costs. Yu et al., (2002) evaluated the feasibility of three Pzq treatment schemes and 
determined  that  the  treatment  of  patients  with  high  risk  activities  and  those  displaying 
symptoms are more cost effective than mass treatment programmes and treatment of positively 
screened patients by Kato Katz examination. Carabin et al. (2000) on the other hand, outlined 
the  importance  of  maximizing  treatment  potential  by  demonstrating  that  the  treatment  of 
children not enrolled in schools can also be cost effective.  
 
While some cost effectiveness data are available for conventional drug treatment regimes such 
as Pzq and metrifonate, there is only small body of information available that assess the cost 
effectiveness  of  applying  new  anti schistosomal  compounds  for  treatment.  Metrifonate,  an 
organophosphosphorus cholinesterase inhibitor, is administered in a three dose regime in two 
week intervals. In response to the surmounting market dominance of Pzq, narrow spectrum of     Chapter 1 
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activity and inadequate demand, metrifonate has been withdrawn from commercial production 
(Korte et al., 1986). Oxamniquine is the only other drug for treating schistosomiasis and is 
regularly administered in regions of high endemicity. However, its narrow spectrum of activity 
is confined to S. mansoni and is not effective against S. haematobium.  A synergistic effect has 
also  been  noted  when  the  Pzq  and  oxaminiquine  were  applied  in  combination.  However, 
resistance  and  potential  toxicity  has  resulted  in  increasing  tepidity  by  health  authorities  to 
administer Oxamniquine.  
 
The anti schistosomal properties of artemisinin and its derivatives were first described in the 
80s  (Le  et  al.,  1981).  The  two  main  derivatives,  artemether  and  artesunate,  showed  high 
efficacies  against  the  juvenile  stages  of  the  parasite  (Xiao,  2005).  Recent  studies  have 
demonstrated the feasibility of applying Pzq and the artemisinins in combinations, which results 
in  significant  worm  burden  reductions  (Utzinger  et  al.,  2003;  Utzinger  et  al.,  2001).  The 
prophylactic properties of the artemisinins have also been demonstrated at high doses with little 
side effects (Wu et al., 2003).  However, the widespread application of these compounds is 
unlikely due to prohibitive costs, multiple dosing regimens and possible selection for resistance 
for malaria through indiscriminate use in regions co endemic with malaria and schistosomiasis 
(White et al., 1999; Utzinger et al., 2001). 
 
More than 100 million doses of Pzq have been administered in China and Egypt alone (Chen, 
2005;  Fenwick  et  al.,  2003).  Dynamic  models  of  transmission  and  morbidity  have  been 
successfully applied to assess the effects of Pzq treatment programmes against target groups, 
coverage and frequency of treatments. Using a dynamic model of schistosomiasis transmission 
and morbidity to assess the correlation between drug efficacy and price, Guyatt & Chan (1998) 
demonstrated that the relative cost effectiveness of different combinations of drug efficacy and 
drug price did not appear to differ for drugs that possess moderate to high efficacies. Guyatt & 
Chan (1998) also emphasized the highly non linear relationship between drug efficacy and cost 
effectiveness. When drug efficacies are > 50 60%, the cost effectiveness ratios were lower and 
similar. Lower drug efficacies on the other hand, produced high and variable cost effectiveness     Chapter 1 
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ratios, particularly when programme costs related to distance travelled were high (Guyatt & 
Chan, 1998). This suggested that drugs possessing <50% efficacy should not be recommended 
for control, in view of drug resistance that are fostered by sub therapeutic use (Warren et al., 
1993). The non linear relationship suggested that an increase of drug efficacy for low efficacy 
drugs had a greater impact on cost effectiveness than an equivalent percentage reduction in the 
prices of more costly brands of Pzq.  
 
The price of Pzq varies widely between US$0.15 to US$0.60 per 600mg tablet (Guyatt & Chan, 
1998). The cost of a single course of treatment at 40mg/kg in 2003 was approximately US$0.30 
for an adult and US$0.20 for a child. Through school based or community directed systems, the 
average treatment cost for a child was an estimated US$0.50 per annum, including operational 
costs (Fenwick et al., 2003). The attractiveness of competitive prices and the successes of Pzq 
treatment regimes in the field have resulted in the adoption of large scale treatment programmes 
in other endemic regions. This will have a significant impetus on the demand for Pzq. The 
market  for  Pzq  is  expected  to  rise  substantially,  with  consumption  increased  to  40  million 
tablets  per  annum  provided  that the  price is  maintained and resistance  to  the  compound  is 
avoided.  
 
The delivery of mass Pzq regimes is based on a ‘blue print’ approach by adapting treatment 
programmes to different endemic areas. While this approach is advantageous in its simplicity 
and cost effectiveness, such strategies may result in the selection for drug resistance. This is 
best exemplified by the selection for anthelmintic resistance in veterinary health. It is important 
to note that while resistance to Pzq has not been demonstrated in the field, resistance to the drug 
has been successfully induced in the laboratory (Ismail et al., 1999; Bennett et al., 1997). The 
potential for the application of combination chemotherapy against schistosomiasis has not been 
explored. Utzinger et al. (2003) suggested that a combinational approach for schistosomiasis is 
feasible if partner drugs possess different modes of action to reduce the likelihood of resistance 
development.     Chapter 1 
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1.13 Aims and Hypothesis 
 
The aims of this study are: 
•  To determine the in vitro and in vivo efficacy of Tcbz against S. mansoni, 
•  To evaluate the effects of combinations of Pzq and Tcbz against S. mansoni. 
 
The hypotheses of this study are that: 
•  Triclabendazole and its metabolites are active against all life stages of the parasite, 
•  Triclabendazole and its metabolites show synergism when applied in combination with 
Pzq, 
•  Drug synergism between Pzq and Tcbz is reproducible in other parasite species, 
•  Combinations  of  Pzq  and  Tcbz  are  cost effective  for  treatment  of  human 
schistosomiasis.      Chapter 2 
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2.1 Growth Medium 
 
2.1.1 Schistosoma medium 169 composition 
 
Table 2.1: Composition of culture medium 169 for the in vitro cultivation of immature 
schistosomulum and maintenance of adult worm adapted from Basch (1981).   
   
Composition  Storage  Stock [ ]  Final [ ]  100mL  
BME  4°C  Liquid     To 100mL 
Lactalbumin hydrolysate  4°C  50x  1g/L  2mL 
Glucose   20°C  100x  1g/L  1mL 
Hypoxanthine   20°C  0.5mM  0.5 M  100 L 
Serotonin   20°C  1mM  1 M  100 L 
Insulin (crystalline)   20°C  8mg/ml  8 g/mL  100 L 
Hydrocortisone   20°C  1mM  1 M  100 L 
Triiodothyronine   20°C  0.2mM  0.2 M  100 L 
MEM vitamins   20°C  100x  0.5x  500 L 
Schneider’s medium  4°C  1x  5%  5mL 
Human Serum/FCS  20°C  1x  10%  10mL 
Hepes  20°C  1M  10mM  1mL 
NaHCO3  20°C  2.2g/L  26mM    
NaOH  20°C     pH 7.4    
Pen/Strep   20°C  10,000U/mL  300U/ml  3mL 
L glutatmine   20°C  100x     1mL 
 
2.1.2 Giardia medium composition 
Table 2.2: Composition of Giardia medium for the in vitro cultivation of Giardia duodenalis. 
 
Composition  Final quantity (1L) 
Ammonium ferric citrate (BDH)  0.01g 
Ascorbic acid (Sigma)  0.2g 
Biosate peptone (BBL)  30g 
Bovine bile (Sigma)  0.5g 
Cysteine hydrochloride (Sigma)  2.0g 
Monopotassium dophosphate (BDH)  1.0g 
Dipotassium phosphate (BDH)  0.6g 
Glucose (Ajax)  10g 
Sodium chloride (BDH)  2.0g 
DDI H2O  900mL 
New Born Calf Serum  100mL 
 
2.1.3 Haemonchus medium composition 
Table 2.3: Composition of Haemonchus medium for larval development assays. 
Composition  Final quantity (100mL) 
Amphotericin B  250 g/mL 
0.8% Saline  80mL 
Yeast extract  1g 
10x Earle’s balanced salt solution  1mL 
DDI H2O  19mL 
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2.2 Biomphalaria glabrata maintenance 
The  intermediate  snail  host,  Biomphalaria  glabrata  (B.  glabrata)  was  obtained  from  the 
Queensland  Institute  of  Medical  Research  (QIMR).  The  original  Puerto  Rican  isolate  was 
sourced from  National  Institute  of  Allergy  and  Infectious  Disease (NIAID)  Schistosomiasis 
Resource Centre. Approximately 50 breeding snails were maintained at any one time in each 
60cm x 30cm x 30cm polystyrene maintenance containers at 25°C on a 12hr light and 12hr dark 
cycle in aquaria containing DDI H2O conditioned with CaCO3 chips (fortified H2O). Snails were 
fed with fresh lettuce leaves ad libitum (Loker & Hertel, 1987). Biomphalaria glabrata infected 
with S. mansoni miracidium were kept separated from uninfected snails. Not more than 50 
infected snails were maintained in each polystyrene container. To minimize exposure to light 
and heat, infected snails were kept in the dark. 
 
2.3 Biomphalaria glabrata infection with miracidium 
The livers from five mice infected with S. mansoni were removed and rinsed thrice in PBS. The 
livers were then macerated to a fine consistency, transferred to 50mL sterile conical tubes and 
suspended in cold PBS.  The mixture was centrifuged at 2000 x rpm on an Eppendorf 5810R 
rotor for 10s and the supernatant removed. Subsequently, the homogenate is resuspended in 
calcium  carbonate fortified  H2O  at  25°C  and  transferred  to  50mL  measuring  cylinders. 
Measuring cylinders were blackened on the sides, leaving the top 5cm of the cylinder exposed 
to allow hatched miracidia to swim to the surface for observation. The liver suspension was then 
transferred into the cylinders and exposed to light from a 100Watt desk lamp for 30min. Twenty 
mature B. glabrata were removed from the maintenance tanks and washed thrice with H2O. 
Snails  were  separated  into  individual  wells  of  a  48 well  culture  plate  (Nunc™,  Roskilde, 
Denmark) filled with 1mL of fortified H2O. Ten miracidia were then pipetted into each well for 
infection and consistently monitored overnight. Following infection with miracidia, the snails 
were gently transferred into a new maintenance tank. The snails were then closely monitored for 
35 days post miracidial infection. 
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2.4 Cercarial shedding  
Cercariae was recovered from snails 35 days following infection with miracidia. All infected 
snails were gently removed and washed thrice in fortified H2O to remove excess food and fecal 
matter. The snails were then transferred into a 50mL beaker and exposed to light and heat under 
a 100 Watt desk lamp for no more than 5min. The beaker was then immediately filled with 
20mL of fortified H2O at 25°C and exposed to light for approximately 30min. Cercariae were 
recovered and enumerated microscopically. 
 
2.5 Infection of definitive mouse host 
Six wks female ARC Swiss outbred mice were used as definitive mammalian hosts. Prior to 
infection, each mouse was weighed and the abdominal region shaved to allow access by S. 
mansoni  cercariae.  Each  mouse  was  subsequently  anaesthetized  with  a  mixture  of  xylazine 
(20mg/kg), ketamine hydrochloride (100mg/kg) and DDI H2O at a 1:1:10 ratio. One hundred 
fifty  L of the mixture was given per 10g of mouse by intraperitoneal injection using a 21G 
needle. Following anesthesia, each mouse was individually restrained on a heat pad using tape. 
A 30mm diameter brass ring was placed on top of the shaven abdominal patch to contain the 
infective  cercariae.  Exactly  120  cercariae  were  then  pipetted  into  the  brass  ring  of  each 
anaesthetized mouse for infection. Mice were exposed and anesthetized for no more than 1hr.  
 
2.6 In vitro cultivation of immature schistosomulum 
Cercariae were shed according to 2.4 and collected in 50mL sterile conical tubes. The tubes 
were chilled on ice for 20min and centrifuged at 350 x g for 5min at 4°C. The top 45mL of 
supernatant was removed and the pellet was resuspended in 25mL of cold ELAC wash medium. 
The  tubes  were  then  gently  shaken  and  chilled  on  ice  for  10min.  The  tubes  were  then 
centrifuged at 350 x g for 5min at 4°C and the wash repeated twice. The cercarial pellet was 
resuspended in 10mL of cold E/LAC and drawn into a 50mL Luer Lock syringe for mechanical 
transformation using a 22G microemulsifying needle. With the microemusifying needle firmly 
screwed to another 50mL Luer Lock syringe, the suspension was emulsified by pushing back     Chapter 2 
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and forth for at least 25 times. The cercariae suspension was then emptied into a fresh sterile 
50mL conical tube and incubated for 15min at 37°C. The top 10mL of the cercarial tail rich 
supernatant was removed and the remaining supernatant made up to 10mL with fresh warmed 
medium 169. The mixture was then incubated for 10min at 37°C. The top 8mL of the cercarial 
tail rich supernatant was then removed and the remaining supernatant made up to 10mL with 
fresh warmed medium 169. The resulting suspension was incubated for a further 5min at 37°C 
and the top 8mL of supernatant removed. The schistosomulum suspension was then made up to 
10mL with warmed medium 169 and transferred into 6mL culture wells (Nunc™, Roskilde, 
Denmark). The schistosomule culture medium was incubated at 37°C in an atmosphere of 5% 
CO2 in air and was replaced with fresh media daily. Any dead schistosomules were immediately 
removed from the medium.  
 
2.7 Schistosoma egg extraction from liver 
Schistosoma mansoni and S. japonicum eggs were isolated from liver tissue according to the 
protocol outlined by Dalton et al. (1997). Schistosoma japonicum livers were obtained from 
infected  mice  routinely  maintained  at  the  QIMR.    Livers  from  three  mice  infected  with  S. 
mansoni and three mice infected with S. japonicum were removed following perfusion and 
macerated to a smooth consistency. The macerated liver was then resuspended in PBS and 
decanted into 50mL Falcon tubes. Twenty mg of collagenase B (Sigma Aldrich, USA), 100 L 
of penicillin (10 g) and 100 L (20 g) of streptomycin was added and the mixture incubated 
overnight with shaking at 37°C. Following incubation, the tube was centrifuged at 400xg for 
5min and the supernatant removed. The pellet was resuspended in 50 mL of fresh cold PBS and 
the wash procedure repeated twice. The pellet was then reconstituted in 25mL PBS, passed 
through a 250 m sieve, followed by a 150 m sieve. The filtrate was re centrifuged at 400 x g 
for  5min,  and  the  supernatant  discarded.  The  pellet  was  resuspended  in  3 mL  of  PBS  and 
applied gently to the top of a Percoll (Sigma Aldrich, USA) gradient prepared by mixing 8mL 
of Percoll with 32mL of 0.25M sucrose in a 50mL Falcon tube. The tube was centrifuged at 
800xg for 10mins and the liver cells suspended at the top of the gradient removed. Pelleted eggs     Chapter 2 
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were  gently  transferred  using  sterile  pasteur  pipettes  and  washed  thrice  with  PBS.  Further 
purification of the eggs  were  achieved  by  resuspension  in  0.5mL  of  PBS,  with  subsequent 
application to a second Percoll gradient, prepared by mixing 2.5mL of Percoll with 7.5mL of 
0.25M sucrose in a 10mL polypropylene tube. The wash procedure was repeated as before and 
the eggs subsequently resuspended in 1mL cold PBS. Schistosoma eggs were stored in a 1.5mL 
microfuge tube at 4°C until required. 
 
2.8 Haemonchus egg extraction from faeces 
Five hundred grams of faeces was collected from 3 sheep infected with H. contortus. Faeces 
were suspended in 600 mL of DDI H2O and two table spoons of kaolin and macerated to a fine 
consistency. The mixture was made up to 1L with DDI H2O and centrifuged at 1,500 x rpm for 
15min at 5°C using an Eppendorf 5810R centrifuge. Following centrifugation, the top layer of 
fecal debris was removed gently and the middle layer of material decanted into a sieve (710 m). 
The filtrate was passed through another sieve (150 m) and the sieve washed with DDI H2O. 
The process was repeated twice more using 80 m and 25 m sieves. The final 200mL of filtrate 
was collected in sterile 50mL Falcon tubes and centrifuged at 3000 x rpm for 5min at room 
temperature using a Kokusan STAT H103 N (RF120 rotor) centrifuge. The top 25mL of the 
suspension was gently removed. One teaspoon of kaolin was added and the mixture made up to 
50mL with 1.275SG saturated sucrose solution. The mixture was recentrifuged at 3000x rpm for 
5min at room temperature using a Kokusan STAT H103 N (RF120 rotor) centrifuge. The top 
20mL of suspension was gently removed and filtered using a 0.22 m filter. The filter was then 
washed repeatedly with DDI H2O. Eggs were then collected reverse flushing the filter paper 
with DDI H2O. Purified eggs were stored at 4°C and used the following day.  
 
2.9 In vitro drug evaluation 
2.9.1 In vitro drug evaluation against immature schistosomulum 
Immature  schistosomules  were  transformed  as  described  in  2.1.5.  Immature  schistosomules 
were maintained in medium 169 for four weeks post transformation. Exactly 30 schistosomula     Chapter 2 
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were transferred into duplicate wells of 48 well culture plates (Nunc™, Roskilde, Denmark). 
One  hundred  times  (x)  or  fold  stock  concentrations  of  Pzq,  Triclabendazole  (Tcbz), 
triclabendazole sulphoxide (Tcbz Sx) and triclabendazole sulphone (Tcbz Sp) were diluted in 
DMSO to make final concentrations of 100 g/mL, 80 g/mL, 40 g/mL, 20 g/mL, 10 g/mL 
and 5 g/mL in medium 169. DMSO concentration in both treated and control wells were ≤ 
0.1% v/v. Cultures were then exposed to individual concentrations of the drugs for 24hrs. After 
24hrs of drug exposure, the drug treated worms were then washed thrice in warmed medium 
169.  The  schistosomulum  was  then  transferred  into  new  48 well  culture  plates  filled  with 
warmed  medium  169  and  monitored  by  light  microscopy  for  seven  days.  Morphological 
changes following drug exposure were monitored at two hourly intervals by light microscopy. 
Real time  video  were  captured  using  a  Sony  HandyCam™  (DCR HC40E)  connected  to  a 
Panasonic Color CCTV Camera (Model WV CP610/G), which was subsequently attached to an 
Olympus CKX41 Compound Microscope. 
 
2.9.2 In vitro drug evaluation against mature worms 
Twenty five 49 day old infected mice were injected with 100uL heparin (Sigma Aldrich, USA) 
and perfused using cold PBS. Exactly 10 adult worms  were distributed in duplicate 6 well 
culture plates (Nunc™, Roskilde, Denmark) in medium 169. Cultures were maintained at 37°C 
in  an  atmosphere  of  5%  CO2  in  air  and  acclimatized  for  at  least  a  week  prior  to  the 
commencement of drug screening. Duplicate cultures were then exposed to both Pzq and Tcbz 
for 24hrs and monitored at one hourly intervals. Cultures were then washed thrice in medium 
169 following 24hrs exposure and transferred to new 6 well culture plates containing warmed 
drug free medium 169. The worms were further assessed 48hrs and 72hrs post drug exposure. 
Worms  were  defined  ‘dead’  if  worms  remained  contracted  and  remained  immotile. 
Morphological changes following drug exposure were monitored at two hourly intervals using 
OPTIMAS
. Pzq stock solutions in DMSO were made to the following concentrations: 100 M, 
30 M, 10 M, 1 M and 0.3 M. Tcbz, Tcbz Sx and Tcbz Sp stock solutions in DMSO were     Chapter 2 
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made  to  the  following  concentrations:  300 M,  100 M,  30 M,  10 M  and  3 M.  The  final 
concentration of DMSO in Medium 169 was ≤ 0.1%. 
 
2.10 Evaluation of combination drug treatment 
2.10.1 Evaluation of drug combinations against Schistosoma mansoni 
The synergistic action of Pzq and Tcbz sx was assessed against both immature and mature 
stages of S. mansoni. Ten mature worms or 30 immature schistosomulum in duplicate 6 well 
culture plates (Nunc™, Roskilde, Denmark) filled with 1mL of medium 169 were assessed with 
both Tcbz and Pzq at one hour intervals following drug combination exposure for an exposure 
period  of  24hrs.  Worms  were  continuously  monitored  at  48  hours  and  72hrs  post drug 
combination  exposure.  For  isobologram  analysis,  the  EC50,  EC25  and  EC10  values  were 
determined from the dose response curves of worms treated with Pzq and Tcbz sx. The stock 
solutions of both drugs were made to give final concentrations for nine combinations of the 
EC50, EC25 and EC10 values in medium 169. The final DMSO concentrations in medium 169 
were  ≤  0.2%  in  both  exposed  and  control  wells.  Cultures  were  exposed  for  24hrs  and 
enumerated. Cultures were then washed thrice in medium 169 following 24hrs exposure and 
transferred to new 6 well culture plates containing warmed drug free medium 169. Further to 
efficacy assessment at 24hrs post drug exposure, the worms were also enumerated at 48hrs and 
72hrs post exposure time points. 
 
2.10.2 Evaluation of drug combinations against Giardia duodenalis 
Giardia duodenalis (G. duodenalis) strain P1c10 was subcultured in Giardia media for at least 
seven days prior to the commencement of drug screening. A total of 25,000 trophozoites were 
enumerated by haemocytometer and subsequently seeded in triplicates into 10mL Nunc™ Flat 
sided polystyrene tubes. One hundred x stock solutions of Pzq, Tcbz, Tcbz sx and Tcbz sp were 
made in DMSO to give final concentrations of 100mM, 10mM, 1mM, 100 M, 10 M, 1 M, 
100nM and 10nM in Giardia media. Cultures exposed to drugs were washed with sterile warm 
PBS and replaced with warmed Giardia media and enumerated using the OPTIMAS
® system of     Chapter 2 
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adherence inhibition (Bong et al., in preparation). The OPTIMAS
® system is a cellular and 
particle enumeration software adapted for the assessment of cell numbers in liquid media. To 
assess for synergistic drug interactions, the EC50, EC25 and EC10 values were determined from 
the individual dose response curves. The stock solutions of both drugs were made to give final 
concentrations for nine combinations of the EC50, EC25 and EC10 values in Giardia media. The 
final DMSO concentrations in Giardia Medium were ≤ 0.2% in both exposed and control wells. 
Cultures exposed to  drugs  were  washed  with sterile  warm  PBS  and  replaced  with  warmed 
Giardia media and enumerated by measuring cells that remained adhered following exposure. 
 
2.10.3 Evaluation of drug combinations against Haemonchus contortus  
Benzimidazole susceptible  and  resistant  Haemonchus  contortus  (H.  contortus)  eggs  were 
screened  using  the  larval  development  assay  developed  by  Animal  Health  Laboratories, 
Department of Agriculture and Food, Western Australia. Eggs were extracted from H. contortus 
infected sheep routinely maintained by the Western Australia Department of Agriculture and 
Food. Approximately 100 eggs were transferred into individual wells of a 96 well microtitre 
plate made up to 100 L with 10 L Haemonchus nutrient media and DDI H2O. The drug stock 
solutions were prepared to give final concentrations of 1mM, 100 M, 10 M, 1 M, 0.1 M and 
0.01 M  in  nutrient  media.  Assays  were  performed  in  triplicates  to  ensure  statistical 
significance. The final DMSO concentration in culture was ≤ 1%. Upon drug exposure, culture 
plates were incubated at 25°C and monitored daily. Upon growth of the larvae to the L3 stage, 
the  worms  were  killed  with  iodine  and  enumerated  using  an  Olympus  BH2  compound 
microscope.  
 
Prior to the commencement of synergistic drug studies, the EC50, EC25 and EC10 values were 
determined from the individual dose response curves. The stock solutions of both drugs were 
made to give final concentrations for all nine combinations of the EC50, EC25 and EC10 values in 
Haemonchus media. Cultures were established as in 2.9.1, with the exception that the final 
DMSO concentration in media was ≤ 2%. Cultures were then incubated at 25°C and monitored     Chapter 2 
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daily. Upon growth of the larvae to the L3 stage (one wk), the worms were killed with 10% 
iodine and enumerated using an Olympus BH2 compound microscope.  
 
2.11 Evaluation of drug action against Schistosoma eggs 
Eggs  were  extracted  from  liver  according  to  2.7.  Exactly  10  eggs  were  enumerated  and 
transferred  into  triplicate  wells  of  Falcon
®  Multiwell™  24 well  culture  plates  (Becton 
Dickinson, USA). Individual culture wells were made up to 1mL with PBS. Pzq, Tcbz, Tcbz Sx 
and Tcbz Sp stock solutions in DMSO were made to give final concentrations of 1mM, 100 M, 
10 M, 1 M, 0.1 M and 0.01 M. 
 
2.11.1 Assessment of praziquantel induced hatching of eggs 
Ten mature and viable S. mansoni or S. japonicum eggs were transferred into triplicate wells of 
Falcon
® Multiwell™ 24 well culture plates (Becton Dickinson, USA). The temporal hatching 
pattern of S. mansoni and S. japonicum eggs after exposure to Pzq was quantified using a stop 
watch according to the following criterion: ‘time to activation’ and ‘time to hatch’. The time to 
activation was defined as the time from which a concentration of Pzq induced the first sign of 
movement of ‘activation’ within the eggs. Time to hatch was defined as the total time in which 
the miracidium detaches/hatches completely from the egg and the vitelline membrane. Real 
time video were captured using a Sony HandyCam™ (DCR HC40E) connected to a Panasonic 
Color CCTV Camera (Model WV CP610/G), which is subsequently attached to an Olympus 
CKX41 compound microscope.  
 
2.11.2 Assessment of triclabendazole and its metabolites on egg viabiliy 
Ten mature and viable S. mansoni or S. japonicum eggs were transferred into triplicate wells of 
Falcon
®  Multiwell™  24 well  culture  plates  (Becton  Dickinson,  USA).  Following  drug 
inoculation, culture plates were incubated for 24hrs at room temperature. The eggs were then 
transferred into fresh wells filled with DDI H2O. Hatching was induced by light exposure at 
room  temperature  and  subsequently  enumerated  under  an  Olympus  CKX41  compound     Chapter 2 
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microscope.  The inhibition of hatching was measured as the proportion of eggs that remained 
unhatched in DDI H2O after exposure to drugs for 24 hrs. 
 
2.12 Dose response and statistical analysis  
Dose response analysis was performed using GraphPad Prism 4 and the EC values calculated as 
follows: [(control negative – control treated) / control negative] x 100%. The standard error and 
the 95% confidence interval (C.I.) of dose response curves were determined using Prism v. 4 
(GraphPad, California).                                                                                                                                          Chapter 3 
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3.1 Introduction 
 
Schistosomiasis is the most important water borne pathogen of humans, infecting more than 207 
million people annually in 74 countries (Steinmann et al., 2006). The drug of choice for the 
treatment of schistosomiasis is praziquantel (Pzq), a pyrazinoisoquinolone shown to be active 
against various cestodes and trematodes. The widespread application of Pzq is underpinned by 
mass  chemotherapeutic  programmes  that  have  been  moderately  effective,  but  may  not  be 
sustainable in the long term. In spite of its relative success, Pzq has inherent shortcomings that 
limit its utility in the field. Moreover, there have been suggestions that the efficacy of some 
generic  brands  of  Pzq  may  be  less  than  50%  efficacy  due  to  unregulated  manufacturing 
practices (Guyatt et al., 1998). The indiscriminate application of suboptimal drug formulations 
may result in lower treatment rates and selection for Pzq resistance. 
  
The  benzimidazole  class  of  compounds  holds  considerable  promise  as  potential  anti 
schistosomals  (el  Sayed &  Allam,  1997).  While most  benzimidazoles  have  broad  spectrum 
activities,  a  few  benzimidazole  derivatives,  such  as  triclabendazole  (Tcbz),  possess  narrow 
spectrum action. Triclabendazole is currently indicated for treatment of livestock infected with 
Fasciola hepatica (F. hepatica) and F. gigantica (Fairweather & Boray, 1999). It is believed 
that Tcbz  exerts  its effects  through  the inhibition  of  microtubule formation (Fairweather  & 
Boray, 1999). In trematodes, the cytoskeleton is thought to play crucial roles in maintaining 
tegumental architecture and the transport of tegumental granules, which are directly involved in 
the synthesis and turnover of the surface membrane and its outer coat (Fairweather & Boray, 
1999). 
 
There are conflicting reports on the efficacy of Tcbz and its metabolites in the literature. El 
Sayed & Allam (1997) reported that Tcbz has high efficacy in vitro.  However, a separate study 
by Keiser et al. (2006) demonstrated that Tcbz and its two metabolites displayed weak and 
inconsistent activities in mice infected with S. mansoni. The study showed that single doses of                                                                                                                                         Chapter 3 
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400mg/kg of Tcbz, Tcbz sulphoxide and Tcbz sulphone failed to reduce hepatic and intestinal 
tissue egg loads, resulting in only a 35.5% reduction in worm burden (Keiser et al. 2006). This 
is in contrast to a study performed by Khalil (2000), who showed a worm burden reduction of 
84%.  The  authors  suggested  that  host  pharmacokinetics  may  be  critical  for  explaining  the 
different susceptibilities observed (Keiser et al., 2006). 
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3.2 Materials and Methods 
3.2.1 Schistosoma mansoni maintenance 
A Puerto Rican strain of S. mansoni was used for this study. Parasites were maintained in 
laboratory reared B. glabrata snails and perpetuated in 6 wk female ARC/Swiss outbred mice. 
Mechanical  transformation  of  cercariae  into  immature  schistosomulum  was  performed 
according to established methods (Ramalho pinto et al., 1974; Basch, 1981; Lazdins et al., 
1982; Pica Mattoccia & Cioli; 2003) and cultured for at least four wks prior to drug screening. 
Mice  were  infected  with  120  cercariae  precutaneously.  Infected  mice  were  subsequently 
sacrificed  49 days  after  cercarial  exposure  and  adult  worms  were  recovered  via  hepatic 
perfusion. Detailed methodology is available in Chapter 2: General Materials and Methods. 
 
3.2.2 Drug treatment 
Praziquantel  (Pzq),  triclabendazole  (Tcbz),  triclabendazole sulphoxide  (Tcbz Sx)  and 
triclabendazole sulphone (Tcbz Sp) were provided by Epichem Pty Ltd. Drugs were prepared in 
dimethyl sulphoxide (DMSO) as 100 x stock solutions. One  L of each drug stock solutions 
were  diluted  in  1mL  of  medium  169  to  give  final  concentrations  of  10 M,  30 M,  50 M, 
100 M, 200 M and 300 M for evaluation against immature worms. Similarly, one  L of each 
drug stock solutions were diluted in medium 169 to give final concentrations of 10 M, 30 M, 
100 M, 150 M, 200 M and 300 M for evaluation against mature worms. The final DMSO 
concentration in treated and control well was ≤ 0.1% v/v.  
 
Following  drug  exposure  after  24hrs,  worms  were  washed  thrice  with  fresh  medium  169, 
replaced  in  wells  filled  with  fresh  medium  169  and  enumerated  microscopically.  For 
transformed immature schistosomula, drug effects were assessed daily for seven days post 
exposure against 30 immature schistosomula in duplicate culture wells. For adult worms, drug 
effects were exposed for 24hrs and assessed at 24hrs, 48hrs and 72hrs after drug exposure 
against 10 mixed sex worms in duplicate culture wells. Both studies were performed according                                                                                                                                         Chapter 3 
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to the methodologies outlined by Pica Mattoccia & Cioli (2003). Morphological changes were 
monitored by light microscopy and images obtained using OPTIMAS
 image analysis software.  
 
3.2.3 Drug efficacy scores 
The effects of drugs against mature worms were performed according to the following scoring 
criteria: 4 (no contraction, movement throughout entire body), 3 (mobile in parts of body and 
contracted), 2 (contracted and immotile) and 1 (maximally contracted and immobile). At the end 
of the observation period, immature and mature worms were defined as ‘dead’ if they remain 
contracted, immotile and appeared opaque (Score 2 and Score 1). 
 
3.2.4 Dose response and statistical analysis 
Drug efficacy was assessed by comparing the mean number of worms in the control versus the 
treated group. The % worm mortality at each drug concentration assessed was calculated as 
follows:    [(control  untreated  worms  –  control  treated  worms)  /  control  untreated  worms]  x 
100%. The 95% confidence intervals and EC50 values determined using Prism v. 4 (GraphPad, 
California).  
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3.3 Results 
3.3.1 Efficacy of triclabendazole against immature schistosomulum 
Transformed schistosomula remained viable in medium 169 for 48hrs before the first signs of 
mortality were observed. An estimated mortality of 20% was observed each week from Wk 1 
through  to  Wk  five.  Intestinal  pigments  were  evident  within  the  first  week  in  transformed 
schistosomula, with the stage of development (Stage 15) and length (2mm) at Wk 4 consistent 
with the observations of Basch (1981). Immature schistosomula were used for drug screening at 
Wk 4. Natural (non drug induced) mortality was taken into consideration by enumerating only 
surviving schistosomula in control wells following each time assessment period.  
 
One hundred % mortality of immature schistosomula was observed within 24hrs at the highest 
concentrations of Tcbz (300 M, 200 M and 100 M). Dose dependent effects were observed in 
immature  schistosomula  exposed  to  Tcbz.  Contraction  followed  by  paralysis  was  observed 
within the first 30min of exposure to ≥ 100 M of Tcbz. Schistosomulum showed evidence of 
severe morphological damage including pronounced ‘mottling’, loss of motility and increasing 
opaqueness. At doses above 30 M, morphological deformities and the loss of cellular integrity 
was  evident,  with  progressive  shortening  (or  contraction)  of  the  schistosomulum  as 
concentration increased (see Figure 3.2). At lower concentrations (10 M), Tcbz continued to 
exert anti schistosomal effects such as blebbing and contractions. The severity of morphological 
damage increased up to four days after drug exposure, with EC50 values remaining consistent 
from four to seven days of exposure.                                                                                                                                          Chapter 3 
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Figure 3.1: Dose response curve of triclabendazole evaluated against immature schistomulum 
at Week four stage and assessed for seven days after exposure.  
 
The concentration of Pzq required to kill 50% of immature S. mansoni (EC50) was 65.2 M. 
Praziquantel treated worms showed signs of mottling and widespread tegumental damage at the 
highest concentration assessed of 300 M. All immature schistosomula exposed to 300 M were 
contracted  and  dead.  At  lower  concentrations,  tegumental  damage  was  less  evident, 
characterized  by  only  50%  mortality  at  concentrations  of  100 M  and  below.  No  further 
increases in worm mortality were observed after drug exposure and media change at 24hrs.  
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Table 3.1: The concentration of triclabendazole (Tcbz) and praziquantel (Pzq) required to kill 
50% (EC50) of Wk four immature schistosomula in vitro and examined for seven days after drug 
exposure. 
 
 
                              EC50 concentration ( M) 
   
Day 1 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
Tcbz   40.3  27.4  18.8  18.8  17.7  17.7  17.7 
Pzq   65.2  65.2  65.2  65.2  65.2  65.2  65.2 
 
There  was  no  significant  differences  between  the  EC50  value  for  Tcbz  evaluated  against 
immature schistosomula over the period of seven days (P>0.05). The EC50 value for Tcbz were 
significantly lower compared to Pzq (P< 0.05).                                                                                                                                          Chapter 3 
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Figure 3.2: Morphological changes 
observed in four wk old immature 
schistosomulum exposed to varying 
concentrations of triclabendazole in 
vitro for seven days.  
 
A:  Untreated  four  wk  old  immature 
schistosomulum (100 ×)  
B:  Untreated  four  wk  old  immature 
schistosomulum (400 ×) 
C:  Four  wk  old  immature 
schistosomulum treated  with 100 M 
praziquantel (400 ×) 
D:  Four  wk  old  immature 
schistosomulum  treated  with  1 M 
triclabendazole (400 ×) 
E:  Four  wk  old  immature 
schistosomulum  treated  with  3 M 
triclabendazole (400 ×) 
F:  Four  wk  old  immature 
schistosomulum  treated  with  10 M 
triclabendazole (400 ×) 
G:  Four  wk  old  immature 
schistosomulum  treated  with  30 M 
triclabendazole (400 ×) 
H:  Four  wk  old  immature 
schistosomulum treated  with 100 M 
triclabendazole (400 ×) 
I:  Four  wk  old  immature 
schistosomulum treated  with 300 M 
triclabendazole (400 ×) 
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3.3.2 Efficacy of triclabendazole and metabolites against mature worms 
Dose dependent  effects  were  observed  in  immature  schistosomula  exposed  to  Tcbz  and  its 
metabolites. Morphological changes induced by Tcbz, Tcbz Sx and Tcbz Sp are illustrated in 
Figure 3.7, 3.8 and 3.9 respectively. There was evidence of precipitation at 300 M of Tcbz, 
Tcbz Sx and Tcbz Sp. Triclabendazole sulphoxide and Tcbz Sp were more soluble in culture 
media 169.  Within the first hour, worms treated with Tcbz, Tcbz Sx and Tcbz Sp exhibited 
immediate contraction and assumed a tightly coiled appearance (Score 2). Worms treated with 
100 M of each compound showed immediate and spasmodic contraction, but remained motile 
for a further three hours. After four hours of drug exposure at 300 M and 100 M of each 
compound,  treated  worms  showed  maximal  contraction  (Score  1)  and  were  ‘mottled’  in 
appearance, with ‘blebbing’ and vacuole formation disseminated along the entire tegumental 
body. Gut movement and peristalsis were lost in treated worms, with the collapse of the ventral 
and oral suckers, ultimately losing structural integrity eight hours after exposure.  
 
At lower concentrations (50 M, 30 M), contraction of worms was evident but motility was 
maintained (Score 3) in most treated worms. At 10 M, worms immediately contract when drugs 
were added but recover after four hours. No morphological damage or loss of motility was 
observed for worms exposed to 3 M of Tcbz and its metabolites (Score 4). The gynaecophoreal 
groove of all treated male worms (except those exposed to 3 M of Tcbz and its metabolites) 
assumed  an  ‘unfurled’  appearance  with  female  worms  demonstrating  stronger  contractions 
compared to male worms. All treated worms (except those exposed to 3 M of Tcbz and its 
metabolites)  were  detached  from  the  bottom  of  the  culture  wells  after  drug  exposure,  and 
remained so for the entire assessed period of 24, 48 and 72hrs. A proportion of worms exposed 
to  10 M  recovered  and  resumed  motility  (Score  3)  when  fresh  media  was  added. 
Triclabendazole Sx and Tcbz Sp appeared to induce effects more rapidly compared to Tcbz,                                                                                                                                         Chapter 3 
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with persistent effects noted at 48hrs and 72hrs after drug exposure. All worms in the control 
wells remained motile, uncontracted (Score 4) with retained structural integrity.  
 
Dose dependent  effects were observed  in  worms  within 30mins  of  exposure  to  Pzq.  Strong 
contractions were observed in worms exposed to Pzq concentrations greater than 10 M (Score 
2).  Weak  contractions  (Score  3)  were  observed  in  worms  at  lower  concentrations.  Treated 
worms showed evidence of coiling, blebbing and vacuolization of the tegument. Worms treated 
at the highest Pzq concentrations of 100 M and 30 M demonstrated maximal contractions only 
after eight hours of exposure, with no evidence of recovery when media was changed. Some 
worms exposed to 3 M, 1 M and 0.3 M of Pzq regained motility after medium wash and fresh 
media replacement. Morphological effects induced by Pzq are illustrated in Figure 3.10. Control 
and  untreated  worms  in  DMSO  can  be  observed  in  Figure  3.11.  Table  3.2  shows  the 
concentrations of Pzq, Tcbz, Tcbz Sx and Tcbz Sp required to kill 50% of adult S. mansoni. 
 
Table 3.2: Effective concentration required to kill 50% (EC50) of adult Schistosoma mansoni 
worms at four hour time intervals.  
 
Concentration ( M) 
 
Time (hrs)  Tcbz  Tcbz Sx  Tcbz Sp  Pzq 
0  0  0  0  0 
4  188.9   137.8   223.5   6.136  
8  122.1   123.7   205.3   3.821  
12  90.6   100.8   193.8   1.898  
16  88.2   77.9   193.8   1.539  
20  88.22  70.4   96.5   1.266  
24  74.2   68.3   91.8   1.266  
48  102.6   55.3   176.2   1.266  
72  102.6  43.2  164.9  1.266                                                                                                                                         Chapter 3 
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Figure  3.3:  Dose  response  curve  for  praziquantel  assessed 
against mature worms at 24, 48 and 72 hrs post exposure.  
Figure 3.4: Dose response curve for triclabendazole assessed 
against mature worms at 24, 48 and 72 hrs post exposure.                                                                                                                                          Chapter 3 
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Figure  3.5:  Dose  response  curve  for  triclabendazole sulphoxide 
assessed  against  mature  worms  at  24,  48  and  72  hrs  post 
exposure.  
Figure  3.6:  Dose  response  curve  for  triclabendazole sulphone 
assessed  against  mature  worms  at  24,  48  and  72  hrs  post 
exposure.                                                                                                                                         Chapter 3 
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Figures 3.3, 3.4, 3.5 and 3.6 shows the dose response curves for adult worms treated with Pzq, 
Tcbz, Tcbz Sx and Tcbz Sp respectively. There was no significant differences in the EC50 
value for Tcbz, Tcbz Sx and Tcbz Sp at 24, 48 and 72 hours after drug exposure (P>0.05). The 
EC50 values for Tcbz, Tcbz Sx and Tcbz Sp were significantly higher compared to the EC50 
value of Pzq at all three time points (P<0.05). 
 
3.3.3 Drug efficacy scores 
All adult worms in the unexposed control groups remained active, characterized by whole body 
movement  and  no  visible  contraction  (Score  4).  Adult  worms  demonstrated  progressive 
contraction and loss of motility when assessed every four hours after exposure to 100 M of 
Pzq, Tcbz, Tcbz Sx and Tcbz Sp (see Table 3.3). After 24hrs post exposure to Tcbz, 50% 
(Score 2: 30%; Score1: 20%) of treated worms were dead.  For Tcbz Sx, 60% (Score 2: 30%; 
Score 1: 30%) of treated worms were dead while the Tcbz Sp treated groups demonstrated a 
mortality rate of 30% (Score 2: 20%; Score 1: 10%). Praziquantel treated groups demonstrated 
100% (Score 2: 30%; Score 1: 70%) mortality at 100 M over 24hrs. 
 
Thirty percent of worms exposed to Tcbz and 20% of worms exposed to Tcbz Sp recovered 
their motility 48hrs after drug exposure. Recovered worms assumed a relaxed appearance but 
morphological changes induced by Tcbz remained evident. A further 10% of Tcbz Sp treated 
worms  recovered  motility  72hrs  after  drug  exposure  and  media  change.  Triclabendazole 
sulphoxide continued to exert anti schistosomal effects for at least 48hrs after the addition of 
fresh  media,  with  worms  characterized  by  progressively  stronger  contractions  and  loss  of 
motility.  Ninety  percent  of  worms  were  dead  after  48  hours,  with  100%  dead  72hrs  after 
exposure to 100 M of Tcbz Sx. 
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Table 3.3: Percentages of worms (%) showing altered contraction and motility (Score 1 to 4) after exposure to 100 M of praziquantel (Pzq), 
triclabendazole (Tcbz), triclabendazole sulphoxide (Tcbz Sx) and triclabendazole sulphone (Tcbz Sp).  
Score  20hr  24hr  48hr  72hr 
  4  3  2  1  4  3  2  1  4  3  2  1  4  3  2  1 
Tcbz  30%  20%  30%  20%  30%  20%  30%  20%  10%  70%  10%  10%  10%  70%  10%  10% 
Tcbz Sx  30%  10%  30%  30%  30%  10%  30%  30%  0%  10%  30%  60%  0%  0%  20%  80% 
Tcbz Sp  40%  40%  10%  10%  40%  30%  20%  10%  10%  80%  10%  0%  10%  90%  0%  0% 
Pzq  0%  10%  20%  70%  0%  0%  30%  70%  0%  0%  30%  70%  0%  0%  30%  70% 
* 4: no contraction, movement throughout body, 3: minimally contracted, motile, 2: contracted and immotile, 1: maximal contraction and immotile
Contraction Score 
Score  4hr  8hr  12hr  16hr 
  4  3  2  1  4  3  2  1  4  3  2  1  4  3  2  1 
Tcbz  40%  50%  10%  0%  40%  50%  10%  10%  30%  20%  40%  10%  30%  20%  40%  10% 
Tcbz Sx  50%  40%  10%  0%  30%  40%  20%  10%  20%  50%  10%  20%  30%  20%  30%  20% 
Tcbz Sp  50%  50%  0%  0%  50%  40%  10%  0%  40%  50%  0%  10%  40%  50%  0%  10% 
Pzq  0%  20%  80%  0%  0%  10%  80%  10%  0%  10%  70%  20%  0%  10%  40%  50%                                                                                                                                         Chapter 3 
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Figure 3.7: Morphological changes observed in mature Schistosoma mansoni after exposure to triclabendazole (Tcbz) for 24 hours.  
(A) Adult worm exposed to 10 M of Tcbz at 100 ×  
(B) Adult worm exposed to 30 M of Tcbz at 100 × 
(C) Adult worm exposed to 100 M of Tcbz at 100 × 
(D) Adult worm exposed to 100 M of Tcbz at 100 ×, showing belbbing of the tegument   
(E) Adult worm exposed to 100 M of Tcbz at 400 ×, showing widespread blebbing of tegument 
(F) Adult worm exposed to 100 M of Tcbz at 400 ×, showing crumpling of ventral sucker 
(G) Adult worm exposed to 100 M of Tcbz at 400 ×, showing blebbing and crumpled oral sucker 
 
Key: (Os) Oral sucker; (Vs) Ventral sucker; (Bb) Blebs; (Vc) Vacuolization. 
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Figure 3.8 Morphological changes observed in mature Schistosoma mansoni after exposure to triclabendazole sulphoxide (Tcbz Sx) for 24 hours. 
(A) Adult worm exposed to 300 M of Tcbz Sx at 100×, showing vacuolization of internal musculature. 
(B) Adult worm exposed to 100 M of Tcbz Sx at 100×, showing blebbing of tegument. 
(C) Adult worm exposed to 100 M of Tcbz Sx at 200×, showing vacuolized tegument. 
(D) Adult worm exposed to 100 M of Tcbz Sx at 100×, showing contracted worm. 
(E) Adult worm exposed to 10 M of Tcbz Sx at 100×, showing no observable pathology. 
(F) Adult worm exposed to 100 M of Tcbz Sx at 400×, showing widespread blebbing and sloughing of tegument. 
(G) Adult worm exposed to 100 M of Tcbz Sx at 400×, showing belbbing of tegument. 
(H) Blebs induced by 100 M of Tcbz Sx at 40x mag. 
 
Key: (Os) Oral sucker; (Vs) Ventral sucker; (Bb) Blebs; (Vc) Vacuolization; (Tm) Tegument 
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Figure 3.9: Morphological changes observed in mature Schistosoma mansoni after exposure to triclabendazole sulphone (Tcbz Sp) for 24 hours. 
(A) Adult worm exposed to 300 M of Tcbz Sp at 100×, showing immediate and maximal muscle contraction upon addition of drugs. 
(B) Adult worm exposed to 100 M of Tcbz Sx at 100×, showing strong muscle contraction upon addition of drugs. 
(C) Adult worm exposed to 30 M of Tcbz Sx at 100×, showing moderate contraction of worm. 
(D) Adult worm exposed to 300 M of Tcbz Sx at 400×, showing widespread blebbing and sloughing of tegument after 24 hours exposure. 
(E) Adult worm exposed to 300 M of Tcbz Sx at 200×, showing blebbing of the tegument after 24 hours exposure. 
(F) Adult worm exposed to 100 M of Tcbz Sx at 200×, showing blebbing of the tegument after 24 hours exposure. 
(G) Adult worm exposed to 30 M of Tcbz Sx at 400×, showing moderate blebbing of the tegument after 24 hours exposure. 
 
Key: (Os) Oral sucker; (Vs) Ventral sucker; (Bb) Blebs; (Vc) Vacuolization; (Tm) Tegument; (Mc) Maximal muscular contraction 
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Figure 3.10: Morphological changes observed in mature Schistosoma mansoni after exposure to praziquantel (Pzq) for 24 hours.  
(A) Adult worm exposed to 100 M of Pzq at 100×, showing immediate muscle contraction upon addition of drugs. 
(B) Adult worm exposed to 100 M of Pzq at 100×, showing maximal muscle contraction after 24 hours of treatment. 
(C) Adult worm exposed to 10 M of Pzq at 100×, showing strong contraction of worm after 24 hours of treatment. 
(D) Adult worm exposed to 100 M of Pzq at 400×, showing blebbing of oral suckers after 24 hours exposure. 
(E) Adult worm exposed to 100 M of Pzq at 200×, showing widespread blebbing of the tegument after 24 hours exposure. 
(F) Adult worm exposed to 10 M of Pzq at 200×, showing someblebbing of the tegument after 24 hours exposure. 
 
Key: Os: Oral sucker; Bb: Blebs, Tm: Tegument; Gc: Gynaecophoric canal 
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Figure 3.11: Untreated 49 day old mature worms in DMSO drug vehicle.  
(A) Adult worm exposed to 0.1% v/v DMSO drug vehicle at 100× 
(B) Adult worm exposed to 0.1% v/v DMSO drug vehicle at 200× 
(C) Adult worm exposed to 0.1% v/v DMSO drug vehicle at 400× showing normal ventral sucker. 
(D) Adult worm exposed to 0.1% v/v DMSO drug vehicle at 400× showing normal oral sucker. 
(E) Adult worm exposed to 0.1% DMSO drug vehicle at 400× showng normal tegument. 
 
Key: (Os) Oral sucker; (Vs) Ventral sucker; (Tm) Tegument. 
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3.4 Discussion 
The objective of this study was to assess the efficacy of Tcbz and its metabolites against S. 
mansoni in comparison to Pzq. The efficacy of Tcbz and its metabolites have been determined 
against Fasciola and other trematodes (Keiser et al., 2005) but there is little available data on 
their anti schistosomal activities. Conflicting reports and incomplete data sets (Khalil, 2000; 
Keiser et al., 2006) have consistently hampered the establishment of baseline values for detailed 
drug studies and the generation of reliable dose response analyses. To address these issues, 
multiple doses of Tcbz and its metabolites were assessed and their effects compared against 
Pzq, the positive drug control. The main finding of this study mirrored Keiser et al. (2006)’s in 
vivo observations; that Tcbz and its metabolites possess weak and inconsistent anti schistosomal 
activity in vitro.  
 
The isolate of S. mansoni used in this study was obtained from the Queensland Institute of 
Medical Research and was adapted for culture according to the protocols recommended by the 
National  Institute  of  Health,  Schistosoma  Laboratory  of  the  Biomedical  Research  Institute, 
Maryland. While every attempt was made to maintain optimal conditions for the perpetuation of 
the parasite, the cold temperate climate of Perth consistently reduced snail survival rates. Snail 
fitness appeared to be a major factor in the survivability of the miracidium. This presented 
considerable problems for the perpetuation of larger parasite populations for high throughput 
screening. As a result, no more than 20 infected snails were ready for cercarial shedding at any 
one time. To circumvent these issues, breeding tanks for infected snails were maintained in 
absolute darkness during the incubation period (35 days). In colder months, breeding tanks were 
insulated  with  several  layers  of  aluminum  foil.  To  ensure  maximal  snail  infections  and 
consistency, only mature snails of approximately 5mm in diameter were chosen. 
 
The methods used to transform and culture immature schistosomulum were adapted from the 
protocols described by Basch (1981) and Pica Mattoccia & Cioli (2003). The high mortality 
rates  observed  in  the  first  two  weeks  of  culture  were  consistent  with  Basch  (1981),  who     Chapter 3 
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observed a reduction of approximately 50% up to Wk 4.  Although there was some individual 
variability in schistosomulum growth, asynchronous development was a prominent feature of 
the culture system.  
 
Triclabendazole  demonstrated  irreversible  dose dependent  activity  against  immature 
schistosomula. Contraction of schistosomules was observed immediately after the addition of 
Tcbz, resulting in worm paralysis at four hrs post exposure. Morphological effects were evident 
within  the  first  six  hours  of  drug  exposure,  with  schistosomules  assuming  a  knobbed  and 
shrunken appearance at concentrations above 30 M. Blebbing of the tegument was also evident, 
and appeared dependent on the concentration and length of ezposure. This finding agrees with 
studies using Fasciola species (Stitt & Fairweather, 1993), where blebbing of the tegument was 
the most commonly observed signs of pathology after exposure to Tcbz. Blebbing primarily 
results from the release of secretory bodies by microtubule based transport processes at the 
surface  membrane  (McConville  et  al.,  2007).  The  large  number  of  blebs  observed  was  a 
reflection of the reduced ability of treated worms to repair its apical membrane (McConville et 
al.,  2007).  The  relatively  high  EC50  value  observed  when  Pzq  was  used  to  treat  immature 
schistosomulum suggests that the juvenile worms were largely refractory to the effects of Pzq. 
While the values observed in this study were significantly lower than that of Pica Mattoccia & 
Cioli  (2004),  it  is  well  known  that  different  Schistosoma  strains  demonstrate  varying 
susceptibilities to Pzq in vitro and in vivo (Keiser et al., 2006). It is also likely that the higher 
susceptibility of immature cultured worms compared to immature worms extracted from mice 
was a result of the culture system. Basch (1981) reported that the mean length of immature 
cultured worms were shorter than immature worms in vivo. When worm pairs were implanted 
into  mesenteric  veins  of  mice,  complete  maturity  of  the  worm  pairs  were  not  attained.  It 
appeared  likely  that  the  stimuli  required  for  full  growth  were  not  provided  by  the  culture 
conditions (Basch, 1981). 
 
The  observed  susceptibility  of  immature  schistosomulum  to  Tcbz  is  similar  to  the  results 
obtained  from  the  exposure  of  juvenile  F.  hepatica  to  Tcbz  (Boray  et  al.,  1983).  This  is     Chapter 3 
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important as immature schistosomules at the pre patent stage (Wk 4 6) are largely refractory to 
the  action  of  Pzq,  with  gradual  resumption  of  sensitivity  upon  maturation  and  egg  laying 
(Gönnert & Andrews, 1977, Xiao et al., 1985, and Pica Mattoccia & Cioli, 2004). During this 
developmental  period,  the  surface  membrane  of  the  immature  schistomulum  is  radically 
reorganized from the cercarial trilaminate unit to a multilaminate membrane that is connected to 
underlying  subtegumental  cells  by  microtubule lined  intrascytoplasmic  processes  (Stirewalt, 
1974).  The  extensive  cytoskeletal  structure  is  responsible  for  connecting  the  outer surface 
membranes to the basal lamina in a dynamic manner that ensures sufficient flexibility of the 
schistosomal  surface  (Jones  et  al.,  2004).  Several  studies  have  identified  the  role  of 
microtubules in surface maturation. In particular, Wiest et al. (1988) demonstrated the inhibition 
of multilaminate membrane formation by the microtubule inhibitor colchicine; resulting in the 
impediment of schistosomule maturation. It is reasonable to assume that Tcbz was likely to act 
via similar mechanisms of action against immature worm tubulin that were more ‘exposed’ than 
adult worm tubulin. This may have accounted for the higher efficacy rates observed in immature 
worms compared to mature worms. 
 
Praziquantel was first introduced as an anthelmintic for the treatment of cestode and trematode 
infections  in  animals.  While  the  molecular  mechanisms  of  action  are  as  yet  undetermined, 
recent  studies  by  Kohn  et  al.  (2001)  implicated  its  action  against  voltage gated  calcium 
subunits. Morphologically, Pzq induced effects were more clearly defined. The stimulation of 
motor activity by calcium influx causes rapid and spastic paralysis, followed by tegumental 
disruption characterized by the formation of vacuoles and vesicles (Pax et al., 1978). Similarly, 
adult worms treated with Pzq in this experiment demonstrated a dose dependent relationship, 
exemplified by the gradual increase of worm contractility and loss of motility with increasing 
drug  concentrations.  Immediate  contraction  was  observed  at  high  concentrations  with  a 
complete  cessation  of  spontaneous  movements.  Widespread  disruptions  were  observed 
throughout  the  body  of  adult  worms,  with  pronounced  blebbing,  vacuolization  and  peeling 
consistent with previous studies (Pax et al., 1978; Becker et al., 1980; Irie et al., 1989; Shaw & 
Erasmus, 1987). Egg laying ceased in paired worms after exposure to Pzq, indicating a loss of     Chapter 3 
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fecundity.  Some  worms  recovered  and  regain  motility  after  media  containing  lower  drug 
concentrations (<100 M) of Pzq was removed. However, recovered worms retained tegumental 
damage associated with drug treatment. Morphological observations of Pzq treated S. mansoni 
also mirrored the observations of Pzq treated S. mekongi (Jiraungkorrskul et al., 2006). Shaw & 
Eramus (1983) proposed that the erosion of teguments and the formation of vacoules could be 
attributed to the dilation of the basal membrane, brought about as a result of water and ionic 
imbalances. Praziquantel has been implicated in the impairment of tegument transport functions 
which can result in such imbalances.  
 
Tegumental blebbing and contractions were more pronounced in Tcbz treated groups compared 
to Pzq treated groups, with the disruptions of blebs evident at higher concentrations. The anti 
schistosomal activity of Tcbz and its metabolites can be ranked according to the severity of 
morphological changes observed in mature worms at each concentration. The results of this 
study showed that the order of efficacy is Tcbz Sx > Tcbz > Tcbz Sp. This observation is 
consistent with earlier studies using Fasciola, which showed Tcbz Sp to be a relatively inert 
metabolite  (Robinson  et  al.,  2004).  Adult  worm  pairs  exposed  to  Tcbz  and  its  metabolites 
showed reduced fecundity and became dissociated, an observation that is also a feature of Pzq 
treatment.  
 
The  results  showed  that  exposure  to  Tcbz Sx  caused  irreversible  mortality  in  adult  worms 
despite replacement of cell culture media. The prolonged effects of Tcbz Sx may be attributed 
to its increased availability and solubility in the media, or may be due to irreversible binding of 
the metabolite to target sites. While the precise molecular mechanism of action for Tcbz and its 
metabolites are unknown, a significant body of knowledge exists for the proposed action of 
Tcbz Sx. It has been suggested that Tcbz Sx primarily acts on microtubule dependent secretory 
processes in the liver fluke (Fairweather & Boray, 1999). In the tegument, Tcbz Sx was shown 
to  block  the  transport  of  secretory  bodies  from  the  cell  body  to  the  apical  surface  of  the 
tegument, causing severe surface damage and total disintegration of the tegument (Fairweather, 
2005).      Chapter 3 
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The results of this study confirmed that Pzq is a more effective drug compared with Tcbz and its 
metabolites.  At  100 M,  Pzq treated  worms  demonstrated  maximal  contractions  and  100% 
mortality within 24hrs compared to Tcbz, Tcbz Sx and Tcbz Sp, which induced a total mortality 
of 50%, 60% and 30% respectively. Only Tcbz Sx and Pzq appeared to maintain persistent 
action  and  (or)  irreversible  binding,  characterized  by  further  increases  or  maintenance  of 
mortality rates for a further 48 hours after removal of media containing 100 M of each drug. 
The dose response curves for Pzq showed uniform dose dependent sigmoidal trends at all three 
time points. This is in contrast to the dose response analyses for Tcbz and its metabolites, which 
were inconsistent and non uniform sigmoidal.  
 
Adult worms treated with lower concentrations (<30 M) of Pzq, Tcbz, Tcbz Sx and Tcbz Sp 
demonstrated  considerable  morphological  damage  and  minimal  contractions,  but  were  not 
defined as ‘dead’ as slight movements were noted particularly within the ventral region of the 
worms. Although these treated worms were not scored as dead, further evaluation at 48 and 
72hrs after exposure revealed minimal movements and no further worm recovery. This has 
significant implications for the current method of in vitro assessment of drug efficacies. It is 
evident  that  the  evaluation  of  worm  mortality  has  to  be  further  improved  to  account  for 
irreversible morphological damage and the loss of fecundity. As indicated by Andrews (1981), 
Xiao et al. (1985) and Pica Mattoccia & Cioli (2004), there were conditions that produced 
maximal contractions, while at the same time not affecting the long term survival of the flukes. 
In addition, such narrowly defined efficacy measures do not take into account of the role of host 
immune responses in the in vivo situation. This is important because host immune responses 
have  been  implicated  in  further  inducing  worm  mortality  through  the  exposure  of  parasite 
antigens following Pzq action on the tegument (Harnett & Kusel, 1986).  
 
This in vitro study suggested that Tcbz and its metabolites possessed weak anti schistosomal 
activities, and supports the in vivo observations of Keiser et al. (2006). While its activity against 
adult  worms  remains  contentious,  Tcbz  demonstrates  good  efficacy  against  immature     Chapter 3 
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schistosomula that were refractory to Pzq. The persistent action of Tcbz and its metabolites and 
its activity against immature stages of S. mansoni suggests that the compounds can be ideal 
candidates for use in drug combinations with Pzq.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Chapter 4 
59 
4.1 Introduction 
The pathology induced by S. mansoni infections is largely attributed to the hypersensitivity of 
the host to soluble egg antigens, which results in a granulomatous response and subsequent 
fibrosis of the liver (Abouel Nour et al., 2006). The current drug of choice for the treatment of 
schistosomiaisis is praziquantel (Pzq), which principally affects mature flukes and reduces egg 
burdens.  
 
The hatching of Schistosoma eggs is easily achieved in fresh water, although hatching can also 
be induced in solutions of high osmolarity. There is currently little information on the ovicidal 
effects of Pzq. Xu & Dresden (1986) demonstrated that the release of leucine aminopeptidase 
was correlated with hatching, and that Pzq caused the rapid release of leucine aminopeptidase 
from eggs in vitro. Treatment with Pzq reduces the viability of mature worm pairs also and 
leads to cessation in egg laying. While the exact mode of action of Pzq on mature worms 
remains undefined, it has been suggested that the β subunit of voltage gated calcium channels 
are involved (Kohn et al., 2001).  
 
Preliminary studies by Matsuda et al. (1983) partially characterized the in vitro and in vivo 
effects of Pzq on S. japonicum eggs. The study demonstrated that the number of mature eggs 
was reduced and the number of empty fresh egg shells was increased in the liver of mice 
infected with S. japonicum that were given four doses of 100mg/kg of Pzq over 24hrs. The 
number of calcified eggs observed in the liver of of mice infected with S. japonicum continued 
to increase for two weeks after treatment (Matsuda et al., 1983). Immature eggs that were 
initially  unaffected  developed  into  unviable  miracidia  that  subsequently  degenerated  and 
calcified. The experiment also demonstrated Pzq induced hatching following the addition of at 
least 1ng/mL of Pzq to the eggs in vitro.  
 
Katsumata  et  al  (1988)  showed  that  Pzq induced  hatching  was  inhibited  by  Ca
2+  channel 
blockers (lanthanum chloride, ruthenium red) and EGTA, a calcium chelator. Conversely, the     Chapter 4 
60 
calcium  ionophore  A23187  stimulated the  hatching of  S.  mansoni  eggs  in  high  osmolarity. 
Recently, Pica Mattoccia et al. (2007) demonstrated that mature worms exposed to calcium 
channel blockers and the actin depolymerization agent, cytochalasin D, were refractory to Pzq. 
The results of this study supported the hypothesis that calcium channels are the primary site of 
action of Pzq in mature worms.  
 
The aim of this study was to characterise morphological changes in S. mansoni eggs exposed to 
Pzq  in  vitro,  and  to  determine  if  the  effects  are  dose dependent.  To  further  elucidate  the 
mechanism of Pzq action on schistosome eggs, the effects of calcium blockers ryanodine and 
dihydropyridine on egg hatching was assessed. The ovicidal efficacies of triclabendazole (Tcbz) 
and its metabolites were also assessed because previous studies have shown that Tcbz reduced 
Schistosoma egg laying and worm fecundity (Khalil, 2000).  
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4.2 Materials and Methods 
4.2.1 Preparation of Schistosoma eggs 
Schistosoma mansoni and S. japonicum eggs were recovered from the livers of infected mice 
according to Dalton et al. (1997). Eggs were extracted from the livers of three mice 49 days 
after infection with S. mansoni and S. japonicum cercariae. Purified eggs were immediately 
stored in cold PBS at 4ºC and were only used after three days to allow for maturation of the 
eggs in PBS (M. Jones, pers. comm.). Eggs culd be stored without hatching due to the high 
osmolarity of PBS. 
 
4.2.2 Evaluation of the effects of praziquantel on egg hatching 
Ten viable mature S. mansoni or S. japonicum eggs were transferred into triplicate wells of 
Falcon
®  Multiwell™  24 well  culture  plates  (Becton  Dickinson,  USA).  The  viability  and 
maturity of the eggs were determined according to Pellegrino et al. (1962). Individual culture 
wells were made up to 1mL with PBS. One hundred times stock solutions of Pzq were made in 
DMSO  and  added  to  triplicate  wells  containing  schistosome  eggs  in  PBS  to  a  final 
concentration of 1mM, 100 M, 10 M, 1 M, 0.1 M and 0.01 M. The untreated control wells 
receieved PBS containing ≤ 1% of DMSO. 
 
The temporal effects of Pzq on the hatching of S. mansoni and S. japonicum eggs was quantified 
by  measuring  the  ‘time  to  activation’  and  the  ‘time  to  hatch’  using  a  stop watch. Time  to 
activation was defined as the length of the first sign of movement or activation within the eggs. 
Time to hatch was defined as the total length of time until the miracidium detached or hatched 
completely from the egg shell and the vitelline membrane. Real time video recordings were 
made at 100 x magnification using a Sony HandyCam (DCR HC40E) connected to a Panasonic 
Color CCTV Camera (Model WV CP610/G), which was subsequently attached to an Olympus 
CKX41 Compound Microscope.  
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4.2.3 Evaluation of triclabendazole and its metabolites on egg viability 
Ten mature S. mansoni or S. japonicum eggs were transferred into triplicate wells of Falcon
® 
Multiwell™ 24 well culture plates (Becton Dickinson, USA).  Individual culture wells were 
made  up  to  1mL  with  PBS.  One  hundred  times  stock  solutions  of  triclabendazole  (Tcbz), 
triclabendazole sulphoxide  (Tcbz Sx)  and  triclabendazole sulphone  (Tcbz Sp)  were  made  in 
DMSO  and  added  to  triplicate  wells  containing  schistosome  eggs  in  PBS  to  a  final 
concentration of 1mM, 100 M, 10 M, 1 M, 0.1 M and 0.01 M. The untreated control wells 
received PBS containing ≤ 1% DMSO. 
 
Eggs were exposed to each treatment for 24hrs at 25ºC. Eggs were then washed and the PBS 
replaced with fresh DDI H2O. Hatching was induced by exposing the culture plates to a 100 
Watt light source. Eggs were then examined microscopically and the number of hatched eggs 
recorded. The percentage of inhibition of egg hatching was corrected for natural mortality in the 
control wells by subtracting the number of unhatched eggs in control wells from the number of 
unhatched  eggs  in  the  treated  wells  before  calculating  the  proportion  that  hatched  in  the 
treatment wells.  
 
4.2.4 Evaluation of calcium blockers on eggs 
Ten viable mature S. mansoni or S. japonicum eggs were transferred into triplicate wells of 
Falcon
® Multiwell™ 24 well culture plates (Becton Dickinson, USA). Individual culture wells 
were  made  up  to  1mL  with  PBS.  Fluorescent labelled  BODIPY
®  FL X  ryanodine  and 
fluorescent labelled  DM BODIPY®  dihydropyridine  (Invitrogen,  California)  were  added  to 
triplicate  wells  at  final  concentrations  of  25 g/mL,  2.5 g/mL,  250  ng/mL,  25ng/mL  and 
0.25ng/mL in 1mL of PBS. Treated culture plates were incubated for 24hrs at 25ºC. The eggs 
were then  washed  by  gentle  pipetting  and  the  PBS  replaced  with  DDI  H2O.  Hatching  was 
induced  by  exposure  of  the  culture  plates  to  a  100  Watt  light  source.  The  percentage  of 
inhibition of egg hatching was corrected for natural mortality in the control wells by subtracting     Chapter 4 
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the number of unhatched eggs in control wells from the number of unhatched eggs in the treated 
wells before calculating the proportion that hatched in the treatment wells. 
 
4.2.5 Dose response and statistical analysis 
The percent inhibition of egg hatching caused by each compound was calculated as: 
Number of eggs hatched (exposed) − Number of eggs hatched (unexposed) 
                         Number of eggs hatched (unexposed) 
 
The EC50 and 95% confidence intervals were determined using Prism 4 (GraphPad, San Diego).  
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4.3 Results 
4.3.1 Effects of praziquantel induced hatching of Schistosoma eggs 
Activation  of  unhatched  miracidia  was  observed  immediately  after  the  addition  of  each 
concentration of Pzq greater or equal to 100nM in PBS. All S. mansoni and S. japonicum eggs 
exposed to 1mM of Pzq were activated within the first 30s after exposure. The mean length of 
time before miracidium activation in the eggs are presented in Table 4.1. 
 
Table  4.1:  Mean  length  of  time  before  miracidial  activation  was  observed  in  Schistosoma 
mansoni  and  Schistosoma  japonicum  eggs  exposed  to  0.01,  0.1,  1,  10,  100  and  100 M  of 
praziquantel. Standard errors are presented in paranthesis. 
 
Concentration ( M) 
 
0.01 M  0.1 M  1 M  10 M  100 M  1000 M 
Schistosoma 
mansoni 
NA  248 (10.9)  136 (8.83)  28 (4.62)  22 (0.58)  22 (0.58) 
Schistosoma 
japonicum 
NA  281 (22.5)  109 (9.55)  91.7 (7.27)  88.3 (7.85)  22 (0.58) 
NA = no observed activation 
 
 
Complete  hatching  of  S.  mansoni  and  S.  japonicum  eggs  was  observed  within  20  mins  of 
exposure to Pzq concentrations above 1 M. Schistosoma mansoni and S. japonicum did not 
hatch when exposed to 100nM and 10nM of Pzq. The mean length of time before complete egg 
hatching was observed is shown in Table 4.2. Untreated eggs in PBS were not activated. When 
untreated  eggs  were  exposed  to  fresh  DDI  H2O  (25ºC),  miracidia  activation  was  observed 
within approximately 420s (SE=30s), and complete hatching was observed in approximately 
720s (SE=160s).   
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Table 4.2: Mean length of time required for Schistosoma mansoni and Schistosoma japonicum 
eggs to hatch following exposure to 0.01, 0.1, 1, 10, 100 and 100 M of praziquantel. Standard 
errors are presented in paranthesis. 
 
 
Concentration ( M) 
 
0.01 M  0.1 M  1 M  10 M  100 M  1000 M 
Schistosoma 
mansoni 
265 (23)  391 (21.8)  752 (72.5)  1116 (122)  N/H  N/H 
Schistosoma 
japonicum 
430 (26.5)  329 (63.9)  499 (32.6)  1260 (34.7)  N/H  N/H 
NA= no hatching observed 
 
4.3.2 Morphological effects observed in eggs exposed to praziquantel 
Untreated S. mansoni and S. japonicum eggs that were exposed to fresh DDI H2O hatched 
within 10 to 15mins. Hatched miracidia were pyriform in shape. Complete detachment of the 
vitelline membrane from the egg shells was observed, with miracidium remaining viable for at 
least six hours.  
 
The first signs of miracidial movement following exposure to Pzq were observed within the 
anterior  terebratorium  followed  by  rapid  beating  of  the  cilia.  Contractions  were  noted 
throughout the entire miracidium within 30s of Pzq exposure. The rapid beating of the cilia and 
strong  contractions  of  the  miracidium  resulted  in  increased  turgescence  of  the  fluid filled 
vitelline membrane (Lehman’s Lacuna). The miracidium subsequently broke through the egg 
shell along an oblique or vertical line, with the vitelline membrane remaining intact. In most 
cases, the vitelline membrane remained attached to the egg shells. The miracidium remained 
contracted and assumed little movement within the confines of the vitelline membrane. The 
terebratorium  eventually  ruptured  the  expanding  vitelline  membrane,  discharging  the 
miracidium,  lipoid  bodies  and  granulofloccular  material  (Cheever  bodies)  into  the  external 
environment.  The  morphological  changes  of  S.  mansoni  and  S.  japonicum  eggs  following 
treatment with Pzq is shown in Figure 4.1 and 4.2. 
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The hatched miracidium appeared deformed, strongly contracted and showed erratic swimming 
motions. Wave like contractions were observed throughout the entire miracidium body. Death 
of the miracidium was evident within five minutes of hatching, with parasites appearing bloated 
and sessile. Miracidial activation was evident at lower concentrations of Pzq but no complete 
hatching was observed. Despite continuous activation of miracidia within the egg, there was a 
gradual loss of movement within four hrs after exposure to Pzq.  
 
A  video  of  the  Pzq induced  hatching  process  is  provided  electronically  (see  Electronic 
Appendix A). 
 
4.3.3 Effects of calcium blockers and inducers on eggs 
Schistosoma mansoni and S. japonicum eggs did not activate or hatch in the presence of DDI 
H2O  after  treatment  with  the  calcium channel  inhibitor  dihydropyridine  at  the  highest 
concentration of 25 g/mL. Activation and hatching in fresh DDI H2O were observed in eggs 
exposed  to  less  than  25 g/mL  of  dihydropyridine.  Miracidial  activation  and  hatching  were 
observed for eggs exposed to 25 g/mL of dihyropyridine followed by exposure to 10 M of 
Pzq. All eggs exposed to a range of ryanodine concentrations hatched when exposed to fresh 
DDI H2O. Activation and hatching of the miracida were observed when ryanodie treated eggs 
were exposed to 10 M Pzq.               Chapter 4 
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Figure 4.1: Representative 
images of Schistosoma 
mansoni (left column) and 
Schistosoma japonicum 
(right column) eggs after 
exposure to 10 M of 
praziquantel. 
 
A: Untreated S. mansoni egg 
at 1000× 
 
B: Untreated S. japonicum 
egg at 1000× 
  
C: Immediate activation of  
S. mansoni eggs with 
detachement of vitelline 
membrane and premature 
discharge of deformed 
miracidium at 400× 
 
D: Immediate activation of  
S. japonicum eggs, 
characterized by blisters of 
the vitelline membrane and 
premature discharge of 
miracidium at 400× 
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Figure 4.2: Schistosoma 
mansoni (left column) and 
Schistosoma japonicum (right 
column) eggs exposed to 
10 M  of praziquantel 
showing hatching of 
miracidium.  
 
A: Detachment of S. mansoni 
vitelline membrane and 
miracidium from eggs shells 
at 1000× 
 
B: Detachment of 
S.japonicum vitelline 
membrane and miracidium 
from eggs shells at 1000× 
 
C: Deformed and contracted 
S. mansoni miracidium 
showing condensed neural 
mass 1000× 
 
D: Deformed and contracted 
S. japonicum miracidium with 
widespread deformities at 
400× 
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4.3.3 Effects of triclabendazole and its metabolites on egg viability 
 
Untreated  eggs  that  were  exposed  to  DDI  H2O  at  25ºC  all  hatched.  The  proportion  of  S. 
mansoni and S.  japonicum eggs that hatched are shown in Table 4.3 below. 
 
Table  4.3:  Percentage  of  Schistosoma  mansoni  and  Schistosoma  japonicum  eggs  hatched 
after  exposure  to  triclabendazole  (Tcbz),  triclabendazole  (Tcbz Sx)  and  triclabendazole 
sulphone  (Tcbz Sp)  at  10nM,  100nM,  1 M,  10 M,100 M  and  1mM.  Standard  errors  are 
presented in patenthesis. 
 
  Concentration ( M) 
   
0.01 M 
 
0.1 M 
 
1 M 
 
10 M 
 
100 M 
 
1000 M 
S. mansoni             
Tcbz  51 (6.57)  52.7 (4.26)  50 (2.89)  29 (2.31)  0  0 
Tcbz Sx  66.7 (1.20)  45 (2.52)  28 (2.51)  18.7 (2.03)  0  0 
Tcbz Sp  54 (7.78)  53.7 (3.72)  45.7 (2.03)  30.7 (1.2)  0  0 
S.  japonicum   
Tcbz  78.6 (2.64)  71 (5.98)  61.1 (5.57)  31.1 (5.88)  0  0 
Tcbz Sx  90 (10.0)  82.3 (9.69)  71.4 (8.27)  20.6 (8.07)  0  0 
Tcbz Sp  69.5 (2.77)  69.4 (3.67)  54.2 (10.5)  42.6 (7.34)  0  0 
 
Eggs  exposed  to  1mM  and  100 M  of  Tcbz,  Tcbz Sx  and  Tcbz Sp  were  unable  to  hatch 
following washing with PBS and exposure to DDI H2O. There was a dose dependent decrease 
in  the  proportion  of  eggs  hatching  exposure  to  Tcbz,  Tcbz Sx  and  Tcbz Sp.  At  lower 
concentrations (<1 M), at least 50% eggs achieved normal hatching.  
 
A loss of shell integrity was observed in eggs exposed to high concentrations (100 M) of Tcbz, 
Tcbz Sx  and  Tcbz Sp,  resulting  in  non viable  miracidia  that  did  not  hatch. The  unhatched 
miracidium gradually detached from the egg shells and the vitelline membrane, resulting in the 
leakage  of  lipoid  bodies.  The  vitelline  membrane  appeared  to  separate  into  two  layers 
(Reynold’s layer and von Lichtenberg’s envelope). Morphological damage was less evident in 
eggs exposed to Tcbz compared to Tcbz Sx and Tcbz Sp. The hatched miracidia exposed to 
lower  concentrations  of  Tcbz,  Tcbz Sx  and  Tcbz Sp  appeared  crumpled,  with  pronounced                    Chapter 4 
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morphological deformities such as vacuolization and blistering of the tegument. Within a few 
minutes the deformed miracidium assumed a bloated appearance and were sessile. In particular, 
the  neural  mass  appeared  condensed.  Most  miracidia  did  not  detach  completely  from  the 
vitelline  membrane,  with  the  anterior  end  remaining  attached  to  the  egg  shells.  The 
morphological effects of S. mansoni and S. japonicum eggs following Tcbz, Tcbz Sx and Tcbz 
Sp treatment are shown in Figure 4.5, 4.6, 4.7, 4.8 and 4.9. 
 
There  was  a  dose dependent  effect  of  Tcbz,  Tcbz Sx  and  Tcbz Sp  on  the  mortality  of  S. 
mansoni  and  S.  japonicum  eggs.  (Figure  4.3  and  Figure  4.4  respectively).  There  were  no 
significant differences in the concentration of Tcbz, Tcbz Sx and Tcbz Sp required to kill 50% 
(EC50) of S. mansoni eggs (Table 4.4). Similarly, there was no significant difference (P>0.05) 
in the percent mortality for S. japonicum eggs exposed to Tcbz, Tcbz Sx and Tcbz Sp (Figure 
4.4).  
 
Table 4.4: Concentration of triclabendazole (Tcbz), triclabendazole sulphoxide (Tcbz Sx) and 
triclabendazole sulphone (Tcbz Sp) required to kill 50% (EC50) of Schistosoma mansoni and 
Schistosoma japonicum eggs. 
 
  Drug concentration ( M) 
  Tcbz  Tcbz Sx  Tcbz Sp 
Schistosoma mansoni  0.096   0.082   0.276  
Schistosoma japonicum  1.73   2.43   1.67  
                    Chapter 4 
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Figure 4.4: Dose response curves of Schistosoma japonicum eggs exposed to triclabendazole 
(Tcbz),  triclabendazole sulphoxide  (Tcbz Sx)  and  triclabendazole sulphone  (Tcbz Sp)  for  24 
hours.  
Figure 4.3: Dose response curves of Schistosoma mansoni eggs exposed to triclabendazole 
(Tcbz), triclabendazole sulphoxide (Tcbz Sx) and triclabendazole sulphone (Tcbz Sp) for 24 
hours. 
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Figure 4.5: Microstructural effects observed in Schistosoma japonicum eggs exposed to triclabendazole (Tcbz), triclabendazole sulphoxide 
(Tcbz Sx) and triclabendazole sulphone (Tcbz Sp).  
(A) Untreated S. japonicum eggs at 100 × 
(B) Single untreated S. japonicum egg at 200 × 
(C) Single untreated S. japonicum egg at 400 × 
(D) Single S. japonicum egg treated with 100 M of Tcbz at 200 × showing drug binding to egg shells. 
(E) Single S. japonicum egg treated with 100 M Tcbz Sx at 200 × showing drug binding to egg shells. 
(F) Single S. japonicum egg treated with 100uM Tcbz Sp at 200 × showing drug binding to egg shells. 
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Figure  4.6:  Microstructural  effects  observed  in  Schistosoma  japonicum  eggs  exposed  to  various  concentrations  of  triclabendazole  (Tcbz), 
triclabendazole sulphoxide (Tcbz Sx) and triclabendazole sulphone (Tcbz Sp).  
(A) Single S. japonicum egg exposed to 10 M of Tcbz, with the integrity of the miracidium remaining largely intact at 200 ×  
(B) Single S. japonicum egg exposed to 10 M Tcbz Sx, with crumpling and miracidium deformities evident at 200 × 
(C) Single S. japonicum egg exposed to10 M of Tcbz Sp showing crumpling of the miracidium at 200 × 
(D) Single S. japonicum egg exposed to 100 M of Tcbz showing detachment of the vitelline membrane from the egg shell at 400 × 
(E) Single S. japonicum egg exposed to 100 M of Tcbz Sx, showing detached vitelline membrane and deformed miracidium at 400 × 
(F) Single S. japonicum egg exposed to 100 M of Tcbz Sp. showing detached vitelline membrane and deformed miracidium at 400 × 
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Figure 4.7: Microstructural effects 
of detached vitelline membrane 
and miracidium of Schistosoma 
japonicum eggs  after exposure to 
triclabendazole (Tcbz), 
triclabendazole sulphoxide (Tcbz 
Sx) and triclabendazole sulphone 
(Tcbz Sp). 
 
(A) S. japonicum egg treated with 
Tcbz Sx showing crumpled 
miracidium at 1000 × 
 
(B) S. japonicum egg treated with 
Tcbz Sp showing vacuolized 
miracidium teguments at 400 × 
 
(C) Hatched and deformed S. 
japonicum miracidium at 400 × 
after treatment with Tcbz at 10 M. 
 
(D) Hatched S. japonicum 
miracidium after treatment with 
Tcbz Sx at 400 × showing 
widespread vacuolization and 
incomplete detachment from the 
vitelline membrane. 
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Figure  4.8:  Representative  images  of  Schistosoma 
mansoni  eggs  after  exposure  to  triclabendazole 
(tcbz),  triclabendazole sulphoxide  (Tcbz Sx)  and 
triclabendazole sulphone (Tcbz Sp) for 24 hours. 
 
(A) Control untreated S. mansoni egg (400 ×). 
(B)  S.  mansoni  egg  treated  with  100 M  Tcbz 
showing drug binding (400 ×). 
(C) S. mansoni egg treated with 10 M Tcbz showing 
detachment  of  vitelline  membrane  and  ruptured 
miracidium (400 ×). 
(D)  S.  mansoni  egg  treated  with  10 M  Tcbz Sx 
showing leakage of lipoid bodies (400 ×). 
(E)  S.  mansoni  egg  treated  with  10 M  of  Tcbz Sp 
showing leakage of lipoid bodies (400 ×). 
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Vc 
Figure 4.9: Representative images of the microstructural effects of discharged Schistosoma mansoni miracidium after 24 hours exposure to 
triclabendazole (Tcbz), triclabendazole sulphoxide (Tcbz Sx) and triclabendazole sulphone (Tcbz Sp). 
 
(A) Discharged S. mansoni miracidium after treatment with Tcbz at 10 M, showing bloatedness and widespread vacuolization of the tegument 
at 1000 × 
(B) Discharged S. mansoni miracidium after treatment with Tcbz Sx, showing widespread deformities to the internal organs and tegument at 
1000 × 
(C) Intact S. mansoni egg and discharged miracidium after treatment with Tcbz Sp, showing bloating and some vacuolization of the tegument 
at 1000 × 
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4.4 Discussion 
 
The findings of this study demonstrated the induction of schistosome egg hatching in solutions 
of high osmolarity in the presence of Pzq which supports the earlier observations of Matsuda et 
al. (1983) and Katsumata et al. (1988). Praziquantel induced hatching of miracidia in PBS was 
a dose dependent process, with hatching observed for all concentrations above 10nM. While 
Katsumata  et  al.,  (1998)  have  suggested  that  the  hatching  induced  by  Pzq  was  a 
Ca
2+/calmodulin dependent process there is no direct evidence to suggest that the mechanism of 
action  is  a  result  of  calcium channel  activation.  However,  the  strong  contractions  of  the 
activated and hatched miracidia suggest that Ca
2+ may play a key role in inducing hatching as 
the  morphological  changes  observed  are  consistent  with  the  effects  of  increased  Ca
2+   
permeability (Pax et al., 1978; Blair et al., 1992). Vacuolization of the miracidial tegument was 
also a prominent observation, with blebs and blisters evident throughout the entire tegumental 
surface. The deformities observed in miracidia teguments are similar to the pathology observed 
in adult worms treated with Pzq (Fallon et al., 1992; Linder & Thors, 1992; Brindley, 1994), 
where disruption of calcium homeostasis has been implicated as a possible mode of action. 
 
It is also likely that Pzq could have played an additional, less direct role in miracidium hatching. 
Xu  &  Dresden (1986) reported the correlation  of  egg  hatching  and leucine  aminopeptidase 
activity in egg extracts, miracidia and adult worms of S. mansoni. The study demonstrated that 
the  release  of  leucine  aminopeptidase  paralleled  hatching,  and  that  inhibitors  of  leucine 
aminopeptidase also inhibited hatching. Xu et al. (1988) further demonstrated that Pzq caused 
the rapid release of this enzyme from schistosome eggs in vitro. More recently, Arima et al. 
(2005)  demonstrated  the  modulatory  roles  of  calcium  on  leucine  aminopeptidase  in 
Streptomyces griceus. If Schistosoma leucine aminopeptidase was both calcium activated and 
stabilized as in the case of Streptomyces griceus, it is likely that Pzq may have a supplementary 
role as a calcium ionophore or carrier. By mobilizing vesicular stores of calcium within the egg, 
Pzq may have activated calcium modulated leucine aminopeptidase, resulting in the premature 
hatching of the miracidium.                                                                                                                                         Chapter 4    
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The results from this study also showed that ryanodine and dihydropyridine did not inhibit Pzq 
induced hatching in PBS. At 25 g/mL, dihydropyridine inhibits normal hatching in DDI H2O 
but did not inhibit hatching after exposure to 10 M of Pzq. Ten  M of Pzq was the minimal 
concentration that induced hatching in both S. mansoni and S. japonicum eggs in the presence of 
dihydropyridine. However, when eggs treated with 25 g/mL of dihydropyridine were exposed 
to  Pzq  concentrations  >10 M,  activation  and  hatching  were  observed.  The  inhibition  of 
hatching in DDI H2O observed after treatment with 25 g/mL of dihydropyridine could be due 
to  the  compound  binding  on  the  surface  of  the  egg  shell,  which  inhibits  normal  hatching. 
Dihydropyridine is a blocker of the α1 subunit of mammalian L type channels (Knaus et al., 
1992). Kohn et al. (2001) has proposed that the β subunit of voltage gated calcium channels 
was a potential target of Pzq. Therefore, it is likely that the failure to observe the effects of 
dyhydropyridine was due to insufficient homology between mammalian and invertebrate L type 
channels. In addition, Fetterer et al. (1980) demonstrated that mehtoxyverapamil (D 600), an 
inhibitor of L type mammalian Ca
2+ channels did not block the Pzq dependent Ca
2+ influx in 
adult schistosomes but blocked tonic contraction resulting from increased K
+ concentrations.  
 
Ryanodine is a plant alkaloid that mobilizes Ca2+ from intracellular stores by activating a class 
of inositol triphosphate insensitive receptors (IP3R; Rousseau et al., 1987; Smith et al., 1988). 
When eggs were exposed to 25 g/mL of ryanodine, there was no normal hatching and Pzq 
induced  hatching.  Ryanodine  has  two  distinct  effects;  at  submicromolar  concentrations, 
ryanodine locks calcium channels in a long lived open state, whereas an inhibition of Ca
2+ 
channel was observed at higher micromolar concentrations (Rousseau et al., 1987; Smith et 
al., 1988). At high concentrations, ryanodine failed to inhibit the actions of Pzq in inducing egg 
hatching. At concentrations below 1 M to 1nM, no activation or hatching of schistosome eggs 
were observed.  Katsumata et al. (1988) demonstrated that ruthenium red at 0.1mM, 0.5mM and 
1mM caused the inhibition of egg hatching under low osmotic pressure. Ruthenium red is potent 
blocker of ryanodine receptors, and thus, ryanodine receptors may play an inhibitory role in the 
normal hatching of miracidium, as shown by Katsumata et al. (1988). It appeared, however, that                                                                                                                                         Chapter 4    
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Pzq induced hatching is independent of this receptor, as ryanodine at high concentrations did 
not inhibit Pzq activation and hatching of miracidium. It is likely that Pzq induced hatching is 
activated through other classes of receptors.   
 
One interpretation of the results of this study is that Pzq induced egg hatching is not calcium 
dependent or Ca
2+ channel activated because ryanodine and dihydropyridine did not result in 
any  observable  inhibition  of  normal  and  Pzq induced  hatching.  It  is  also  likely  that  the 
concentrations  used  to  treat  the  eggs  were  not  high  enough.  Another  interpretation  is  that 
ryanodine and dihydropyridine failed to penetrate the egg shells due to their high molecular 
weights. The fluorescent tags bound to the compounds may have impeded the diffusion of the 
compounds  across  the  cross linked  protein  shell.  Neill  et  al.  (1988)  demonstrated  that  the 
cytoplasmic layer or von Lichtenberg’s envelope interposed between the host and the miracida 
can effect a barrier against simple passive diffusion.  
 
While Tcbz and its metabolites did not induce premature hatching of the miracidium, loss of egg 
shell and miracidia integrity was observed. This was characterized by the rupture of egg shells, 
and may be evidence of drug penetration into the enveloped miracidium. It has been shown that 
benzimidazoles (Bzs) can penetrate helminths and cestodes via passive diffusion and is the main 
transport mechanism for the accumulation of drugs within the parasites (Mottier et al., 2003; 
Mottier et al., 2006). Interestingly, Tcbz and its metabolites showed a similar ability to penetrate 
the tegument of trematode parasites by passive diffusion (Mottier et al., 2004).  
 
Although the mode of action of Tcbz in schistosomes is unknown, the drug belongs to a class of 
microtubule inhibiting drugs. The crumpling effect and vacuolization of the miracidia tegument 
is  similar  to  the  effects  of  Tcbz  and  its  metabolites  against  another  traematode  parasite, 
Fasciola. It is likely that Tcbz and its metabolites caused miracidial pathology via the inhibition 
of  microtubule  polymerization  (Stitt  &  Fairweather,  1993;  1994).  Morphologically,  the 
compounds  can  be  ranked  in  decreasing  order  of  efficacy:  Tcbz Sx  >  Tcbz Sp  >  Tcbz. 
However, there was no statistical difference in the EC50 values at a 5% level of confidence,                                                                                                                                         Chapter 4    
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suggesting that the parent compound was as effective as its metabolites in inducing miracidial 
deaths. Hatching studies suggested that the drugs continued to induce effects even at 10nM, 
with hatched miracidia that appeared non viable and bloated.  
 
The efficacy of Tcbz and its metabolites against adult schistosomes have been explored recently 
(Keiser et al., 2006). However, their action against the egg stages has not been investigated. 
While  the  screening  of  drugs  against  the  adult  worms  may  be  useful  for  establishing  the 
efficacies of the compounds against systemic stages, the eggs of S. mansoni and S. japonicum 
are the primary causes of host pathology. The results of this study show that research to evaluate 
the activity of new anti schistosomal compounds should not be limited to quantifying the effects 
of fecundity and integrity in adult and immature stages, but should also be extended to include 
potential ovicidal activities for further alleviation of disease. Given the structural robustness of 
the schistosome egg shell, the high efficacies of Tcbz and its metabolites against S.  mansoni 
and S.  japonicum eggs warrants further investigations. 
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5.1 Introduction 
 
The aim of combination therapy is to elicit an amplified effect or treatment outcome. Drug 
synergism can be defined as the joint action of discrete compounds, such that the total effect 
generated is greater than the sum of the two effects when used alone. Combination treatments 
are commonly used in livestock parasite control, and are routinely used against single or co 
infections of different parasites species (Abbot et al., 2004).  
 
The use of drug combinations to treat human schistosomiasis is currently being evaluated by the 
UNDP/World Bank/ WHO Special Programme for Research and Training in Tropical Diseases 
(Utzinger et al., 2003). In particular, a combination of praziquantel (Pzq) and oxamniquine 
(Oxm) has been shown to significantly reduce adult worm and egg burden in humans infected 
with S. mansoni (Shaw & Brammer, 1983). Recent field trials have also demonstrated drug 
synergism against S. mansoni and S. japonicum infections (Pugh & Teesdale, 1983). However, a 
recent study has shown that limitations in the experimental models used may have resulted in 
overestimation of drug efficacy (Utzinger et al., 2003). Combinations of Pzq and artemisinin 
derivatives have also been demonstrated to reduce worm burdens compared to monotherapy 
regimens  (Utzinger  et  al.,  2001a;  Xiao  et  al.,  2000).  However,  the  use  of  a  combination 
treatment of Pzq and artemisinin derivatives is unlikely in endemic areas where people are also 
infected with Plasmodium spp. because of the risk that drug resistance will develop against 
artemisinin (White et al., 1999, Utzinger et al., 2001b). 
 
Triclabendazole (Tcbz) is a benzimidazole anthelmintic that has been shown to have measurable 
efficacies for the treatment of S. mansoni infections (Keiser et al., 2006). Triclabendazole is 
currently registered for veterinary and human use for the treatment of infections with a variety 
of trematode species such as Fasciola, Paragonimus and Clonorchis (Keiser et al., 2005). More 
importantly, Tcbz is effective against juvenile Fasciola (Coles, 1986; Keiser et al., 2005).  
                                                                                                                                      Chapter 5 
82 
The aim of this study was to determine the in vitro efficacy of a combination of Pzq and Tcbz 
for the treatment of S. mansoni. To assess the specificity of the combination, the drugs were 
evaluated against Haemonchus contortus, an intestinal nematode and Giardia duodenalis, an 
intestinal protozoan. While Tcbz has been shown to be active against certain trematode species, 
it is not active against nematodes (Coles, 1986; Hennessey et al., 1987; Keiser et al., 2005). 
Similarly, there are no previous studies demonstrating the efficacy of Tcbz for the treatment of 
G. duodenalis.  
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5.2 Materials and Methods 
 
5.2.1 Schistosoma maintenance 
A  Puerto  Rican  strain  of  S.  mansoni  was  used  in  this  study.  Schistosoma  mansoni  were 
maintained  in  laboratory reared  B.  glabrata  snails  and  perpetuated  in  6 wk  female  Swiss 
outbred mice. Mice were infected percutaneouly with 120 cercariae and maintained for 49 
days. Mice were subsequently sacrifices and adult schistosomes were recovered from the liver 
and messsentery by hepatic perfusion with PBS.  
 
5.2.2 Giardia maintenance 
Giardia  duodenalis  ATCC  P1c10  strain  was used  for this  study. Twenty five  thousand  G. 
duodenalis P1c10 trophozoites were seeded into 10 mL Nunc™ flat sided tubes filled with 
warmed Giardia media (see Chapter 2; General Materials and Methods) and incubated at 37°C 
until monolayer growth was achieved.  
 
5.2.3 Haemonchus maintenance 
A benzimidazole susceptible strain of H. contortus was maintained in mixed sex Merino sheep, 
aged  12  months  at  the  Department  of  Animal  Health,  Western  Australian  Department  of 
Agriculture and Food. Feces were collected three months after infection and eggs separated 
from fecal matter using sucrose floatation (Animal Health Laboratories, 2007). Feces collected 
overnight were immediately processed the following day. Purified eggs were transferred into 
Nunc™ 96 well microtitre plates filled with nutrient media (see Chapter 2; General Materials 
and Methods) and immediately used for drug studies.  
 
5.2.4 Experimental Design 
Individual  dose  response  analysis  for  Pzq  and  triclabendazole sulphoxide  (Tcbz Sx)  were 
initially  performed  to  establish  the  EC50,  EC25  and  EC10  values  required  for  subsequent 
combination isobologram analysis. The combinations of EC50, EC25 and EC10 values of Pzq and 
Tcbz Sx used are detailed in Table 5.1 below.                                                                                                                                      Chapter 5 
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Table  5.1:  Combinations  of  the  EC50,  EC25  and  EC10  values  of  praziquantel  (Pzq)  and 
triclabendazole sulphoxide (Tcbz Sx) used in this study. 
 
EC combinations of Pzq and Tcbz Sx 
EC10+ EC10  EC25+ EC10  EC50+ EC10 
EC10+ EC25  EC25+ EC25  EC50+ EC25 
EC10+ EC50  EC25+ EC50  EC50+ EC50 
 
 
5.2.5 In vitro efficacy of single and combination treatments of praziquantel and 
triclabendazole–sulphoxide. 
 
5.2.5.1 Schistosoma mansoni 
Triclabendazole sulphoxide was chosen for drug combination evaluation because it is the most 
active form of the drug with the highest in vivo efficacy (Robinson et al., 2004). The in vitro 
efficacy of each treatment was determined using methods described by Pica Mattoccia & Cioli 
(2004). Individual drug efficacy experiments were initially performed using six concentrations 
of each drug in triplicate wells of 24 well cell culture plates each filled with 1mL of warmed 
medium 169 and 10 adult S. mansoni worms. One hundred times stock solutions were prepared 
in  dimethyl sulphoxide  (DMSO)  to  make  final  concentrations  of  10 M,  30 M,  100 M, 
150 M, 200 M and 300 M in medium 169. The final DMSO concentration in treated and 
control wells was ≤ 0.1% v/v. Worms were exposed for no more than 24 hrs and were washed 
thrice by pipetting with PBS and the media replaced with fresh media 169. Stock solutions of 
Pzq and Tcbz Sx were preparaed to provide final concentrations equivalent to their EC50, EC25 
and EC10 values in DMSO (Table 5.1). Each drug combination was tested in duplicate wells 
containing 10 mixed sex adult worms.  The final DMSO concentration in treated and control 
well was ≤ 0.2% v/v. Worms were exposed to each treatment for 24 hrs and then washed thrice 
by pipetting with PBS and the media replaced with fresh media 169. The number of dead 
worms were then counted. 
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5.2.5.2 Haemonchus contortus 
Approximately  100  eggs  were  transferred  into  quadruplicate  wells  of  Nunc™  96 well 
microtitre plates. The in vitro activity of Pzq and Tcbz Sx was determined using methods 
described by the Animal Health Laboratories, Department of Agriculture and Food, Western 
Australia. Albendazole (Abz) was used as a positive control drug. Microtitre plates containing 
treated eggs were incubated at 25°C and monitored microscopically for no more than seven 
days. All worms were killed by adding iodine to each well when L3 stage worms were first 
noted in untreated controls. For the evaluation of drug combinations, the EC50, EC25 and EC10 
values derived from the above experiment were mixed to give the nine combinations of the 
EC  values  shown  in  Table  5.1  and  evaluated  as  described  above.  The  final  DMSO 
concentrations for drug combination evaluation were ≤ 2% in both treated and control wells. 
 
5.2.5.3 Giardia duodenalis  
 
Giardia duodenalis strain P1c10 was subcultured in Giardia media for a week prior to the 
commencement of drug screening. A total of 25,000 trophozoites were enumerated and seeded 
into triplicate 10mL Nunc™ Flat sided polystyrene tubes filled with warmed Giardia Media. 
The final concentration of the DMSO in each tube was ≤ 1% v/v. Stock solutions of Pzq, Tcbz 
Sx and Abz (positive control) were made in DMSO to provide final concentrations of 1mM, 
100 M,  10 M,  1 M,  100nM,  10nM  in  Giardia  media.  Culture  tubes  containing  Giardia 
monolayers and each treatment were incubated for 24hrs at 37°C. The proportion of Giardia 
adhered to flat sided culture tubes was determined using OPTIMAS
® image analysis software. 
Digital images were captured from six areas of each culture tubes and the efficacy of drugs 
determined  as  percentages  of  adherence  inhibition  compared  to  untreated  controls.  For 
combination evaluation, Pzq and Tcbz sx were mixed to give nine combinations of the EC50, 
EC25  and  EC10  values  previously  determined  by  singular  dose  response  analyses.  The 
combinations were then exposed against 25,000 Giardia trophopzoites in 10mL Nunc™ Flat 
sided polystyrene tubes. Final DMSO concentrations per tube were ≤ 2% in treated and control 
tubes.                                                                                                                                       Chapter 5 
86 
 
5.2.6 Statistical analysis 
 
 
For S. mansoni, the efficacy of each single and combination treatment was determined by 
calculating the percent worm mortality as follows:  
 
[Control untreated worms – treated worms] × 100%  
Control untreated worms 
 
For  G.  duodenalis,  the  efficacy  of  single  and  combination  treatment  was  determined  by 
calculating the percent inhibition of adherence) as follows:  
 
[control trophozoites adhered − treated trophozoites adhered after drug treatement] × 100%.        
    Control trophozoites adhered 
 
For  H.  contortus,  the  efficacy  of  single  and  combination  treatment  was  determined  by 
calculating the inhibition of L3 stage larval development as follows:  
 
[Control untreated L3 worms − treated L3 worms] x 100% 
Control untreated L3 worms 
 
The EC50 values for each compound and each parasite species were determined using Prism 
V4.0 (GraphPad, San Diego). 
 
 
5.2.7 Combination dose response and isobologram analysis 
 
The level of synergy between Pzq and Tcbz Sx was determined by isobologram analysis. A 
scatter plot of the precent mortality or inhibition was plotted for Pzq and Tcbz Sx for the 
various EC concentrations. A trend line is then drawn between a benchmarked concentration 
ECX (or the effective concentration to elicit X % mortality) of both Pzq and Tcbz Sx. The EC50, 
EC25 and EC10 values that are plotted below the trend line shows drug synergism while values 
plotted above the trend line shows drug antagonism. Values that are plotted along the trend line 
show additive effects between drugs.                                                                                                                                      Chapter 5 
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The fractional inhibitory concentration (FIC) is the interaction coefficient indicating whether 
the combined inhibitory effect of the drugs is synergistic, additive or antagonistic at a chosen 
benchmarked concentration ECX.  
 
The average FIC is derived from the average three FICs calculated using the EC50, EC25 and 
EC10 values of the two drugs. As a rule, an FIC of <1 would indicate synergism, a value of 1 
indicating additive effects while a value of >1 would indicate drug antagonism.  
 
The FIC at ECX = (A + B), where 
A= (ECX of Pzq and Tcbz Sx combination)/ (ECX of Pzq alone) 
B= (ECX of Pzq and Tcbz Sx combination)/ (ECX of Tcbz alone) 
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5. 3 Results 
 
5.3.1  Efficacy  of  praziquantel  and  triclabendazole sulphoxide  against 
Schistosoma mansoni 
 
5.3.1.1 Efficacy of individual drug treatment  
 
The concentration of Pzq and Tcbz Sx required to kill 50% (EC50), 25% (EC25) and 10% (EC10) 
of S. mansoni in 24hrs are shown in Table 5.2. The EC50, EC25 and EC10 values for Pzq are 
significantly lower compared to the EC50, EC25 and EC10 values values for Tcbz Sx (P<0.05).      
 
Table  5.2:  Concentrations  of  praziquantel  (Pzq)  and  triclabendazole sulphoxide  (Tcbz Sx) 
required to kill 50% (EC50), 25% (EC25) and 10% (EC10) of Schistosoma mansoni worms after 
24 hours of exposure in vitro.  
 
                           Concentration ( M) 
  Pzq   Tcbz Sx  
EC50  3   96  
EC25  1.6   67  
EC10  1.1   55  
 
 
5.3.1.2 Efficacy of combination drug treatment 
 
The  percent  mortality  of  worms  treated  with  each  combination  is  shown  in  Table  5.3. 
Immediate and rapid contractions were observed in worms immediately after exposure of each 
combination  treatment.  Worms  died  within  one  hour  after  exposure  as  evidenced  by  the 
cessation of movement. The high efficacies observed were characterized by high mortality 
rates  and  no  worm  recovery,  with  exposed  worms  maximally  contracted  following  fresh 
medium change and further observations for 48hrs. Mortality rates of greater than 50% (EC50) 
were observed for worms exposed to all combinations of Pzq and Tcbz Sx.                                                                                                                                      Chapter 5 
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Table  5.3:  Percent  mortality  of  adult  Schistosoma  mansoni  treated  with  combinations  of 
praziquantel (Pzq) and triclabendazole sulphoxide (Tcbz Sx). Standard errors are presented in 
parenthesis. 
 
Drug combination 
Pzq + Tcbz Sx 
Concentration ( M)  % Mortality (SE) 
EC50 + EC50  96 + 3  100 (0) 
EC50 + EC25  96 + 1.6  100 (0) 
EC50 + EC10  96 + 1.1  100(0) 
EC25 + EC50  67 + 3  100(0) 
EC25 + EC25  67 + 1.6  80 (5.78 ) 
EC25 + EC10  67 + 1.1  80 (5.78 ) 
EC10 + EC50  55 + 3  76.7(3.34) 
EC10 + EC25  55 + 1.6  56.7 (3.34) 
EC10 + EC10  55 + 1.1  56.7 (3.34) 
   
   
Figure  5.1:  Microstructural  effects  of  adult  Schistosoma  mansoni  exposed  to  an  EC50  + 
EC50 combination of praziquantel and triclabendazole sulphoxide.  Maximal contraction and 
vacuolization of internal worm musculature was evident. 
Vc: Vacuolization 
Vc                                                                                                                                      Chapter 5 
90 
 
 
                                   
                                   
                                   
                                   
                 
0
0.2
0.4
0.6
0.8
1
0 10 20 30 40 50 60
EC%  for Pzq concentrations
P
r
o
p
o
r
t
i
o
n
 
K
i
l
l
e
d
EC50  TSX  conc.
EC2 5 TSX  conc.
EC10  TSX  conc.
 
0
0.2
0.4
0.6
0.8
1
0 10 20 30 40 50 60
EC%  for Tcbz Sx concentrations
P
r
o
p
o
r
t
i
o
n
 
K
i
l
l
e
d
EC50 PZQ conc.
EC25 PZQ conc.
EC10 PZQ conc.
 
Figure 5.2: Proportion of Schistosoma mansoni worms killed 
by triclabendazole sulphoxide plotted against the praziquantel 
EC50, EC25 and EC10 concentrations.  
Figure 5.3: Proportion of Schistosoma mansoni worms killed 
by praziquantel plotted against the triclabendazole sulphoxide 
EC50, EC25 and EC10 concentrations.  
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Figure 5.2 and 5.3 showed > 50% worm mortality for all combinations assessed and suggested 
strong drug synergism. The EC90 (concentration required to elicit 90% mortality) was chosen as 
the  benchmark  value  (ECX)  and  was  used  to  derive  the  fractional  inhibitory  concentration 
because of the high mortality rates observed. Figure 5.4 shows the EC90 isobologram derived by 
plotting the EC50, EC25 and EC10 concentrations of Pzq against the concentration of Tcbz Sx 
required to kill 90% of worms. The three EC values plotted below the trend line shows drug 
synergism between Pzq and Tcbz Sx. The average fractional inhibitory concentration (SE) was 
0.644 with a standard error of 0.055.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: EC90 isobologram of praziquantel (Pzq) and triclabendazole sulphoxide (Tcbz Sx) 
combinations assessed against Schistosoma mansoni.  
 
 
5.3.2  Efficacy  of  praziquantel  and  triclabendazole sulphoxide  against 
Haemonchus contortus 
 
5.3.2.1 Efficacy of individual drug treatment 
 
Haemonchus contortus in untreated wells demonstrated good development into the L3 stages, 
with at least 80% of eggs embryonating and hatching. The efficacies of Pzq and Tcbz Sx were 
determined  against  H.  contortus  using  the  larval  development  assay  (LDA).  The  EC50  of 
albendazole, the positive control compound, were significantly lower compared to the EC50 of 
Pzq and Tcbz Sx (P<0.05). A significantly higher concentration of Pzq was required to inhibit 
50% of L3 stage development (EC50 of 181 M) compared to Tcbz Sx. Praziquantel assessed 
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against H. contortus larvae demonstrated EC50, EC25 and EC10 values that were significantly 
higher compared to the EC50, EC25 and EC10 values of Tcbz Sx. Triclabendazole sulphoxide 
also caused observable changes in H. contortus eggs at concentrations above 100 M. Affected 
eggs  were  opaque,  bloated  and  were  unembryonated.  At  lower  concentrations  (10 M  to 
100 M), L1 and L2 stage larvae were sessile and displayed no visible movement, and were 
characterized as dead. Table 5.4 shows the concentrations of Pzq, Tcbz Sx and Abz required to 
inhibit 50% of H. contortus larvae from developing into the L3 stage. 
 
Table  5.4:  Concentration  of  praziquantel  (Pzq),  triclabendazole sulphoxide  (Tcbz Sx)  and 
albendazole (Abz) required to required to inhibit 50% (EC50), 25% (EC25) and 10% (EC10) of 
Haemonchus controtus L3 stage development after 24 hours of exposure in vitro.  
  
 
 
  Concentration ( M) 
  Pzq   Tcbz Sx   Abz 
EC50  181  0.279  0.0054 
EC25  132  0.039  0.0008  
EC10  96  0.0054  0.0001 
 
 
5.3.2.2 Efficacy of combination drug treatment 
 
The percent inhibition of L3 stage development for drug combination studies is shown in Table 
5.5. Mortality rates of greater than 50% were observed for worms exposed to all combinations 
of Pzq and Tcbz except for the lowest combination of the two compounds (Pzq EC10 and Tcbz 
Sx EC10) which showed 47.1% inhibition. Figure 5.5 and 5.6 showed > 50% inhibition of L3 
larval stage for most concentrations of Pzq and Tcbz Sx combinations. The EC70 (concentration 
eliciting  70%  inhibition)  was  chosen  as  the  benchmark  value  and  was  used  to  derive  the 
fractional inhibitory concentration.  
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Table  5.5:  Percent  inhibition  of  L3  development  of  Haemonchus  contortus  treated  with 
combinations of praziquantel (Pzq) and triclabendazole sulphoxide (Tcbz Sx). Standard errors 
are presented in parenthesis. 
 
 
Drug combination  
Pzq + Tcbz Sx 
Concentration ( M) 
% inhibition of L3  
development (SE) 
EC50 + EC50  181 + 0.279  94.1 (2.4) 
EC50 + EC25  181 + 0.039  82.4 (3.53) 
EC50 + EC10  181 + 0.0054  76.5 (1.73) 
EC25 + EC50  132 + 0.279  88.2 (3.53) 
EC25 + EC25  132 + 0.039  82.4 (3.53) 
EC25 + EC10  132 +0.0054  64.7 (2.73) 
EC10 + EC50  96 + 0.279  70.6 (3.0) 
EC10 + EC25  96 + 0.039  58.8 (3.93) 
EC10 + EC10  96 + 0.0054  47.1 (8.98) 
 
 
Figure  5.7  shows  the  EC70  isobologram  derived  by  plotting  the  EC50,  EC25  and  EC10 
concentration  of  Pzq  against  the  concentration  of  Tcbz Sx  required  to  inhibit  70%  of  H. 
contortus L3 larval development. The EC50, EC25 and EC10 values plotted below the trend line 
showed  drug  synergism  between  Pzq  and  Tcbz Sx.  The  average  fractional  inhibitory 
concentration (SE) was calculated to be 0.68 with a standard error of 0.058.  
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Figure 5.5: Proportion of inhibition of L3 stage development 
of  Haemonchus  contortus  worms  by  triclabendazole 
sulphoxide plotted against praziquantel EC50, EC25 and EC10 
concentrations.  
Figure 5.6: Proportion of inhibition of L3 stage development 
of  Haemonchus  contortus  by  praziquantel  plotted  against 
triclabendazole sulphoxide  EC50,  EC25  and  EC10 
concentrations.  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 10 20 30 40 50 60
EC%  for Tcbz Sx concentration
P
r
o
p
o
r
t
i
o
n
 
i
n
h
i
b
i
t
e
d
EC50 PZQ conc.
EC25 PZQ conc.
EC10 PZQ conc.
 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60
EC%  for Pzq concentration
P
r
o
p
o
r
t
i
o
n
 
i
n
h
i
b
i
t
e
d
EC50 TSX conc.
EC25 TSX conc.
EC10 TSX conc.
                                                                                                                                      Chapter 5 
95 
 
 
 
 
Figure 5.7: EC70 isobologram of praziquantel (Pzq) and triclabendazole sulphoxide (Tcbz Sx) 
combinations assessed against Haemonchus contortus.  
 
 
5.3.3  Efficacy  of  praziquantel  and  triclabendazole sulphoxide  against  Giardia 
duodenalis 
 
5.3.3.1 Efficacy of individual drug treatment 
The concentration required for Pzq and Tcbz Sx required to inhibit 50% (EC50), 25% (EC25) 
and 10% (EC10) of G. duodenalis trophozoite adherence in 24hrs are shown in Table 5.6. 
Albendazole and Tcbz Sx inhibited the adherence of Giardia trophozoites, with EC50 values of 
6.17 M  and  12.9 M  respectively.  Both  Abz  and  Tcbz Sx  caused  crumpling  of  Giardia 
trophozoites at concentrations above 10 M, with detachment evident at lower concentrations. 
Loss of flagella was also observed, with some trophozoites appearing sessile and arrested at 
various  stages  of  binary  multiplication.  Praziquantel  was  ineffective  at  inhibiting  Giardia 
adherence. Motility recovery and cell muliplication was observed for Pzq treated trophozoites 
following drug exposure for 24 hours and replacement with fresh media. The EC50 of Abz, Pzq 
and Tcbz Sx were significantly different at P<0.05. 
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Table  5.6:  Concentration  of  praziqantel  (Pzq),  triclabendazole sulphoxide  (Tcbz Sx)  and 
albendazole  (Abz)  required  to  inhibit  50%  (EC50),  25%  (EC25)  and  10%  (EC10)  of  Giardia 
adherence after 24 hours of exposure in vitro. 
 
  Concentration ( M) 
  Pzq   Tcbz Sx   Abz 
EC50      589  6.17  12.9 
EC25  295  2.14  2.95 
EC10  151  0.76  0.1 
 
 
5.3.3.2 Efficacy of combination drug treatment 
The percent inhibition of trophozoite adherence for combination drug treatment is shown in 
Table 5.7. Combinations of Pzq and Tcbz Sx exposed to Giardia trophozoites showed weak 
inhibition of adherence.  
 
Table 5.7: Inhibition of adherence of Giardia duodenalis trophozoites following exposure to 
combinations of praziquantel (Pzq) and triclabendazole sulphoxide (Tcbz Sx). Standard errors 
are presented in parenthesis. 
 
Drug combinations 
Pzq + Tcbz Sx 
Concentrations ( M) 
% Inhibition of 
adherence (SE) 
EC50 + EC50  589 M + 6.17 M  62.3 (4.04) 
EC50 + EC25  589 M + 2.14 M  53.3 (6.66) 
EC50 + EC10  589 M + 0.76 M  46 (1) 
EC25 + EC50  295 M + 6.17 M  55.5 (5.22) 
EC25 + EC25  295 M + 2.14 M
  55.7 (0.58) 
EC25 + EC10  295 M + 0.76 M  58.7 (1.15) 
EC10 + EC50  151 M + 6.17 M  62 (7.55) 
EC10 + EC25  151 M + 2.14 M  50 (8) 
EC10 + EC10  151 M + 0.76 M  17 (8.19)                                                                                                                                      Chapter 5 
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Figure 5.8: The propotion of Giardia trophozoites adherence 
inhibited  by  triclabendazole sulphoxide  plotted  against  the 
praziquantel EC50, EC25 and EC10 concentrations.  
Figure 5.9: The proportion of Giardia trophozoites adherence 
inhibited by praziquantel plotted against the triclabendazole 
sulphoxide EC50, EC25 and EC10 concentrations.                                                                                                                                       Chapter 5 
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Figure 5.8 and 5.9 showed the inhibition of trophozoite adherence by the EC50, EC25 and EC10 
combinations of Pzq and Tcbz Sx.  Moderate inhibition of adherence was observed even at the 
highest concentration assessed. The EC50 (concentration eliciting 50% inhibition) was chosen as 
the benchmark value and was used to derive the fractional inhibitory concentration. The best fit 
of the EC50, EC25 and EC10 values plotted shows weak synergy or drug addition between Pzq 
and Tcbz Sx. 
 
Figure  5.10  shows  the  EC50  isobologram  derived  by  plotting  the  EC50,  EC25  and  EC10 
concentration of Pzq against the concentration of Tcbz Sx required to inhibit 50% of Giardia 
trohpozoites. The average fractional inhibitory concentration (SE) was 0.89 with a standard 
error of 0.18. The FIC value was indicative of weak synergy or additive effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.10:  EC50  isobologram  of  praziquantel  and  triclabendazole sulphoxide  combinations 
assessed against Giardia duodenalis trophozoites.  
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5.4 Discussion 
 
This study was conducted to assess the level of drug synergism between Pzq and Tcbz Sx 
against S. mansoni, H. contortus and G. duodenalis in vitro. In addition to S. mansoni, H. 
contortus and G. duodenalis were assessed with the drug combination for the following reasons: 
1) H. contortus and G. duodenalis have well established models for combination drug testing in 
vitro (Jiménez Cardoso et al., 2004; Kotze et al., 2006), and is useful as benchmarks for this 
study,  2)  To  assess  the  specificity  and  relative  efficacies  of  the  Pzq  and  Tcbz Sx  drug 
combination against unrelated parasite species, and 3) to demonstrate the relative extent of 
morphological damages associated with drug treatment against the three parasites using light 
microscopy. A combination of Pzq and Tcbz Sx was selected for two reasons; 1) there was 
likely to be a high correlation between the in vitro and in vivo effects because both Pzq and 
Tcbz Sx have been shown to be the predominant active forms in vivo (Robinson et al., 2004) 
and  2)  the  in  vitro  efficacy  of  Tcbz Sx  for  each  parasite  species  was  significantly  higher 
compared to the parent Tcbz and the metabolite Tcbz Sp. The checkerboard method of synergy 
assessment using a combination of EC50, EC25 and EC10 values showed that the Pzq Tcbz Sx 
combination  was  synergistic  against  S.  mansoni  and  H.  contortus,  and  was  moderately 
synergistic/additive against G. duodenalis, characterized by average FIC values that were <1. 
 
The results from experiments using S. mansoni showed that Pzq was more effective compared 
to  Tcbz Sx.  In  addition,  S.  mansoni  worms  exposed  to  Pzq  showed  more  pronounced 
morphological effects compared to worms exposed to Tcbz Sx. Adult worms showed maximal 
contraction within 24hrs drug exposure to Pzq. Triclabendazole sulphoxide, on the other hand, 
demonstrated persistent effects, characterised by continued mortality up to 72hrs after drug 
exposure. This could have been due to irreversible binding of Tcbz Sx to exposed worms. The 
use of Pzq and Tcbz Sx in combination appeared to accelerate the effects of each compound on 
S. mansoni, with worms contracting immediately after exposure and mortality evident within the 
first hour of exposure. Combinations of Pzq and Tcbz Sx at EC50+ EC50, EC50+ EC25, EC25+ 
EC50 and EC10+ EC50 caused 100% mortality of adult S. mansoni. The lowest combination                                                                                                                                      Chapter 5 
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dosage of Pzq EC10 and Tcbz Sx EC10 caused 55% worm mortality, demonstrating a 2.75 fold 
amplification of efficacy compared to the sole additive effects of the drugs when used alone. 
These results and the high FIC shows that significant synergism exists between Pzq and Tcbz 
Sx when used against S. mansoni in vitro. 
 
The results from the experiments using H. contortus showed that Tcbz Sx was more effective 
compared to Pzq. The EC50, EC25 and EC10 values of Tcbz Sx were in the nanomolar range, 
while  Pzq  values  resided  within  the  micromolar  range.  At  concentrations  above  100 M, 
pronounced and observable morphological changes to H. contortus eggs were observed. Viable 
eggs that were exposed to Tcbz Sx and assessed seven days later appeared ‘calcified’, bloated 
and  unembryonated.  This  observation  was  consistent  with  the  observations  for  Abz treated 
Haemonchus eggs, where a bloated and opaque appearance was seen. The consistency of this 
observation  suggested  that  Tcbz Sx  and  Abz  elicited  action(s) through  similar  mechanisms, 
albeit observations that Abz was the more effective drug. Pzq, on the other hand, demonstrated 
weak activity and possessed no ovicidal activity, with L3 stage inhibition only evident at the 
higher  concentrations  assessed.  When  Pzq  and  Tcbz Sx  were  assessed  in  combination,  an 
amplification inhibition of L3 stage development was observed. These results demonstrate that 
drug synergism exists between Pzq and Tcbz Sx when used against H. contortus in vitro.  
 
The results of experiments using G. duodenalis showed that Pzq has a weak effect in vitro as 
evidenced by the high EC50, EC25 and EC10 values. Giardia duodenalis treated with the highest 
concentration of 1mM of Pzq were sessile and malformed, appearing luminescent and bloated. 
However,  at  concentrations  below  1mM,  trophozoites  appeared  unaffected,  even  at  these 
relatively high concentrations. In addition, G. duodenalis trophozoite recovered and multiplied 
after 48hrs after exposure with Pzq at all concentrations. While the in vitro activity of Pzq on 
Giardia have not been previously investigated, Flisser et al. (1995) reported that a single oral 
dose of 5mg/kg Pzq was effective in treating human giardiasis. It is possible that the parent Pzq 
was ineffective against Giardia in vivo and that the metabolites of Pzq were responsible for the                                                                                                                                      Chapter 5 
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elimination of Giardia in vivo. Flisser et al. (1995) further postulated that Pzq may have altered 
internal flora, leading to the expulsion of Giardia.  
 
Triclabendazole sulphoxide  demonstrated  a  high  level  of  efficacy  against  G.  duodenalis 
trophozoites.  Morphological  changes  associated  with  the  exposure  of  Tcbz Sx  included 
bloating, cessation of binary multiplication, loss of adherence with pronounced crumpling of the 
entire trophozoite body. Loss of flagella was also observed, with some trophozoites appearing 
luminescent. Such morphological changes were also observed in trophozoites exposed to Abz, 
the  positive  control.  Surprisingly,  Abz  demonstrated  higher  EC50  values  (less  effective) 
compared  to  Tcbz Sx  at  24hrs  after  drug  exposure.  However,  Abz  possessed  pronounced 
persistent inhibition at 48 and 72hrs post exposure whereas trophozoites treated with Tcbz Sx 
appeared to recover after 48hrs of exposure, with binary multiplication evident at concentrations 
below 100 M. The FIC of 0.89 for Pzq and Tcbz combinations suggested weak drug synergism 
or drug addition effects. 
 
It is not possible to determine the mechanism of synergy observed for Pzq and Tcbz Sx against 
S. mansoni and H. contortus. Morphological changes induced in G. duodenalis trophozoites 
after exposure to Tcbz Sx suggest that the compound inhibited microtubule formation which 
agrees  with  observations  of  Abz  exposure  (Reynoldson  et  al.,  1992).  Triclabendazole 
sulphoxide had a moderate effect on H. contortus eggs compared to the strong ovicidal activity 
and larvicidal activity of Abz. Lacey et al. (1987) showed that there is a strong correlation 
between the inhibition of egg hatching and the inhibition of tubulin depolymerization which 
leads to microtubule disruption.  
 
The cytoskeletal elements (including microtubules) of schistosomes are not good targets of drug 
action  due  to  their  internal  localization  (Jones  et  al.,  2004).  Nevertheless,  the  cytoplasmic 
bridges  of  tegumentary  cytoplasm  possess  a  ring  of  microtubules,  primarily  used  for 
anterograde transport (Wiest et al., 1988). Further work by Jones et al. (2004) showed that the 
stable  microtubules  are  distributed  within  the  interconnecting  tegumental  bridges  of                                                                                                                                      Chapter 5 
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schistosomes. The bridges represented areas rich in microtubules that extended into the distal 
cytoplasm and were separated from other bridges, resulting in intervening regions that were 
entirely devoid of microtubules. Recent studies have shown that Tcbz Sx inhibit microtubule 
formation by binding to beta tubulin subunits of F. hepatica (Fairweather & Boray, 1999). 
 
However, weak and inconsistent activities of Tcbz Sx were observed when the compound was 
applied against S. mansoni (Keiser et al., 2006)  This could be due to the poor presentation of 
Schistosoma microtubules (Jones et al., 2004). In S. mansoni, tubulin is positioned as vertical 
lines stretching across the whole thickness of the syncytium, while F. giagantica tubulin was 
disseminated  in  tegumental  cell  bodies,  cytoplasmic  processes  and  the  basal  layer  of  the 
tegumental  syncytium  (Tansatit  et  al.,  2006).  It  is  therefore  likely  that  the  organization  of 
Fasciola microtubule is more accessible to Tcbz Sx action compared to Schistosoma tubulin. 
 
If the combination of Pzq and Tcbz Sx elicited effects through two independent mechanisms of 
action, it is possible that tegument sloughing (as a result of the action of Pzq) may have exposed 
schistosome  microtubules  which  enhanced  Tcbz Sx  induced  disruption.  It  has  also  been 
previously  demonstrated  by  Linder  &  Thors  (1992)  that  Pzq  exposes  the  surface  spines 
consisting of paracrystalline actin following tegumental disruption. In a separate study, Pzq was 
shown to expose and disrupt underlying subtegumental/ parenchymal tissues (Shaw & Erasmus, 
1987). The close proximity of schistosome actin to the underlying microtubule would allow 
increased access to these structures following the effects of Pzq. This may have accounted for 
the apparent synergy of Pzq and Tcbz Sx, resulting in worm contractions and mortality rates 
that were rapid and unrecoverable.  
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6.1 Introduction 
Praziquantel (Pzq) is usually delivered in a single dose for control, or as a two dose regime for 
contol and prevention. Praziquantel is used to treat human schistosomiasis because it has a large 
therapeutic  index  and  has  good  efficacy  against  all  schistosome  species.  Recent  reports  of 
treatment failure have prompted an evaluation of alternative treatment that may be required if 
extensive resistance develops against Pzq. 
 
One alternative to Pzq is triclabendazole (Tcbz), a benzimidazole active against a range of 
trematodes and cestodes. Triclabendazole has previously been shown to possess good efficacy 
for the treatment of human Paragonimiasis and Fascioliasis (Keiser et al., 2005). Early reports 
by Mansoury (1997), el Sayed & Allam (1997), Schmidt (1998) and Khalil (2000) demonstrated 
that Tcbz significantly reduced worm burdens by up to 84% in mice infected with S. mansoni. 
More recently, however, Keiser et al., (2006) revealed that Tcbz and its metabolites possessed 
weak  and  inconsistent  anti schistosomal  activities  in  vivo,  characterized  by  worm  burden 
reductions of only 35% at 120mg/kg. It is difficult to interpret these conflicting reports because 
of inconsistencies in experimental methodologies, as well as the varying inherent susceptibilities 
of schistosome strains (Soliman et al., 1986; el Mansoury, 1995). 
 
Combination  drug  therapies  are  increasingly  being  used  to  treat  parasitic  diseases  such  as 
malaria where multi drug resistance have developed. The aim of this study was to assess the 
efficacy of a combination of Pzq and Tcbz for the treatment of mice infected with S. mansoni. 
Drug efficacy was evaluated on the basis of adult worm burden reduction, tissue egg loads and 
oogram patterns (Keiser et al., 2006).  
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6.2 Materials and Methods 
6.2.1 Schistosoma maintenance 
Schistosoma mansoni (Puerto Rican strain) was maintained in B.  glabrata snails for 35 days in 
the Queensland Institute of Medical Research. Percutaneous infection of 25 mice was performed 
with  120  cercariae  for  each  mouse.  Mice  were  maintained  for  49  days  before  the 
commencement of drug trials. Mice were randomly allocated into groups of five and housed at 
ambient temperature on a 12hr light/dark cycle for one week prior to infection. Food and water 
were administered ad libitum.  
 
6.2.2 Drug efficacy 
Praziquantel and Tcbz (Epichem Pty Ltd., Australia) were suspended in 2.5% Cremophor EL 
(Sigma Aldrich,  St  Loius,  USA).  Each  group  of  mice  were  weighed  to  obtain  the  average 
weights. Individual groups of mice were then treated with Pzq (80mg/kg), Tcbz (120mg/kg), 
Pzq Tcbz (80mg/kg+120mg/kg) and Pzq Tcbz (250mg/kg+250mg/kg) by oral gavage. The Pzq 
dose chosen was based on the ED50 value of a previous study by Pica Mattoccia & Cioli (2004). 
The Tcbz dose was chosen based on the protocol described in Keiser et al., (2006). An untreated 
group  was  maintained  as  control.  Mice  were  sacrificed  four  days  after  drug  treatment  and 
hepatic perfusion performed. Adult worms were recovered from the hepatic and portomesenteric 
vessels by perfusion according to the protocols of Smithers & Terry (1965). Worms from the 
mesenteric veins were removed, sexed and enumerated using a microscope. The total number of 
worm mortalities was calculated by subtracting the total worm burden of each treated group 
from the worm burden of the untreated group. 
 
6.2.3 Oogram pattern and tissue egg load analyses 
Oogram analysis was performed by excising three fragments from the middle part of the small 
intestines. The fragments were cut longitudinally, washed with saline and compressed between 
microscope slides. The slides were then examined microscopically at 100 × magnification. A 
total of 100 eggs per animal were enumerated and the stages of egg development assessed     Chapter 6 
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according to Pellegrino et al. (1962). The tissue egg load analysis was determined as follows: 
0.3g  of  the  liver  and  small  intestine  from  each  mouse  were  digested  in  5 mL  5%  KOH 
overnight. Three digest aliquots of 150 L were then examined microscopically and the number 
of eggs counted. Hepatic and intestinal tissue egg loads were expressed as eggs per gram (epg), 
determined by multiplying the number of eggs enumerated by the total volume of the KOH and 
dividing this value by the weight of the sample.  
 
6.2.4 Statistical analysis 
 
Statistical analysis was performed using Prism v.4 (GraphPad, San Diego). Drug efficacy was 
assessed by comparing the mean number of worms in treatment groups against the untreated 
control group. The statistical significance of any differences were determined using an unpaired 
two tailed students’ test with unequal variance at a 95% confidence limit.  
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6.3 Results  
6.3.1 Tissue egg load analysis 
There was a significant decrease in the mean hepatic egg load and the mean intestinal egg load 
in mice treated with Pzq, Tcbz and the two drug combinations compared to untreated contol 
mice  (P<0.05;  Table  6.1).  Praziquantel  (80mg/kg)  treated  mice  showed  significantly  lower 
hepatic  and  intestinal  egg  loads  compared  to  Tcbz  (120mg/kg)  and  Pzq Tcbz  combination 
(80mg/kg and 120mg/kg) treated mice. The hepatic and intestinal egg loads were significantly 
lower (P<0.05) in mice treated with Pzq (80mg/kg) compared to mice treated with the highest 
Pzq  and Tcbz  combination  dose (250mg/kg  and  250mg/kg).  There  was  also a  significantly 
lower (P<0.05) hepatic and tissue egg load in mice treated with Tcbz (120mg/kg) compared to 
mice treated with Pzq (80mg/kg), Pzq Tcbz (80mg/kg  120mg/kg) and Pzq Tcbz (250mg/kg   
250mg/kg). 
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Table 6.1: Mean hepatic and intestinal egg loads in eggs per gram (epg) of mice infected with Schistosoma mansoni and treated with Pzq 
(80mg/kg),  Tcbz  (120mg/kg),  Pzq Tcbz  combination  (80mg/kg   120mg/kg)  and  Pzq Tcbz  combination  (250mg/kg     250mg/kg).  Standard 
deviations and standard errors are presented in parenthesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean number of eggs (10
3) 
Drug ( dose in mg/kg)  Hepatic counts (SD)  Intestinal counts (SD)  Hepatic epg (SD)  Intestinal epg (SD)  Hepatic epg (SE)  Intestinal epg (SE) 
             
             
Untreated control  49.4 (16)  32.2 (8.5)  16.5(5.3)  10.7(2.8)  16.5 (2.37)  10.7 (1.25) 
             
             
Pzq (80)  24.4 (4.28)  1.4 (1.14)  8.13(1.43)  0.47(0.38)  8.13 (0.64)  0.47 (0.17) 
             
             
Tcbz (120)  45.2 (10.4)  3.8 (2.17)  15.1(3.5)  1.27(1.2)  15.1 (1.56)  1.27 (0.54) 
             
             
Pzq   Tcbz (80 120)  28.8 (6.6)  2.2 (2.68)  9.6(2.2)  0.73(0.89)  9.6 (0.98)  0.73 (0.4) 
             
             
Pzq   Tcbz (250 250)  18 (6.12)  0.2 (0.45)  6(2.0)  0.067(0.022)  6 (0.89)  0.067 (0.001) 
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6.3.2 Oogram pattern analysis 
There were significantly more immature eggs compared to mature eggs in the intestines of the 
untreated control mice group and in mice treated with Tcbz (P<0.05; Table 6.2). There were 
significantly more mature eggs than immature eggs in the intestines of mice treated with Pzq at 
80mg/kg  (P<0.05).  A  significantly  higher  (P<0.05)  numbers  of  mature  eggs  compared  to 
immature eggs was observed in the intestines of mice treated with the highest combination doses 
of Pzq and Tcbz (250mg/kg 250mg/kg). There was no statistical difference between the number 
of mature and immature eggs in the intestines of mice treated with the lower combination dose 
of Pzq and Tcbz (80mg/kg 120mg/kg). 
 
Table  6.2:  Oogram  pattern  of  mice  infected  with  Schistosoma  mansoni  and  treated  with  
praziquantel  (Pzq;  80mg/kg),  triclabendazole  (Tcbz;  120mg/kg),  Pzq Tcbz  combination 
(80mg/kg +120mg/kg) and Pzq Tcbz combination (250mg/kg +250mg/kg). Standard errors are 
presented in parenthesis. 
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
           
 
6.3.3 Worm burden reduction 
Mice treated with the four dosage regimens demonstrated mean worm burden reductions that 
were significantly different to each other at P<0.05 (Table 6.3). Mice treated with 80mg/kg of 
Pzq showed significantly higher mean worm burden reductions compared to mice treated with 
120mg/kg of Tcbz. Mice treated with Pzq and Tcbz (80mg/kg 120mg/kg) significantly higher 
Percentage of eggs at each development stage 
 
Dose 
(mg/kg) 
First 
immature 
Second 
immature 
Third 
immature 
Fourth 
immature 
Total 
immature  Mature  Dead 
 
Untreated  12.1 (2.9)  18.3 (12.6)  32.8(5.8)  13.7 (2.5)  77 (10)  22.7 (10.3)  0.4 (0.5) 
               
Pzq  3.42 (5.7)  1.64 (2.25)  6.06 (10.7)  2.04 (3.5)  13.16 (6.9)  71 (12.1)  15.8 (6.74) 
80               
               
Tcbz  1.25 (2.8)  6.8 (5.6)  35 (11.2)  17.8 (12)  60.9 (8.4)  8.9 (4.3)  30.2 (5.4) 
120               
               
Pzq   Tcbz  0 (0)  0 (0)  3.8 (6.2)  23.7 (28.5)  27.6 (24)  61 (24)  11.5 (9.15) 
(80 120)               
               
Pzq   Tcbz  0 (0)  0 (0)  0 (0)  6.2 (15.4)  6.2 (15.4)  68.5 (22.1)  25.7 (10) 
(250 250)               
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worm burden reductions compared to mice treated with 80mg/kg of Pzq and mice treated with 
120mg/kg of Tcbz. The worm burden reductions in mice treated with the highest combination 
dose of Pzq and Tcbz (250mg/kg 250mg/kg) were significantly higher than all other treatment 
groups (P<0.05). The order of efficacy according to percentage reduction of worm burden is 
Pzq Tcbz (250mg/kg 250mg/kg) > Pzq Tcbz (80mg/kg 120mg/kg) > Pzq (80mg/kg) > Tcbz 
(120mg/kg).  
 
There was no significant differences in the number of male and female worms receovered 
from  untreated  mice.  Praziquantel  (80mg/kg),  triclabendazole  (120mg/kg)  and  Pzq Tcbz 
(80mg/kg 120mg/kg) treated mice showed higher female worm burden reductions that were 
statistically significant (P<0.05). Infected mice treated with the highest drug combination of 
Pzq Tcbz (250mg/kg 250mg/kg) showed significantly higher male worm burden reduction.  
 
No premature deaths or adverse behavioural symptoms were noted for the treatment groups.     Chapter 6 
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Table  6.3:  Worm  burden  of  mice  infected  with  Schistosoma  mansoni  and  treated  with  praziquantel  (Pzq;  80mg/kg),  triclabendazole  (Tcbz; 
120mg/kg), Pzq Tcbz combination (80mg/kg +120mg/kg) and Pzq Tcbz combination (250mg/kg +250mg/kg). Standard deviation and standard 
errors are presented in parenthesis. 
 
 
 
 
Number of worms 
 
Treatment 
 
Mean 
(SD) 
 
Mean males 
(SD) 
Mean females 
(SD) 
% Mean worm 
reduction (SE) 
% Female worm  
reduction (SE) 
% Male worm 
reduction (SE) 
             
                   
Untreated  47 (11.5)  22.4 (5.6)  24.6 (6.1)  0  0  0 
             
                   
Pzq   32.6 (5.68)  16.2 (2.95)  16.4 (3.21)  30.6 (2.54)  33.3 (1.32)  27.7 (1.43) 
80                   
                   
             
Tcbz   36.6 (4.04)  18.2 (3.11)  18.4 (1.52)  22.1 (1.8)  25.2 (1.39)  18.8 (0.68) 
120                   
                   
                   
Pzq   Tcbz  26.6 (4.83)  13.2 (2.39)  13.4 (2.7)  43.4 (2.16)  45.5 (1.07)  41.1 (1.21) 
(80+120)             
                   
                   
Pzq   Tcbz  12.4 (4.04)  5.6 (2.88)  7.2 (1.3)  73.6 (1.8)  70.7 (1.29)  75 (0.58) 
(250+250)                   
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6.4 Discussion 
The results of this study demonstrated that Tcbz at 120mg/kg was partially effective in treating 
mice infected with S. mansoni as evidence by a reduction in the mean worm burden.  The 
reduction in worm burden following treatment with Tcbz is lower compared to the worm burden 
reductions observed by Keiser et al. (2006) for the Egyptian strain (35.5%) at 120mg/kg, but is 
considerably higher than those observed for a Liberian strain assessed at 400mg/kg (6.6%). The 
subcurative dose of Pzq used in this study (80mg/kg) was derived from published observations 
by  Pica Mattoccia  &  Cioli  et  al.  (2004).  Cioli  et  al.  (2004)  suggested  that  Pzq susceptible 
isolates possessed ED50 values that were <100mg/kg, with results suggesting a mean ED50 of 
approximately 70±7 mg/kg. In a separate study by Pica Mattoccia & Cioli (2004), an ED50 
value of 80.1mg/kg was reported using mature, bisexual worms. In this study, the worm burden 
was only reduced by 30.6% following treatment with 80mg/kg Pzq. The difference observed is 
likely to be a result of the dosing regimen employed. Pica Mattoccia & Cioli (2004) treated 
mice orally for five consecutive days using different doses of Pzq. Keiser et al. (2006), on the 
other hand, only administered single doses of Pzq. This may have accounted for the mortalities 
of mice observed in Keiser et al. (2006) for both treated and untreated groups. In this study, a 
single  dose  of  80mg/kg  was  used.  It  is  also  important  to  note  that  different  isolates  of  S. 
mansoni  possess  variable  susceptibilities  to  drugs  (Soliman  et  al.,  1986;  el  mansoury  & 
Bayoumi, 1995). Botross et al. (2006) further demonstrated that S. mansoni isolates that were 
less sensitive to Pzq induced lower inhibition of hepatic drug metabolizing enzymes, resulting 
in higher metabolic transformation of Pzq.  
 
In addition, treated mice were sacrificed four days after treatment compared to four weeks and 
three weeks used by Keiser et al. (2006) and Pica Mattoccia & Cioli (2004) respectively. This 
time point was used because Pzq and its metabolites are eliminated in humans within four days 
after oral dosing (Dayan, 2003). Mice were also perfused within four days instead of extended 
periods  of  time  to  minimize  deaths associated  with prolonged  infections  and incipient  host 
morbidity. While most in vivo anti schistosomal challenge trials were analyzed two to four     Chapter 6 
112 
weeks post drug administration (Keiser et al., 2006, Xiao et al., 2006, Pica Mattocia & Cioli, 
2004),  the  results  of  this  study  reflected  the  immediate  effects  post drug  administration. 
Therefore, the lower than expected reduction observed in this study was likely to be a result of 
variations  within  the  dosing  methodologies  and  inherent  variations  in  strain drug 
susceptibilities, although adult worm resistance and (or) loss of drug sensitivity should not be 
discounted.  
 
The worm burden reduction observed in this study suggested that the combinations have the 
potential to exert additive effects against S. mansoni worms. Individual doses of Pzq and Tcbz 
induced a 30.6% and 22.1% reduction in worm burden in mice infected with S. mansoni. The 
theoretical efficacy of the combination assuming an additive effect would be 45.9% ( i.e. 30.6% 
+ [22.1/100 × (100 30.6)] ). Therefore, the observed efficacy of 43.4% ± 2.16% suggests a drug 
addition effect for a combination of Pzq and Tcbz (80mg/kg 120mg/kg) in vivo. 
 
When Pzq Tcbz was administered at a higher combination dose (250mg/kg + 250mg/kg), a 
mean worm burden reduction of 73.6% was observed. The purpose of this combination dose 
was to assess the effects of the drugs at high concentrations, as well as the potential toxicity to 
treated mice. No mice died as a result of the experiment, and no signs of toxicity were observed 
during  the  trials.  Pica Mattoccia  &  Cioli  (2004)  demonstrated  an  approximate  80%  worm 
burden reduction when a total of 250mg/kg of Pzq was administered daily for five days. While 
250mg/kg doses of Pzq and Tcbz were not assessed as single doses in this experiment, it is 
unlikely that the combination would have induced a reduction of worm burden above 80%. This 
is based on previous work by Keiser et al. (2006) who suggested that a high single dose of 
500mg/kg Pzq elicited 92.9% worm burden reductions. Keiser et al. (2006) also reported that a 
total dose of 400mg/kg Tcbz elicited 6.6% worm burden reduction against a Liberian strain, 
with a worm burden reduction of 18.6% observed for two consecutive doses of 200mg/kg Tcbz. 
There  is  no  currently  no  efficacy  data  in  the  literature  for  Pzq  and  Tcbz  administered  at 
250mg/kg. The lack of comparable data makes it difficult to demonstrate that the high Pzq Tcbz     Chapter 6 
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combinations assessed (250mg/kg + 250mg/kg) were additive or synergistic. However, this dose 
regime appeared safe for administration in mice infected with S. mansoni. 
 
The  hepatic  tissue  egg  load  observed  in  untreated  control  mice  was  in  agreement  to  the 
observations of Keiser et al., (2006) However, lower intestinal egg loads compared to hepatic 
egg loads were persistently observed for all mice groups, which is in contrast to the study 
performed by Keiser et al. (2006). This observed difference is unlikely to be a result of the 
sampling regimen as all care was taken to ensure that samples were obtained from the middle 
part of the small intestine. It is possible that the worms used in this study have lower levels of 
fecundity compared to those used by Keiser et al. (2006). There was a significant reduction in 
egg counts in both liver and intestinal samples from mice treated with Pzq. Interestingly, mice 
treated  with  Tcbz  showed  significant  reduction  in  intestinal  egg  load  but  no  significant 
reduction  in  hepatic  egg  loads  compared  to  untreated  mice.  This  can  be  explained  by  the 
different mechanisms of drug actions against S. mansoni eggs. Praziquantel, in addition to its 
effects against adult worms, has been shown to cause pre mature hatching of viable eggs in vitro 
(Matsuda et al., 1983, Katsumata et al., 1988). Praziquantel treatment also induces a reduction 
in  the  number  of  mature  eggs  and  an  increase  in  the  number  of  empty  egg  shells  in  vivo 
(Matsuda et al., 1983). Triclabendazole and its metabolites in previous in vitro experiments 
(Chapter four) have been shown to cause the premature rupturing of eggs. It is evident that Tcbz 
caused a reduction in egg output that was lower compared to Pzq treated mice.  
 
At the lower combination dose (80mg/kg 120mg/kg), a significant reduction of hepatic and 
intestinal egg load was observed compared to untreated mice. However, the difference in the 
tissue  egg  loads  was  not significant  when compared  to  Pzq treated  groups.  When  a  higher 
combination dose was administered (250mg/kg 250mg/kg), a statistically significant reduction 
in hepatic and intestinal egg load was observed compared to the Pzq treatment group. This 
demonstrates  that  a  combination  of  Pzq  and  Tcbz  at  doses  of  250mg/kg  each  can  be 
administered to improve treatment efficacy in mice.  
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There is currently no data available on the pharmacokinetic profile of Tcbz in humans or mice. 
Alvarez Bujidos  et  al.  (1993)  demonstrated  the  elimination  half life  of  triclabendazole 
sulphoxide and triclabendazole sulphone to be 16.86hrs and 13hrs respectively. Lecaillon et al. 
(1998)  demonstrated  an  elimination  half life  of  11.2hrs  for  the  sulphoxide  metabolite  and 
11.8hrs for the sulphone metabolite. On the other hand, Pzq elimination is rapid, with a half life 
of one to two hrs in unmetabolized Pzq (Cioli & Pica Mattoccia, 2003) and three to eight hours 
for  metabolites in  most  species (EMEA,  1996;  Dollery,  1999). While  the  clearance  of  Pzq 
metabolites is limited by the rate of metabolism, most metabolites are completely cleared by 
four days post oral administration (Dayan, 2003). Tcbz and its metabolites, on the other hand, 
bind strongly to serum albumin and can remain in plasma for extended periods of time in treated 
animals. The difference in the rate of elimination of both Pzq and Tcbz could explain why more 
dead eggs were observed in Tcbz treated mice compared to Pzq treated mice. Where Pzq and its 
metabolites are cleared rapidly, serum bound Tcbz and its metabolites may have continued to 
exert ovicidal effects. 
 
At lower combination doses, a large reduction of immature eggs was observed. At the higher 
combination  dose,  there  were  significantly  less  eggs  at  immature  stages  of  development. 
Interestingly, both drug combinations induced large reductions in the number of first, second 
and third stages of immature eggs, with most eggs observed at mature stages of development. It 
is  not  possible to  identify  the  exact  cause,  but it may  be  possible  that  the drugs  caused  a 
cessation or a reduced capacity in egg laying, as evidenced by the lack of immature eggs. It was 
also  possible  that  the  number  of  mature  eggs  observed  were  ‘residual’  eggs  that  were  in 
transition within the mesentery or small intestines, and were laid prior to drug administration. 
Moreover, it has been noted in previous in vitro experiments (Chapter 3) that adult females 
continue to expel eggs following treatment even though the eggs were largely unviable. While 
the mean numbers of dead eggs for both combinatorial treatment groups were not statistically 
different to those of the Pzq treated group, it is important to note that a significant egg burden 
reduction was observed in both intestinal and hepatic samples.  
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7.1 Introduction 
Schistosomiasis affects more than 600 million people annually, resulting in a loss of between 
1.53 million and 4.5 million disability adjusted life years worldwide (Gryseels et al., 2006; 
Utzinger & Keiser, 2004; WHO 2002). Current schistosomiasis control programmes are based 
on the provision of a single annual dose of praziquantel (Pzq) to reduce morbidity associated 
with  the  disease.  The  administration  of  a  single  dose  rate  of  40mg/kg  Pzq  has  been  well 
received and its price has significantly reduced following the expiration of its patent in the early 
90s. Although competitive pricing from generic producers of Pzq has enabled greater public 
acceptance, operational expenses such as distribution and delivery can still add considerable 
costs to control programmes. While care is taken to ensure that there is minimal, indiscriminate 
use of Pzq, such measures are difficult to enforce in developing countries, particularly when 
drugs are administered through mass treatment schemes.  
 
Recent studies have shown that triclabendazole (Tcbz) may be suitable for the treatment of 
human  schistosomiasis  (Khalil,  2000;  Schmidt,  1998;  Mansoury,  1997;  el  Sayed  &  Allam, 
1997). However, further research is required because some studies have shown that the efficacy 
of triclabendazole and its metabolites is variable in vivo (Keiser et al., 2006). One approach that 
has not been explored is the use of combinations of Pzq and other trematocides such as Tcbz.  
 
Drug combinations are increasingly being used for the treatment of parasitic diseases such as 
malaria where drug resistance has limited the efficacy of existing compounds. Whilst there is no 
convincing evidence of Pzq resistance in schistosomes (Gryseels et al., 2001), studies have 
consistently shown that standard doses of 40mg/kg Pzq generally only cure 70 90% of human 
infections (Stelma et al., 1995; Kumar & Gryseels, 1994; Davis, 1993; WHO, 1993; Gryseels et 
al.,  1987).  In  Senegal,  unusually  low  cure  rates  of  18 38%  have  been  reported  by  Danso 
Appaiah & De Vlas (2002), raising concerns for the emergence of resistance or tolerance to Pzq. 
 
Triclabendazole was used in this study because: (1) Tcbz and its metabolites are currently ‘off 
patent’ and are available from generic manufacturers, (2) Tcbz is cheap to produce and there are Chapter 7 
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existing  distribution  chains  in  endemic  regions  for  treating  other  trematode  infections  of 
animals,  (3)  Tcbz  has  regulatory  approval  for  veterinary  use  with  established  efficacy, 
pharmacokinetic  and  mammalian  toxicity  profiles  and  may  reduce  the  costs  of  obtaining 
regulatory approval for human use, (4) the WHO has expressed a desire to assess the use of 
Tcbz for treating parasite co infections of Schistosoma and Fasciola (TDR, 2005), (5) there are 
no  alternative  drugs  for  the  treatment  of  human  schistosomiasis  and (6) there  is  a  need  to 
mitigate  capital  risks  where  the  funding  for  drug  development  and  delivery  are  highly 
constrained.  
 
Cost effectiveness analyses for human schistosomiasis have been performed to evaluate the 
efficacy of existing chemotherapeutic schemes, delivery strategies and diagnostic technologies. 
However,  the  use  of  cost  effectiveness  analyses  for  schistosomiasis  control  programmes  is 
challenging due to the complexities of valuing the benefits arising from each programme. The 
aim of this chapter is to develop an economic model to evaluate the cost effectiveness of a new 
combination drug for the treatment of human schistosomiasis in a region of intense transmission 
where the efficacy of Pzq treatment is low. The cost effectiveness of a drug combination of Pzq 
and Tcbz can be determined by comparing the costs to treat a target population with the benefits 
derived from treatment as a measure of (1) the gross national income (GNI) saved and (2) the 
number of days lost to disease despite treatment. 
 
 
 
 Chapter 7 
117 
7.2 Materials and Methods 
7.2.1 Data sources  
Data for this cost effectiveness analysis were primarily derived from peer reviewed literature 
and published sources. Economic data projections were obtained from electronic sources such 
as the World Bank (http://www.worldbank.org, 2007) and the International Monetary Fund 
(http://www.imf.org,  2007).  Epidemiological  and  population  projections  were  derived 
primarily  from  the  WHO  (http://www.who.int,  2007)  and  US  Census  Bureau 
(http://www.census.gov, 2007).  
 
7.2.2 General assumptions 
Several assumptions were necessary for the development of this analysis: 
•  The Pzq Tcbz combination would be available in a single dose formulation, 
•  The  combination  therapy  would  be  administered  via  exisiting  mass  treatment 
programme frameworks, 
•  The  combination  therapy  can  increase  the  efficacy  of  treatment  for  human 
schistosomiasis through its additive effects, 
•  The combination therapy is assumed to be active against all species of schistosomes 
and will be available on a global scale, 
•  Two drug combinations using different concentrations of Pzq and Tcbz at 1 1 drug 
ratio (600mg 600mg) and 0.5 0.5 drug ratio (300mg 300mg) were used, 
•  There are negligible adverse drug interactions between Pzq and Tcbz, 
•  Further research and development as well as regulatory approval will be achieved at 
minimal expense over a period of five years. 
 
All costs were expressed in United States dollars (US$) for the present value of money (2007). 
For cost projections, prices were inflated at a global core inflation rate of 3% per annum (pa.) 
from 2007 to 2030 (http://www.imf.org/external/pubs/ft/weo/2007/01/index.htm, 2007).  
 
7.2.3 Drug and operational costs 
Current and past median prices for one 600mg Pzq tablet was derived from the Management 
Sciences  for  Health  International  Drug  Price  Indicator  Guide  for  the  years  1996  to  2006 Chapter 7 
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(http://www.msh.org/resources/publications/IDPIG_2004.html, 2007). The International Drug 
Price  Indicator  lists  pharmaceutical prices  on  the international  market  including  the  list  of 
suppliers,  international  development  agencies  and  government  procurement  agencies.  The 
median prices depicted in the guide reflect the median prices of purchase from nine major 
suppliers in the international market.  
 
On average, two 600mg Pzq tablets are required to treat each child annually, whilst an adult 
would require an average of three to five 600mg tablets (Gabrielli et al., 2006; Guyatt et al., 
1994). The current total cost of treating a child (age 5 14) is approximately US$0.30 at a dose 
of 60mg/kg body weight (Fenwick et al., 2003; Kusel & Hagan, 1999; Guyatt et al., 1994).  
 
The average prices for Tcbz were derived from the quoted average retail prices for 1kg and 
100kg of generic Tcbz from five Chinese suppliers (www.chemexper.com): CstChem Ltd., 
Labseeker  Co.  Ltd.,  Shanghai  Pi  Chemicals  Ltd.,  HalloChem  Pharma  Ltd.  and  Yick Vic 
Chemicals & Pharmaceuticals (HK) Ltd. Suppliers that provided prices outside of the average 
price range per kg were not included in the analyses. The average market value of a 250mg 
tablet of Tcbz was obtained from the WHO (www.who.int, 2004).  
 
The sale prices for a single 600mg 600mg tablet of Pzq and Tcbz in 2007 was calculated using 
the estimated gross margin for a 600mg tablet of Pzq in 2005. The gross margin is the ratio of 
gross  profit  to  sales  revenues  expressed  as  a  percentage.  A  gross  margin  of  83.5%  was 
calculated for each 600mg Pzq tablet (Reich et al., 1998). The prices of each Pzq and Tcbz 
tablets were then increased using the average percent inflation (3%) of Pzq tablets from 2000 to 
2005. A loss of 3% of raw materials during production was also assumed (Reich et al., 1998). 
 
The operational cost for the delivery of the combination therapy for children and adults was 
based on the existing frameworks to deliver Pzq treatments. Table 7.1 shows the sources used 
to determine the mean operational costs and drug costs used in this analysis. 
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Table 7.1: Sources of operational costs for the delivery of praziquantel treatments. 
  % Cost  
  Operational  Drug 
Gabrielli et al. (2006)  30.6  69.4 
Kabatereine et al. (2006)  11.3  88.7 
Van der Werf et al. (2004)  60  40 
The Partnership for Child Development (1999)   32  68 
The Partnership for Child Development (1999)  19  81 
Guyatt et al. (1994)  24  76 
 
7.2.4 Patient number projections 
The total global demand and availabililty of Pzq is summarised in Table 7.2.  
 
Table 7.2: Current availability of praziquantel (600mg) and the current proportion of people with 
access to praziquantel (Pzq) treatment. 
 
  Millions 
Proportion  
(%) 
Reference 
 
Global demand for Pzq (tablets)  
 
424 
   
Garbielli et al.(2006) 
Reich et al. (1998) 
 
Current availability of Pzq (tablets) 
 
89  
   
Garbielli et al.(2006) 
 Reich et al. (1998) 
 
Current availability 
   
21 
 
 
 
Number of people requiring Pzq  86.5    Brady et al. (2006) 
 
Number of people targeted  22    Brady et al. (2006) 
Current treated   
 
25 
 
 
 
The global population and its rate of increase (or decrease) by age group were based on current 
and  projected  data  available  on  the  US  Census  Bureau  website 
(www.census.gov/ipc/www/idbpyr.html,  2007). The  rate  of  increase  in the total  number  of 
persons  infected  with  schistosomiaisis  from  2007  through  to  2030  was  assumed  to  be 
proportional to this rate of increase. Approximately 200 million people are assumed to be Chapter 7 
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infected with schistosomiasis (Yosry, 2006). Eighty percent of the 200 million people currently 
inhabit  sub Saharan  Africa,  where  the  annual  mortality  is  estimated  to  be  280,000  people 
(Southgate et al., 2005).   
 
7.2.5 Cost effectiveness analysis  
The cost effectiveness of the new drug combination was compared to the cost effectiveness of 
Pzq treatment in Senegal. In particular, areas of intense S. mansoni transmission in Senegal, 
such as areas in proximity to dams, were used in this analysis. Senegal was chosen as previous 
studies have suggested low treatment efficacies using 40mg/kg of the Pzq. Table 7.3 shows the 
epidemiology and economic assumptions used to develop the analysis. 
  
Table 7.3: Demographic, epidemiological and economic data for Senegal. 
 
 
Economic indicators 
   
References 
 
Total population  11,658,172  www.worldbank.org, (2007) 
GNI per capita (US$)  710  www.worldbank.org, (2007) 
Maximum working days pa.  313  www.worldbank.org, (2007) 
GNI per capita/ per day (US$)  2.27  www.doingbusiness.org, (2007) 
 
Epidemiology indicators 
   
 
Total population 
 
11,658,172  www.worldbank.org, (2007) 
Proportion at risk of schistosomiaisis (%)  35.30  Steinmann et al., (2006) 
Total at risk  4115335  See Electronic Appendix B 
Proportion at risk near large dams (%)  2.20  Steinmann et al., (2006) 
Total at risk near dams  90537  See Electronic Appendix B 
Breadwinner proportion (%; male adults>15yrs)  0.46  www.gvu.unu.edu/about.cfm, (2007) 
Total number of breadwinners at risk  41828  See Electronic Appendix B 
 
The numbers of days lost due to S. mansoni infections and the resulting numbers of days saved 
due to Pzq treatment was calculated based on a study by Blas et al., (2006) for S. japonicum 
infections. The model assumes that a Pzq Tcbz drug combination has 100% efficacy while 
standard Pzq treatment has only 70 90% efficacy in Senegal. Chapter 7 
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7.2.6 Stochastic model development 
A stochastic model (CostMod v1.0) was developed using Microsoft Excel (Microsoft Inc., 
Redmond) with the PopTools v.2.7.5 add in (CSIRO, Canberra). PopTools is an add in for PC 
versions of Microsoft Excel™ that allows for the analysis of matrix population models and 
simulations  of  stochastic  processes.  The  input  parameters  are  represented  by  distribution 
functions to account for the inherent variabilities of each parameter (Vose, 1998). The input 
distribution ensures that for each parameter value that is randomly drawn from Monte Carlo 
sampling, there is an associated probability that the parameter will assume this value. The re 
calculation of the model is known as an iteration, where each iteration uses a value randomly 
drawn from the input distribution. Using PopTools, ten thousand iterations were generated for 
each simulation using Monte Carlo sampling. The Monte Carlo output for each sampling or 
simulation event is depicted according to the median, 2.5
th lower and 97.5
th upper confidence 
(95%  confidence  intervals)  values.  Input  parameters  were  modelled  by  assigning  expert 
(PERT)  or  normal  confidence  distributions. The  PERT  distribution  is  used  exclusively  for 
modelling expert estimates (Vose, 2004). All PERT and normal distribution estimates used in 
this  analysis  was  derived  from  published  and  peer reviewed  sources.  The  model  output  is 
expressed  as  the  total  gross  national  income  (GNI)  and  the  number  of  days  lost  despite 
treatment (reduced illness days) as a result of drug combination treatment (Electronic Appendix 
B). Table 7.4 shows the distribution parameters of the variables used in CostMod. Normal 
distributions  were  parametised  using  the  mean  and  standard  deviations  while  PERT 
distributions were parametised using the minimum, most likely and maximum estimates with a 
weighting of four. 
 
Table  7.4:  Distribution  parameters  of  variables  used  in  CostMod  for  the  estimation  and 
calculation of drug production price, operational costs and days lost due to schistosomiasis. 
The mean and standard deviations of the distribution are presented in parenthesis. 
 
Variable  Distribution parameter 
Production price of triclabendazole/kg (US$)  Normal (14.6, 0.53) 
Production price of praziquantel/kg (US$)  Normal (35.13, 10.7) 
Operational costs of drug combination (US$)  PERT (31.2, 16.8) 
Days lost to Schistosoma mansoni (Days)  PERT (9.08, 2.76) Chapter 7 
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7.3 Results  
7.3.1 Production costs of praziquantel and triclabendazole 
The cost to purchase the raw materials for the manufacture of Pzq in 1993 was an estimated 
US$85 per kg (Reich et al., 1998). In 2007, the cost of raw materials has decreased to ~US$34 
per kg. At a production loss of 3% (~66 tablets) from each kg of raw materials, approximately 
1600 Pzq tablets (600mg) can be manufactured. The cost to produce each tablet is US$0.02. 
 
Ciba Geigy’s patent for triclabendazole expired on the 3
rd April, 2006. Prices of Tcbz prior to 
the  expiration  of  its  patent  (2006)  were  not  included  in  this analysis. The  average  quoted 
price/kg for 100kg of Tcbz from five generic manufacturers of Tcbz was US$14.60, compared 
to the average quoted price of US$105.25/kg for 10kg of the compound. At US$14.60/kg for 
raw Tcbz, the cost to produce each 600mg tablet is US$0.009.  
 
7.3.2 Sale price of praziquantel and triclabendazole 
The median supplier price for a 600 mg Pzq tablet was compiled from the International Drug 
Price Indicator (www.msh.org, 2007). The median sale price derived from eight manufacturers 
was  approximately  US$0.1173  for  2005  (see  Electronic  Appendix  B:  Purchase  Costs 
worksheet). At a production cost of US$0.02, the gross margin is approximately is 83.5% or 
US$0.098. The average price inflation of Pzq tablets was approximately 3% from 2000 to 
2005. Assuming that all manufacturers inflate their sale prices by 3%, the new mean supplier 
price for 2007 will be US$0.133. 
 
Assuming  the  same  gross  margin  of  83.5%,  the  sale  price  for  a  600mg  tablet  of  Tcbz  is 
US$0.055. Table 7.5 shows the estimated production costs and the resultant sale price of each 
600mg tablet of Pzq and Tcbz. For a detailed breakdown of production costs and sale prices, 
please see (Electronic Appendix B: Production Costs worksheet) 
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Table  7.5:  Production  costs  and  sale  price  of  one  600mg  tablet  of  praziquantel  (Pzq)  and 
triclabendazole (Tcbz) in 2007. 
 
  Cost (US$) 
  Pzq  Tcbz 
Raw materials/kg  34  14.6 
Number of tablets/kg*  1600  1600 
Cost to produce/tablet  0.02  0.009 
Gross margin at 83.5%  0.098  0.046 
Sale price per tablet (2007)  0.118  0.055 
     * Assumes 3% production loss 
 
7.3.3 Sale price of praziquantel triclabendazole drug combinations 
Each child is currently given an average of two 600mg Pzq tablets per treatment and an adult is 
given five tablets per treatment (Guyatt et al., 1994; Guyatt & Chan, 1998). The Monte Carlo 
simulated mean costs to treat children and adults per year using the drug combinations are 
shown in the following Table 7.6.  
 
Table 7.6: The mean costs to treat a child and an adult per year derived from Monte Carlo 
simulations. The 95% confidence intervals are presented in parenthesis. 
 
  Cost in (US$) 
   
Child 
 
Adult 
Number of tablets per treatments   2  5 
Number of treatments per year  1  1 
Median cost of combination     
600mg 600mg drug combination  0.376 (0.220, 0.534)  0.942 (0.543, 1.34) 
300mg 300mg drug combination  0.189 (0.108, 0.268)  0.471 (0.270, 0.666) 
 
 
A detailed breakdown of the Pzq Tcbz drug combination sale price derived from Monte Carlo 
simulation is illustrated in Electronic Appendix B: Production Costs worksheet. 
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7.3.4 Patient number projections 
Table  7.7  shows  the  total  number  of  children  (ages  <15)  and  adults  (ages  >15)  and  the 
projected  rates  of  increase  in  each  population  group  in  five  year  increments 
(www.census.gov/ipc/www/idbpyr.html, 2007).  
 
Table 7.7: Global and Senegalese population distribution of children and adults from 2007 to 
2030 in five year increments. 
 
Number of people ( x 1,000,000) 
 
 
Year 
 
Total 
 
Children  
 
Adult 
 
% children 
 
% increase 
  2007  6600  1811   4789  27   
Global  2010  6838  1830  5008  26.7  3.6 
  2015  7230  1875  5355  25.9  5.76 
  2020  7608  1916  5692  25.2  5.23 
  2025  7964  1931  6033  24.2  4.67 
  2030  8296  1926  6370  23.2  4.17 
Senegal  2007  11.7  6.3  5.4  46.0    
 
Approximately 42 million people are treated with Pzq each year based on the assumption that 
21%  of  the  total  200  million  people  infected  with  schistosomiais  would  gain  access  to 
treatment. Table 7.8 illustrates the global distribution of children and adults that would be 
treated with Pzq treatement at the rate of population change shown in Table 7.6.  
 
Figure 7.8: Projections of the number of children and adults receiving praziquantel treatment 
from 2007 to 2030 in all countries. 
 
 
                      Number of people ( x 1,000,000) 
 
Year 
 
Total 
 
Children 
 
Adult  
 
2007 
 
42.00 
 
11.3 
 
30.7 
2010  43.5  11.6  31.9 
2015  46.0  11.9  34.1 
2020  48.4  12.2  36.2 
2025  50.7  12.3  30.7 
2030  52.8  12.3  40.5 
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7.3.5 Drug costs, operational costs and total costs of programme 
The drug costs for a drug combination of Pzq Tcbz in the first year of production (2013) are 
illustrated in Table 7.9.  
 
Table 7.9: Projected drug costs of a combination of praziquantel triclabendazole (Pzq Tcbz) at 
different drug ratios compared to the drug costs for Pzq alone in 2013.  
 
  US$ (2007 dollars) 
   
Mean  Lower CL*  Upper CL 
Pzq Tcbz drug costs (600mg 600mg)  4,253,048  2,738,291  7,019,735 
Pzq Tcbz drug costs (300mg 300mg)  2,124,480  1,501,788  4,139,643 
Pzq drug costs (600mg)  2,993,203  1,187,873  4,749,331 
*Lower CL denotes lower confidence limits; Upper CL denotes upper confidence limits 
 
The average simulated operational costs were 29.6% of the total costs of treatment. The total 
costs (drug + operational) to deliver a Pzq Tcbz drug combination (1 1 and 0.5 0.5 drug ratio) 
treatment programmes compared to Pzq treatment programmes only are summarized in Table 
7.10.  Detailed  cost  projections  are  shown  in  Electronic  Appendix  B:  Programme  Costs 
worksheet. 
 
 
 
Table 7.10: Projected total costs to treatment programme using a combination of praziquantel 
triclabendazole at different drug ratios compared to the total cost to deliver Pzq treatment alone 
in 2013.  
 
 
  US$ (2007 dollars) 
   
Mean  Lower CL*  Upper CL 
Pzq Tcbz drug costs at 1 1  4,837,540  2,738,291  7,019,735 
Pzq Tcbz drug costs at 0.5 0.5  2,717,606  1,501,788  4,139,643 
Pzq drug costs  3,622,203  1,534,281  5,848,886 
*Lower CL denotes lower confidence limits; Upper CL denotes upper confidence limits 
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7.3.6 Cost effectiveness analysis 
Table 7.11 shows the mean simulated outputs for a population of breadwinners in Senegal 
treated  with  Pzq  at  70,  80,  90  and  100%  efficacy  rates  and  Pzq Tcbz  drug  combination 
treatment at a dose rate of 600mg each. Detailed cost effectiveness data is shown in Electronic 
Appendix B: Cost effectiveness analysis worksheet. 
 
Table 7.11: The mean gross national income (GNI) saved per capita per year (US$) for every 
US$1 spent, the  total number of days  lost  despite treatment and the total number of days 
saved with praziquantel (Pzq) treatment at 70, 80, 90 and 100% efficacy and a combination of 
praziquantel and triclabendazole (600mg 600mg).  
 
 
Treatment regimen  Efficacy 
GNI  
US($) 
Total days lost 
despite treatment 
Total days 
saved 
 
Pzq  70%  11.72  73728 
 
0 
Pzq  80%  13.66  49152  24576 
Pzq  90%  15.60  24576  49152 
Pzq  100%  19.42  0  73728 
Pzq Tcbz  100%  13.40  0  73728 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 7 
127 
7.4 Discussion 
The purpose of this study was to determine the cost effectiveness of delivering a combination 
drug  containing  Pzq Tcbz  for  the  treatment  of  schistosomiasis.  This  was  achieved  by 
calculating  the  estimated  costs  of  development,  manufacture  and  supply  of  the  Pzq Tcbz 
combination therapy and Pzq therapy. The new treatment was considered cost effective if the 
total cost to deliver a treatment programme to reduce morbidity was not significantly greater 
compared to the costs of delivering Pzq alone. The costs of the analysis are measured as the 
costs (US$) to treat a targeted population of breadwinners (>15 years old) at risk of infection 
with S. mansoni who live in close proximity to dams. The outputs or benefits are measured as 
the amount of gross national income (GNI) per capita saved in US$ as a result of treatment and 
the number days lost despite treatment (or illness days reduced as a result of treatment). 
 
The use of a drug combination of Pzq Tcbz at the drug ratio of 1 1 or 600mg 600mg was based 
on a standard dose of Pzq of 40mg/kg in humans and assumed that Tcbz would be administered 
in  the  drug  combination  at  the  same  dose  rate.  Praziquantel  is  currently  provided  in  a 
formulation containing 600mg of active ingredients per tablet. The basis for the use of a 1 1 
(600mg 600mg) drug combination ratio in this analysis was to improve the current efficacy of 
Pzq. Recent studies have suggested that the efficacy of Pzq treatment is approximately 70% at 
the standard dose of 40mg/kg (Danso Appiah & De Vlas, 2002). This is important because a 
significant number of worms would survive treatment even when Pzq is 95% effective. More 
importantly,  it  has  been  demonstrated  that  Pzq  at  40mg/kg  is  <70%  effective  for  treating 
infections  in  Northern  Senegal  and  that  the  low  cure  rates  observed  were  suggestive  of 
resistance  to  Pzq  treatment  (Gryseels  et  al.,  1987;  Davis,  1993;  WHO,  1993;  Kumar  & 
Gryseels, 1994). The use of a combination of Pzq and Tcbz may improve the current efficacy 
of  treatment  against  human  schistosomiasis  in  regions  with  intense  transmission  such  as 
Senegal.  Danso Appiah  &  De  Vlas  (2002)  suggested  that  the  low  cure  rates  observed  in 
Senegal were a result of the insensitivity of immature schistosomula to Pzq at the time of 
treatment.  If  Tcbz  is  shown  to  be  effective  against  immature  schistosomula  in  humans,  a Chapter 7 
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combination of Pzq and Tcbz at 600mg each may: (1) increase efficacy rates above 70 90% 
against mature worms and (2) reduce treatment failure due to the insensitivity of immature 
schistosomula to Pzq. 
 
The results  of  this analysis  show  that a  combination  of  Pzq Tcbz  at  a  lower  dose  rate  of 
300mg 300mg would reduce the total costs of the drug combination by approximately 50%. 
The  application  of  this  dose  rate  is  likely  to  be  well accepted  in  view  of  its  lower  costs. 
However,  the  lower  dose  rate  of  the  combination  is  unlikely  to  significantly  increase  the 
efficacy of treatment. The higher dose rate of 600mg 600mg may be more reliable, in light of 
recent Pzq treatment failures at the standard dose of 40mg/kg (Dabo et al., 2000; Wolfe, 2003; 
Silva et al., 2005; Alonso et al., 2006). This is further reinforced by Warren et al. (1983), who 
suggested  that  the  development  of  drug  resistance  can  be  fostered  by  under dosage.  It  is 
possible that other drug combination ratios of Pzq Tcbz may be as effective in improving 
treatment efficacy, such as a combination of 600mg 300mg. 
 
At current supplier prices, the costs of a Pzq Tcbz drug combination would not be sustainable 
for  mass  drug  treatment  regimens.  If  Tcbz  were  to  used  for  the  treatment  of  human 
schistosomiasis, a significant reduction in sale price is necessary to make the combination 
sustainable. Currently, the gross margin for the manufacture of Tcbz tablets is approximately 
99% for a 600mg tablet at a supplier price of US$0.96, based on the WHO negotiated price of 
US$0.40  for  each  250mg  tablet  of  Tcbz.  Albendazole  (Abz),  another  benzimidazole,  is 
currently supplied at US$0.23 for a 400mg tablet, of which US$0.20 was the drug cost (Bundy 
& de Silva, 1998). The low purchase prices of Abz suggested that the sale price of Tcbz can 
potentially be reduced to a similar level. If the gross margin for Tcbz was similar to Pzq 
(83.5%), the cost of each Tcbz tablet can be reduced to approximately US$0.055. Further cost 
reduction is also likely for Pzq. The Schistosomiasis Control Initiative currently purchases 
600mg Pzq tablets at US$0.007 from Shin Poong Pharmaceutical (www.schisto.org, 2007). 
With improvements in peptide acetal chemistry, radical and solid phase synthesis, the cost to Chapter 7 
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synthesize  Pzq  is  expected  to  decrease  more  in  the  near  future  (Todd  et  al.,  2002;  El 
Fayoummy et al., 2006). 
 
Census data used in this analysis projected only modest increases in the population of children 
<15 yrs, with a downward trend for the age group expected within the next 20 years, which has 
the potential to affect the cost of disease control programmes in the future. An increase in the 
number of adults would exponentially increase the costs of control programmes due to the 
higher dosage required (five tablets per adult compared to two tablets per child).  
 
While  population  distribution  and  growth  data  were  compiled  from  published  sources,  the 
economic  model  did  not  implicitly  account  for  the  effects  of  current  control  programmes, 
socio political  and  environmental  variables.  It  was  recently  suggested  that  an  increase  in 
ambient temperatures by 1.7ºC by 2030 would result in a northward expansion of the current 
Schistosoma  transmission  regions  in  China  (LePing  et  al.,  2004).  In  addition,  accurate 
prevalence rates of schistosomiasis in children and adults were not available. As a result, age 
and sex group specific prevalence data as well as projected infection rates for each group 
distribution were based on the projected changes in population rates. Despite such limitations, 
this  economic  model  can  be  modified  to  accommodate  different  age  and  sex specific 
prevalence rates of schistosomiasis.  
 
According to DiMasi et al. (2003), the current out of pocket cost for the development of a new 
drug is approximately US$403 million (in year 2000 dollars) for approximately 10 years. The 
level of research funding to further develop a new drug combination is better estimated using 
public priavate partnership models. Using this model, the cost of development of artemisinin 
combinational  treatments  for  malaria  was  an  estimated  US$20  million  and  the  cost  of 
development of synthetic peroxides was an estimated US$35 million (Moran et al., 2005). 
Public private initiatives are being increasingly encouraged to provide public goods in a cost 
efficient manner (Nishtar, 2004). While it is unlikely that manufacturers or private sources of 
funds  will be  made  available to progress the  development  of this  combination,  the  use  of Chapter 7 
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combination  chemotherapy  is  likely  to  be  important  developments  that  will  slow  the 
development of resistance (Appleton & Mbaye, 2001). 
 
The results of the cost effectiveness analysis show that an average of 24,576 to 73,728 days 
will be saved by increasing the efficacy of current treatment programmes from 70% to 100%. 
This analysis has assumed that the efficacy of treatment can be increased to 100% by using a 
combination of Pzq and Tcbz. However, the higher costs of a manufacturing a combination 
therapy  may  negate  any  economic  benefits  obtained.  Therefore,  the  development  of  a 
combination therapy is only justified if 1) it is not possible to increase the efficacy of Pzq 
treatment  through  the  administration  of  a  higher  dose  or  2)  significant  resistance  to  Pzq 
develops in schistosomes. 
 
It is difficult to define the level of increased cost that is ‘acceptable’ for a control programme. 
However, there is evidence that the most expensive drugs are often the most cost effective 
because they are significantly more effective than other treatments, and thus reduces the need 
for repeated therapy (Wiseman et al., 2006). This study has shown that a drug combination 
based  on  Pzq  and  Tcbz  is  more  cost effective  when  administered  in  regions  of  intense 
transmission,  where  current  Pzq  treatment  is  not  100%  effective.  This  indicates  that  the 
increased treatment costs associated with the drug combination has been ‘compensated’ by its 
increased  efficacy.  The  analysis  also  shows  that  Pzq  treatments  are  more  cost effective  if 
treatment efficacies are >80% when compared to the new combination treatment. The cost 
effectiveness model has demonstrated the cost efficacy of a combinatorial dose of Pzq and 
Tcbz for the treatment of schistosomiaisis, provided that: (1) a dose rate of two tablets per child 
and five tablets per adult treated once annually for control, (2) the approximate mean cost of a 
single formulation tablet at a dose rate of 600mg 600mg was US$0.164 (3) the operational 
costs accounted for an minimal estimated 29.6% of total treatment costs, (4) the Pzq Tcbz 
combinations have 100% efficacy for treatment against human mansonial schistosomiasis and 
(5) that existing treatment using Pzq is < 80% effective.  
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8 General Discussion 
 
The aims of this study were to assess the therapeutic potential of triclabendazole (Tcbz) and a 
combination of praziquantel (Pzq) with Tcbz for the treatment of Schistosoma mansoni (S. 
mansoni) infections. The efficacy of Tcbz in vitro was initially determined using different life 
stages of S. mansoni. The synergistic effects of a combination of Pzq and Tcbz were then 
determined  in  vitro  and  in  vivo.  The  outcomes  of  this  study  lend  further  support  to  the 
published observations of Keiser et al. (2007); that Tcbz in singular applications showed weak 
anti schistosomal effects.  
 
The Puerto Rican strain of S. mansoni used for this study was obtained from the Queensland 
Institute  of  Medical  Research  and  was  adapted  for  culture  according  to  the  protocols 
recommended by the National Institute of Health, Schistosoma Laboratory at the Biomedical 
Research Institute of Maryland. While all attempts were made to ensure that optimal conditions 
were maintained, the perpetuation of the life cycle was consistently hampered by the temperate 
climate of Perth. The small scale of the culture system presented considerable challenges for 
the  experimental  design  and  evaluation  of  drugs.  Consequently,  some  components  of  this 
research were performed in collaboration with the Queensland Institute of Medical Research. 
 
A detailed dose response analysis of Tcbz and its metabolites against the various life stages of 
S.  mansoni  has  not  been previously  performed.  Triclabendazole  demonstrated  considerable 
efficacy against 6 wk old immature worms in vitro. However, there was only moderate efficacy 
against mature worms in vitro as evidenced by worm mortality at high concentrations only. The 
efficacy  of  Tcbz  and  its  metabolites  were  significantly  inferior  to  Pzq.  However,  the 
metabolites  of  Tcbz  did  demonstrate  some  interesting  effects  against  adult  worms  with 
evidence of irreversible and persistent drug actions against adult worms. 
 
The effects of Tcbz and its metabolites were also analyzed against the egg stages of S. mansoni 
and S. japonicum (Chapter Four). This study is the first to quantitatively assess the effects of     Chapter 8     
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Pzq, Tcbz and its metabolites against the egg stages of Schistosoma sp. in vitro. The result of 
this  study  supported  the  findings  of  Matsuda  et  al.  (1983),  who  observed  the  premature 
hatching  of  miracidium  from  eggs  exposed  to  Pzq.  Praziquantel induced  hatching  was 
demonstrated to be a dose dependent process, with hatching observed at concentrations above 
10nM. Premature rupturing of the egg shells was observed following exposure of eggs to Tcbz 
and its metabolites, characterized by gross ultrastructural deformities such as a loss of egg shell 
integrity,  pronounced  disruption  of  unhatched  miracidia  and  premature  rupturing.  This  is 
important because the premature hatching of eggs may reduce the severity of the host response 
to Schistosoma eggs, which are the primary cause of host pathology.  
 
This is the first time that drug synergism between Tcbz Sx and Pzq has been demonstrated in 
vitro. Synergism was observed when adult S. mansoni and H. contortus larvae were exposed to 
combinations of Tcbz Sx and Pzq. A weak synergistic or additive effect was observed in G. 
duodenalis. The results of this chapter suggested that a combination of Tcbz Sx and Pzq may 
increase  the  efficacy  of  treatment  for  human  intestinal  schistosomiasis.  Moreover,  the 
synergistic effects observed for H. contortus suggested that the combination could potentially 
be used against other parasitic infections in livestock.  
 
The worm burden reductions observed when Pzq and Tcbz were used individually to treat mice 
infected with S. mansoni were lower than those of published studies (Keiser et al., 2007; Pica 
Mattoccia & Cioli, 2003). This was likely a consequence of variabilities in strain susceptibility 
or host responses to treatment. A combination of Pzq and Tcbz at 80mg/kg and 120mg/kg 
respectively demonstrated additive effects, characterized by reduced worm and egg burden as 
well as a cessation in egg laying. At higher doses of the combination, significant worm burden 
reductions were also observed. As this is the first study of its kind, it is difficult to assess the 
effects of higher combination doses in mice due to the variabilities in dosages administered in 
other studies. However, this study has shown that the administration of a high dose (250mg/kg 
each) of Pzq and Tcbz did not show any observable toxicity or side effects. This study also 
showed that Tcbz possessed some ovicidal activities, albeit at lower egg burden reductions than     Chapter 8     
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Pzq.  Further  work  using  a  range  of  combination  doses  is  necessary  to  explore  the  dose 
response  relationship  of  the  drug  combinations  using  a  larger  mouse  cohort.  In  particular, 
additional studies are required to assess the effects of the combinations against several strains 
of S. mansoni.  
 
A cost effectiveness model was also developed to assess the cost effectiveness of applying a 
combination of Pzq and Tcbz to treat human schistosomiaisis (Chapter Seven). The stochastic 
model served as a theoretical framework for projecting the total costs required to deliver a 
combination of praziquantel and triclabendazole at a dose rate of 600mg each. Senegal was 
chosen for this case study as there are published reports indicating that Pzq treatment efficacies 
were <70%.  Using Monte Carlo simulations, the model assessed the cost effectiveness of the 
drug combination intervention by measuring the gross national income (GNI) and reduced 
illness days as a result of treatment with the drug combination. The model demonstrated that a 
combination of Pzq and Tcbz can potentially be more cost effective when applied within a 
focus of intense transmission where the efficacy of Pzq is <80%. This has implications for 
treatment programmes where the commitment of funds is highly constrained. If approved for 
use, the Pzq Tcbz drug combination can potentially be administered as a contingent control 
measure to (1) reduce treatment failures associated with low Pzq efficacies (<80%) or (2) be 
used as the sole control measure in regions of high disease endemicity only.  
 
The development of combination therapies for schistosomiasis is warranted while Pzq control 
is still sustainable. Abbott et al. (2004) for Sustainable Control of Parasite in Sheep (SCOPS) 
suggested  that  combination  therapies  are  best applied  when  individual drugs  are  still  fully 
effective  and  where  resistance  alleles  remain  at  low  frequencies.  Ideally,  compounds  with 
independent mechanisms  of action are used to target different biochemical pathways or to 
exploit novel mechanisms of action (s). The sequential action of drug combinations against 
multiple targets will circumvent the development of resistant alleles as the probability for the 
development of simultaneous mutations is highly unlikely, provided that such mutations are not     Chapter 8     
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linked (White et al., 1999). Compared with the current policy of singular drug regimens, drug 
combinations have great potential in impeding resistance development.  
 
In addition to minimizing the side effects of drugs through the delivery of lower, effective 
therapeutic doses, drug combinations can also maximize and preserve the lifespan of existing 
compounds in the market and public health systems. Based on the observations above, a drug 
combination of Pzq and Tcbz Sx can potentially: 
 
•  Demonstrate  an  amplification  of  efficacy  against  S.  mansoni,  leading  to  reduced 
treatment frequency, 
•  Demonstrate narrow spectrum of activity against Schistosoma species, 
•  Demonstrate prolonged and persistent action to compliment Pzq’s rapid onset of anti 
schistosomal effects, 
•  Demonstrate separate and distinct mode of actions,  
•  Demonstrate activity against both juvenile and adult worms. 
 
It is also to be noted that while combination chemotherapy may prove to be more effective in 
alleviating disease or Pzq resistant infections, such strategies may lead to short term increases 
in costs.  It is, however, likely that the translated long term benefits will outweigh immediate 
shortfalls by extending the useful lifespan of existing compounds. As is the case with many 
drug  combinations  for  the  treatment  of  schistosomiasis,  potential  limiting  factors  to  the 
application of the Pzq/Tcbz Sx drug combination include 1) limited knowledge and public 
awareness  of  combinations  due  to  the  market  dominance  of  Pzq,  2)  further  costs  of 
development  and  studies  into  appropriate  formulation,  efficacy  and  tolerability  and  3) 
operational issues such as indiscriminate use, post market surveillance and market acceptance 
(Mutabingwa, 2005).  
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Recent indications of resistance and (or) tolerance to Pzq necessitates the development of new 
anti schistosomal  drugs  in  the  event  that  widespread  resistance  occurs.  The  use  of  a 
combination of Pzq and Tcbz for treatment is a possible alternative. In view of the current lack 
of  promising  candidates,  Tcbz  in  combination  with  Pzq  has  the  potential  to  address  the 
shortcomings of administering Pzq alone, and may represent a new line of treatment against 
human intestinal schistosomiasis.   
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Key terminology and definitions 
 
Terminology 
 
Definitions 
Additive effects  A biological response to the exposure to multiple 
substances that equals the sum of responses of all the 
substances added together. 
Cost of delivery  The total costs, including drug and operational costs, to 
deliver control measures. 
Cost of production  The actual cash costs to produce or manufacture. 
Global core inflation rate  A measure of trend movements in aggregate prices which 
eliminates high frequency movements such as energy and 
food inflation. 
Gross national income  Previously known as the gross national product, GNI is the 
total value of goods and services provided by a country. 
Inflation  An increase in the overall level of prices over a period of 
time. 
Logistical costs  Planning, execution and control costs. 
Operational costs  The costs incurred to maintain operations, eg., salaries, 
transport, rent, etc. 
Public-private partnerships  Partial privatization of a service in which elements are 
provided through a partnership between the government 
and private company (s). 
Revenue  The actual income received from total sales. 
Reduced illness days  The reduction in the number of days afflicted with illness 
or disease. 
Sub-optimal/therapeutic 
treatment 
The concentration of drugs eliciting less than 100% 
efficacy. 
Supplier price/ purchase price  The price to purchase goods from the supplier. 
Synergism  The concentration of substances required to elicit an effect 
that is larger than the sole additive effects of the substances 
Time value of money  The principle that an amount of money anticipated as 
income in the future is worth less that the amount at 
present. 
 